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Abstract 
 
Coronary heart disease is the commonest cause of death in the UK, in the main as 
a consequence of acute myocardial infarction (AMI)) causing 1 in 5 and 1 in 7 
deaths in men and women respectively – a total of around 88,000 deaths per 
year. Presently, timely and effective reperfusion with primary percutaneous 
coronary intervention (PCI) for AMI remains the most effective treatment 
strategy for limiting infarct size, preserving left ventricular ejection fraction and 
improving clinical outcomes. However, the process of reperfusion (known as 
myocardial ischaemia-reperfusion (I/R) injury) can itself induce cardiomyocyte 
death, for which there is currently no effective therapy.  
 
A potential solution to the problem of I/R injury may exist in the form of 
inorganic nitrite (NO2-). Over the last decade evidence has accumulated 
supporting the view that nitrite, which is abundant in blood and tissues, 
represents a significant stable intravascular endocrine reservoir and tissue 
storage form of nitric oxide (NO) that exerts a number of beneficial effects. 
Endogenous NO generation maintains vascular tone, inhibits vascular smooth 
muscle contraction/growth, platelet aggregation, and leukocyte adhesion to the 
endothelium. However, during ischaemia the ability of the predominant isoform 
that underlies this NO synthesis i.e. endothelial NO synthase (eNOS) is severely 
attenuated as a result of inadequate delivery of oxygen and co-factors. It is clear 
that identification of strategies that look to restore or replace diminished NO 
have therapeutic potential.  
 6 
Extensive preclinical evidence exists to suggest that nitrite (as a source of NO) is 
an effective therapeutic strategy for preventing myocardial I/R injury. In this 
project using a randomised clinical trial it was shown whether sodium nitrite 
reduces I/R injury and subsequent infarct size in patients undergoing primary 
PCI for AMI, and the mechanisms by which this may have occurred. Additionally 
the potential long-term benefits of nitrite supplementation post PCI were 
examined in-vitro models of I/R injury.   
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 29 
Chapter 1.0 
 
 
Introduction 
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1.1 Ischaemic heart disease (IHD) 
 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide 
accounting for 30% of global deaths in 2008, and is likely to remain so until at 
least 2030 (WHO Cardiovascular disease factsheet 2013). In the United Kingdom 
(UK) CVD accounts for almost 180,000 deaths each year, with almost half (45%) 
from IHD and nearly a quarter (27%) from stroke (Townsend et al., 2012). IHD by 
itself is the most common cause of death in the UK (mainly as a consequence of 
acute myocardial infarction (AMI)) causing around one in five male and one in 
eight female deaths respectively– a total of around 80,000 deaths per year. 
Importantly IHD is the leading cause of premature mortality in the UK causing 
almost 46,000 premature deaths in 2010. The financial consequences of IHD are 
considerable, costing the UK economy approximately £6.7 billion per annum in 
direct health care costs, loss of productivity and informal care, predominantly as 
a consequence of the morbidity associated wth AMI (Townsend et al., 2012). 
 
It is the formation of atheroma, lipid rich deposits, within the epicardial coronary 
arteries that causes IHD. The reduction in arterial diameter may lead to a slow 
but progressive increase in symptoms or an atheromatous plaque may rupture 
suddenly leading to thrombotic occlusion of the coronary artery and the most 
notable manifestation of IHD, acute myocardial infarction (Thim et al., 2008). ST-
segment elevation myocardial infarction (STEMI) is reported as being 
responsible for 25-47% of all AMI (Mandelzweig et al., 2006; Yeh et al., 2010), 
accounts for 800 hospital admissions every year per million population in Europe 
and occurs in approximately 103,000 people in the UK each year (Townsend et 
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al., 2012). STEMI is distinguished by an abnormal elevation of the ST-segment on 
the electrocardiogram (ECG) and is the electrical manifestation of an acute 
occlusion of a coronary artery. ST segment elevation has been recognized as a 
sign of myocardial ischaemia and damage for nearly 100 years with the 1st 
description back in 1920 by Harold Pardee, with the abnormality described as the 
"T wave as being tall and starts from a point well up on the descent of the R 
wave"(Pardee, 1920). The ST segment is the portion of the ECG that lies between 
the end of the S wave (which signifies the end of ventricular contraction) and the 
beginning of the T wave (signifying repolarsiation of the ventricles). It is usally 
isoelectric (neither positive or negative) with a ST segment considered to be 
elevated and indicative of myocardial infarction if it is 1mm or more above the 
baseline (Figure 1.1). As soon as the coronary artery blood supply is interrupted, 
myocardial damage begins and the longer the blood supply is occluded the 
greater the amount of heart muscle lost. In animal models of experimental 
coronary artery occlusion a ‘wave-front’ of myocardial injury spreads from the 
endocardium (inner layer of heart muscle) to the epicardium (outermost layer), 
whereupon the infarction is described as transmural (Reimer et al., 1977).  
Without urgent treatment this may lead to death from cardiac 
rupture/arrhythmia/failure or more often will result in substantial morbidity 
through the development of chronic cardiac failure.  
 
Presently, timely and effective reperfusion with primary percutaneous coronary 
intervention (PCI) (involving balloon dilatation of the occluded segment with 
stent insertion) remains the most effective treatment strategy for reducing 
myocardial infarct (MI) size, preserving left ventricular (LV) ejection fraction, and 
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preventing the onset of heart failure (Berger et al 1999; Cannon et al., 2000; 
McNamara et al., 2006;  Lambert et al, 2010). However, despite the introduction 
of primary PCI, and other recent advances such as decreasing symptom to balloon 
times (total ischaemic time), resulting in a reduction in mortality of ~50% at 30 
days (Widimsky et al., 2010), substantial mortality and morbidity rates still 
persist with respect to longer term outcome (Fox et al., 2010; Menees et al., 
2013). In-hospital mortality rates lie at 3−7% depending on the country, whilst 5-
6% of patients have a subsequent cardiovascular event by 30 days (Lambert et 
al., 2010) and 15-20% of patients develop heart failure.  
 
Figure 1.1 Typical ECG appearance of ST-elevation myocardial infarction  
a). Normal epicardial coronary arteries and corresponding normal electro-cardio-gram (ECG)  
b). Occluded Left anterior descending coronary artery and consequential ECG displaying ST-
segment elevation indicating an ST elevation myocardial infarction. 
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One of the main determinants of prognosis after AMI is the size of the infarct 
(Burns et al., 2002; Gibbons et al., 2004; Wu et al., 2008), and importantly 
increased infarct size is associated with an increased incidence of heart failure 
and arrhythmias (Majidi et al., 2009; Timmer et al., 2010; Saia et al., 2010). Thus, 
such statistics together clearly support the need for identification of additional 
strategies that might decrease infarct size and improve outcome.  
 
1.2 Ischaemia-Reperfusion injury (I/R Injury)  
 
In the setting of STEMI the immediate reopening of acutely occluded coronary 
arteries via primary PCI is the treatment of choice to salvage the ischaemic 
myocardium. However, paradoxically the sudden re-initiation of blood flow, leads 
to a local acute inflammatory response with further endothelial and myocardial 
damage. This phenomenon, described as 'reperfusion injury' (Carden and 
Granger, 2000) may explain why, despite optimum myocardial reperfusion, the 6-
month mortality after AMI approaches 12% (Fox et al., 2006) and the incidence of 
heart failure approaches 15-20% (Lambert et al., 2010; Saia et al., 2010). Animal 
studies suggest that whilst 50% of the final infarct size is due to the ischaemic 
insult the remaining 50% is due to reperfusion injury (Yellon and Hausenloy, 
2007). Although, the process of myocardial reperfusion continues to be optimized 
with recent advances in primary PCI technology (thrombus aspiration, novel 
stents), anti-platelet (Prasugrel, Ticagrelor) and anti-thrombotic therapy 
(Bivalirudin), there is currently no effective therapy for reducing myocardial I/R 
injury per se. Therefore, these data underscore the importance of discovering 
novel therapeutic targets for protecting the heart against acute I/R injury so as to 
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limit the infarct size, prevent the onset of heart failure, and reduce cardiac 
mortality. 
 
It is now over 50 years since the first observation that reperfusion following 
ischaemia was associated with myocardial injury was made by Jennings and 
colleagues (Jennings et al., 1960). Their report based on experiments in vivo in an 
open-chest anaesthetised model in dogs subjected to coronary ligation showed 
that reperfusion appeared to accelerate the development of necrosis, with the 
histological changes seen following 30-60 minutes of I/R comparable to the 
degree of necrosis normally seen after 24 hours of permanent coronary 
occlusion. These histological changes comprised contracture of myofibrils, 
disruption of the sarcolemma, and the appearance of intra-mitochondrial calcium 
phosphate particles, features which appeared within minutes of myocardial 
reperfusion and which differed from those induced by myocardial ischaemia 
alone, confirming myocardial I/R injury as a distinct pathological entity. 
Recognition of these findings only became apparent in the mid-1970s, when the 
significance of I/R injury in reperfused myocardial infarction came into focus in 
experimental canine models (Mathur et al., 1975). Subsequent work, stimulated 
initially by both the advent of intracoronary mechanical and thrombolytic 
reperfusion and the emergence of intravenous thrombolytic therapy, 
systematically evaluated multiple potential mechanisms of reperfusion injury and 
explored potential approaches to the prevention or reduction of I/R injury (for 
reviews see: (Braunwald and Kloner, 1982; Bolli and Marban, 1999; Ito, 2006; 
Yellon and Hausenloy, 2007).  
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The injury to the heart caused by myocardial reperfusion causes four types of 
cardiac dysfunction (Figure 1.2).  Some of these of are reversible, short lived and 
easily managed, which include myocardial stunning and reperfusion arrhythmias. 
However it is the irreversible forms of myocardial reperfusion injury, which 
include microvascular obstruction and lethal myocardial reperfusion injury, 
which contribute to the final myocardial infarct size, diminish the benefits of 
myocardial reperfusion in terms of myocardial salvage and are the main targets 
for cardioprotection. 
 
Figure 1.2. Myocardial reperfusion injury results in 4 types of cardiac dysfunction 
 
Myocardial stunning. This is a term which describes the “ mechanical 
dysfunction that persists after reperfusion despite the absence of irreversible 
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damage and despite restoration of normal or near-normal coronary flow” (Bolli 
and Marban, 1999) and was initially described by Heyndrickx et al in 1975 
(Heyndrickx et al., 1975) In this scenario, reperfusion of either a globally or 
regionally ischaemic myocardial tissue results in a period of prolonged, yet 
reversible, contractile dysfunction. The myocardium is essentially “stunned” and 
requires a prolonged period of time before complete functional recovery.  
 
Reperfusion arrhythmias. Experimental animal studies from the 1980s 
(Manning and Hearse, 1984) were among the first to describe ventricular 
arrhythmias specifically induced by reperfusion. In reperfused-STEMI patients, 
the most commonly encountered reperfusion arrhythmias are idioventricular 
rhythm, ventricular tachycardia, and fibrillation (Kukreja and Janin, 1997). These 
are usually short-lived and managed easily in the clinical setting (Hausenloy et al., 
2013).  
 
Microvascular obstruction. Microvascular obstruction was first described in 
1966 (Krug et al., 1966) in the feline heart as the “ inability to reperfuse a 
previously ischaemic region.” Despite intensive research, the underlying cause 
remains unclear although the major contributory factors are thought to include 
capillary damage with impaired vasodilatation, external capillary compression by 
endothelial cell and cardiomyocyte swelling, micro-embolization of friable 
material released from the atherosclerotic plaque, platelet micro-thrombi, and 
neutrophil plugging (Ito, 2006). In reperfused STEMI patients it has been 
reported that the development of the coronary no-reflow phenomenon, the 
angiographic manifestation of microvascular obstruction, is determined by 
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several factors which include the extent of myocardial injury, the size of the 
myocardium at risk of infarction, the patency of the infarct-related artery, 
(Iwakura et al., 2001) and the presence of thrombus (Yip et al., 2002) in the 
culprit lesion. Even when post-primary PCI epicardial coronary flow appears 
normal (TIMI flow 3 (TIMI Study group, 1985)), 30–40% of these patients 
actually have evidence of microvascular obstruction when undergoing cardiac 
imaging such as cardiac magnetic resonance (CMR) imaging (Figure 1.3) (Bogaert 
et al., 2007). The presence of microvascular obstruction in reperfused-STEMI 
patients is associated with a larger MI size, worse LV ejection fraction, adverse LV 
remodelling, and worse short-term and long-term clinical outcomes (Ito, 2006; 
Bogaert et al., 2007). 
 
Figure 1.3. Microvascular obstruction.  
The left panel displays early gadolinium enhancement revealing evidence of microvascular 
obstruction (*) and the right panel, late gadolinium enhancement depicting a transmural 
myocardial infarct (arrow) with a core of microvascular obstruction (*). 
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Lethal myocardial reperfusion injury. Lethal myocardial reperfusion injury 
refers to the reperfusion-induced death of cardiomyocytes, which were viable or 
reversibly injured at the end of ischaemia (Piper et al., 1998). The existence of 
lethal myocardial reperfusion injury as a distinct entity, which is capable of 
independently inducing cardiomyocyte death following a sustained episode of 
myocardial ischaemia, has been hotly debated over the years (Braunwald and 
Kloner, 1985; Kloner 1993; Piper et al., 1998). Part of the problem has been the 
inability to directly demonstrate that the actual process of reperfusion induces 
the death of cardiomyocytes, which were viable at the end of the ischaemic 
episode. However, the most convincing means of showing the existence of lethal 
reperfusion injury as a distinct mediator of cardiomyocyte death is to show that 
the myocardial infarct size can be reduced by an intervention used at the 
beginning of myocardial reperfusion. Now extensive indirect evidence has been 
provided by a large number of pre-clinical animal studies demonstrating 40–50% 
reductions in MI size with therapeutic interventions applied at the onset of 
myocardial reperfusion (For review, see Yellon and Hausenloy, 2007).  
 
1.3 Mechanisms of Lethal Reperfusion Injury 
 
In vitro and in vivo experimental data strongly suggest that reperfusion injury is 
initiated during the first few moments of reperfusion and proceeds over minutes 
to hours in a cascade involving numerous interactive mechanisms leading to 
damage or death of myocardium and coronary vascular endothelium (Piper et al., 
1998). This reperfusion injury contributes to contractile dysfunction, metabolic 
derangements, and ultimately cell death by necrosis, apoptosis, and autophagy. 
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The mechanisms underlying lethal reperfusion injury include: (1) generation of 
reactive oxygen species (oxygen paradox); (2) intracellular calcium accumulation 
(calcium paradox); (3) rapid normalization of intracellular pH (pH paradox); (4) 
an inflammatory response and (5) opening of the mitochondrial permeability 
transition pore (mPTP).  
 
1.3.1 Generation of Reactive oxygen species (ROS) (Oxygen paradox) 
 
ROS are short-lived oxygen-derived free radicals, which act as signaling 
molecules and play important roles in biological processes at low concentrations. 
However, excessive amounts of ROS can damage or destroy organelles, cells and 
tissues leading to an array of pathologies including DNA mutations possibly 
underlying cancer, parkinsons disease, ageing and atherosclerosis. Importantly, 
there is an abundance of evidence that the overproduction of ROS is involved in 
the pathophysiology of myocardial I/R injury. Molecular oxygen, when 
reintroduced into a previously ischaemic myocardium, undergoes a sequential 
reduction leading to ROS formation such as superoxide anion (O2-), hydroxyl 
radical (OH), and peroxynitrite (ONOO-) within the first few minutes of reflow 
(Bolli et al., 1989). In 1973, Hearse and colleagues reported that the 
reoxygenation of globally arrested (hyperkalemic) anoxic hearts for 100 minutes 
was accompanied by a release of creatine phosphokinase indicative of cell death, 
a phenomenon later called the ‘oxygen paradox’ (Hearse et al., 1973). The 
exogenous administration of oxygen radical generators has since replicated the 
myocardial morphological damage and contractile dysfunction observed after I/R 
injury (Ytrehus et al., 1986; Bolli et al., 1989), with subsequent studies using 
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oxygen free radical scavengers confirming this explosive cell necrosis is caused 
by ROS (Lucas et al., 1980).  
 
The major sources of ROS in the ischaemic heart include the enzyme xanthine 
oxidase, the mitochondrial electron transport chain, and the NADPH oxidase 
system (for review, see Zweier and Talukder, 2006). Xanthine oxidase has been 
particularly implicated as a generator of free radicals in the reperfused heart, as 
its substrates (NADH) accumulate during ischaemia (Thompson-Gorman and 
Zweier, 1990). Oxidative stress may increase by as much as 100-fold during 
ischaemia and reperfusion, due to significant acceleration in ROS production 
(Zweier et al., 1987; Zweier and Talukder, 2006).   
 
The formation of ROS causes damage to cardiomyocytes and vascular tissue, 
especially the coronary vascular endothelium, which is the ‘front line’ defense 
against destructive processes derived from the intravascular space. These ROS 
are highly reactive and quickly overwhelm the cell’s endogenous free radical 
scavenging system including superoxide dismutase, catalase, glutathione 
peroxidase and uric acid (Vaage et al., 1997). This, in turn, triggers cellular injury 
by reactions with lipids, proteins, and nucleic acids. The deleterious actions of 
ROS on cells and tissues includes damage to DNA (Toyokuni, 1999); lipid 
peroxidation leading to membrane damage and calcium (Ca2+) overload 
(Steinberg, 2013); damage to the sarcoplasmic reticulum leading to Ca2+ 
dyshomeostasis and contractile dysfunction (Rowe et al., 1983); denaturation of 
proteins, enzymes and ion channels (Zweier and Talukder, 2006); impairment of 
metabolism i.e. glycolysis; activation of adhesion molecules on vascular 
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endothelium thereby stimulating an increase in PMN adhesion (Serrano et al., 
1996) and acting as chemoattractants to neutrophils and other inflammatory 
cells resulting in white cell plugging of capillaries and microvascular obstruction 
(Zimmet and Hare, 2006). In addition to damaging nuclear and cytosolic 
elements, ROS can trigger the opening of the mPTP (Zorov et al., 2009), which 
results in cell death by necrosis, further details of which are described in section 
1.3.5. 
 
Importantly ROS reduce the bioavailability of NO, which has far-reaching effects 
on the myocardium. Under normal conditions NO generation elicits vasodilation 
(Moncada and Higgs, 1993; Quyyumi et al., 1995), but also exerts a number of 
other beneficial, protective effects during I/R, likely by influencing oxygen 
consumption (Clementi et al., 1999), inhibiting platelet aggregation (Radomski et 
al., 1987), inhibiting leukocyte adhesion (Kubes et al., 1991; Ahluwalia et al., 
2004) and is also important for free radical scavenging (Beckman et al., 1990).  
 
NO levels are repressed directly by the reaction of ROS with NO in particular to 
form the potent oxidant ONOO- which itself may cause further damage (Wang and 
Zweier, 1996). ONOO- is believed to react with and damage many important 
biological molecules including thiols, lipids, proteins, and nucleic acids by a 
number of mechanisms (Pryor and Squadrito, 1995; Wang and Zweier, 1996). 
However there has been some controversy with regards to whether ONOO- is 
harmful or protective in the setting of I/R injury (Grisham et al., 1998; Ronson et 
al., 1999; Ferdinandy and Schulz, 2001). It is now generally accepted that it is 
likely that ONOO- produced within the myocardium is cytotoxic and contributes 
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to I/R injury but exogenously produced or infused ONOO- appears to be 
protective mainly via its reaction with thiols to generate nitrosothiols and related 
products which exert anti-neutrophil actions (Ferdinandy and Schulz, 2001). 
 
Additionally ROS can alter nitric oxide synthase (NOS) function (the primary 
family of enzymes implicated in endogenous NO generation) inducing a switch 
from being an NO to O2− generator (See later section 1.5.2). All 3 NOS isoforms 
can become potent sources of O2− with depletion of either the substrate L-
arginine or the co-factor tetrahydrobiopterin (BH4) triggering this fundamental 
alteration in NOS function (Xia et al., 1996; Xia et al., 1998; Chen et al., 2010) (see 
laterv section 1.5.2). Since BH4 can be readily depleted by oxidants this results in  
‘uncoupling’ of NOS switching it from NO to O2− generation. Other mechanisms 
that could trigger uncontrolled O2− generation include the release of FAD from 
the NOS enzyme and disruption of dimerization, which is critical for NO 
generating capacity (Xia and Zweier, 1997). This increased formation of O2− 
rapidly removes NO to form ONOO-, and this can then itself or via ONOO- oxidize 
BH4 that has not been removed during ischaemia. The effects are two-fold, firstly 
this results in a self-sustaining of the production of O2− resulting in a vicious cycle 
(Ma et al., 1993) but also depression of NO generation.  This reduction in 
availability of endogenous NO may contribute to the pathogenesis of MI since 
inhibiting NO or its production is associated with larger infarct sizes (Johnson G 
III et al., 1991; Jones et al., 1999). 
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1.3.2 Intracellular Ca2+ accumulation (Ca2+ paradox) 
 
It was first reported in the 1970s that reperfusion following brief coronary 
occlusion was associated with accelerated accumulation of intracellular Ca2+ 
(Shen and Jennings, 1972). It is now well established that at the time of 
myocardial reperfusion, there is an abrupt increase in both intracellular and 
mitochondrial Ca2+ which overwhelms the normal mechanisms that regulate Ca2+ 
in the cardiomyocyte; this phenomenon is termed the Ca2+ paradox (Zimmerman 
and Hulsmann, 1966). The accumulation of intracellular Ca2+ during ischaemia 
occurs in response to the loss of energy homeostasis and as a result of changes in 
the acute regulation of sarcolemmal and sarcoplasmic reticulum cation transport 
mechanisms (Figure 1.4). Specifically during ischaemia the depletion of 
adenosine triphosphate (ATP) results in subsequent inhibition of the energy-
dependent sarcolemmal Na+/K+ ATPase, increased activity of Na+-H+ exchanger 
and reverses the activity of the Na+-Ca2+ exchanger (Inserte et al., 2005). ROS 
adversely influences Ca2+-handling proteins in the sarcoplasmic reticulum as 
described is section 1.31 which leads to higher levels of cytosolic Ca2+ and 
facilitates Ca2+ entry through L-type channels and the entry of Ca2+ into the cell 
due to a loss of membrane integrity (Bersohn et al., 1997).  
 
The physiological consequences of this Ca2+ accumulation are arrhythmias, 
hypercontracture of the cardiomyocytes causing cell death and/or opening of the 
mPTP (Minezaki et al., 1994) which leads to cell death by necrotic or apoptotic 
pathways. In addition, the contractile apparatus becomes desensitized to Ca2+, 
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thereby impairing the contractile function of the myofibrils (Piper et al., 1998; 
Nakanishi et al., 1991) and changes in left ventricular ejection fraction after AMI 
(Urquhart et al., 1985; Urquhart et al., 1984) . 
 
Figure 1.4 Schematic of Ca2+ paradox in myocardial I/R injury 
Panel A displays the normal pathways controlling cellular [Ca2+]. Panel B displays the events 
leading up to [Ca2+] overload during I/R. A drop in pH triggers Na+/H+ exchanger mediated Na+ 
influx, resulting in Na+ overload. Reverse-mode Na+/Ca+ exchange across the plasma membrane 
then results in Ca2+ overload and subsequent mitochondrial [Ca2+] overload. Ca2+ cycling across 
the mitochondrial membrane can lead to propagation Ca2+ export by Ca2+-ATPases. Adapted from 
(Brookes et al., 2004) 
 
1.3.3. Rapid normalization of intracellular pH (pH Paradox) 
 
The rapid restoration of physiologic pH during myocardial reperfusion, which 
follows the washout of lactic acid and the activation of the Na+-H+ exchanger, 
contributes to lethal I/R injury. This phenomenon is termed the pH paradox 
(Lemasters et al., 1996). Both interstitial and tissue pH rapidly decrease with 
onset of ischaemia. This tissue acidosis inhibits the potentially deleterious effects 
of hypercontracture (Ladilov et al., 1995), cell-cell communication by gap 
junctions, calpain activation, Na+-H+ exchanger and opening of the mPTP (Piper et 
al., 2004; Kim et al., 2006). However, reperfusion rapidly restores tissue pH by 
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washout of H+ from the interstitial space, which then unleashes the 
aforementioned mechanisms to cause cell injury.  In neonatal rat cardiomyocytes, 
experimental studies have shown that reoxygenation with acidic buffer is 
cardioprotective, an effect that may be mediated by the inhibition of mPTP 
opening (Bond et al., 1991).   
 
Alternative strategies such as administration of Na+-H+ exchanger inhibitors have 
been shown to be cardioprotecive before ischaemia whereas administration 
specifically at reperfusion has not shown a consistent cardioprotective effect with 
some studies showing benefit (Satoh and Kitada, 2004; Gumina et al., 1998) and 
others not (Klein et al., 1995). The failure of Na+-H+ exchanger inhibitors to 
reduce infarct size when administered at reperfusion may be related to the 
contribution of other mechanisms to reperfusion injury such as Ca2+ overload.  
 
1.3.4. Mitochondrial permeability transition pore (mPTP)  
 
Mitochondria are known for being the powerhouse of cells, generating ATP 
through oxidative phosphorylation. However in mammalian mitochondria it has 
been increasingly acknowledged that a latent non-specific pore within the inner 
mitochondrial membrane, known as the mPTP, plays a pivotal role in cell death 
during reperfusion. It was originally discovered back in the 1970s (Haworth and 
Hunter, 1979) however its critical involvement in myocardial I/R injury was 
revealed a decade later (Crompton et al., 1987). In studies using isolated cardiac 
myocytes (Nazareth et al., 1991b; Leyssens et al., 1996) and Langendorf perfused 
hearts (Griffiths and Halestrap, 1993; Griffiths and Halestrap, 1993) it was 
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demonstrated that mPTP opening occurs during reperfusion, and that preventing 
this opening provides protection against I/R injury. These pioneering studies 
were slow to be appreciated however and it is only in recent years that data has 
accumulated from many different laboratories confirming the central role of 
mPTP opening in reperfusion injury and its importance as a pharmacological 
target for cardioprotection (Weiss et al., 2003; Halestrap, 2009; Perrelli et al., 
2011). 
 
Despite extensive studies, the identity of the pore-forming proteins of the mPTP 
are still debated. Until recently, three molecules were accepted as key structural 
components of the mPTP, including adenine nucleotide translocase (ANT) in the 
inner membrane, cyclophilin D (Cyp-D) in the matrix, and the voltage dependent 
anion channel (VDAC), also known as porin in the outer membrane. However it 
appears that some of these components (VDAC and ANT) are in part dispensable 
(Baines, 2010) with CypD being the only essential regulator of pore opening, and 
the only genetically proven indispensable mPTP component with CypD knockout 
mice shown to be protected from I/R injury (Baines et al., 2005; Baines et al., 
2007).   
 
Under physiological conditions the mPTP remains closed and due to inhibition by 
cellular acidosis the pore remains quiescent during ischaemia (Griffiths and 
Halestrap, 1995). The pore is sensitive to a number of stimuli; alterations in Ca2+ 
concentration, generation of ROS, restoration of physiological pH and the 
presence of inorganic phosphate (Lapidus and Sokolove, 1994), conditions, all of 
which are created within a few moments of reperfusion. Opening of the pore 
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results in it becoming freely permeable to solutes of up to 1.5 kDa including 
protons (Massari and Azzone, 1972; Haworth and Hunter, 1979) (Figure 1.5). The 
crossing of protons results in a rapid dissipation of the electrical gradient across 
the membrane, uncoupling of oxidative phosphorylation (failure of ATP 
generation) and reversal of the ATP synthesis machinery catalyzing the 
hydrolysis of ATP produced by glycolysis, resulting in a rapid decline in cellular 
ATP concentration (Halestrap et al., 2004). If the pore remains open, this leads to 
cell death by necrosis. At the same time, as proteins are unable to cross the 
membrane, an osmotic gradient is generated causing the mitochondria to swell, 
rupturing the outer mitochondrial membrane and releasing cytochrome C 
(Zoratti and Szabo, 1995). Cytochrome C then associates with apoptosis inducing 
factor and caspase-9, which induces caspase-3 release and apoptosis. The pro-
apoptotic members of the Bcl-2 (B-cell lymphoma-2) family are also up-regulated 
and contribute to apoptotic cell death in this setting (Gustafsson and Gottlieb, 
2003).  
 
Importantly, the mPTP remains closed during myocardial ischaemia and opens 
only during the first few minutes of reperfusion (Griffiths and Halestrap, 1995) 
making it an ideal target for therapeutic manipulation in the setting of AMI. In 
accordance with mPTP opening in the early minutes of reperfusion 
cardioprotecion from I/R injury using mPTP inhibitors cyclosporine A, NIM811 
or sanglifehrin A given at reperfusion have been reported both in vitro and in 
vivo (Griffiths and Halestrap, 1993; Griffiths and Halestrap, 1995; Hausenloy et al 
2003) and by inhalational anaesthetics that inhibit pore opening (Ge et al., 2010). 
Furthermore, mice lacking cyp-D have been reported to sustain smaller 
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myocardial infarcts than control animals (Baines et al., 2005). Additionally the 
pharmacological inhibition of the mPTP in human atrial trabeculae subjected to 
simulated I/R injury also exhibit cardioprotection (Shanmuganathan et al., 2005). 
This inhibition of mPTP opening is believed to partly underlie the mechanism of 
several proposed cardioprotective mechanical “conditioning” interventions 
including ischaemic pre-conditioning and postconditioning (Hausenloy et al., 
2004) (Argaud et al., 2005).  
 
Figure 1.5. Proposed Molecular Mechanism of the mitochondrial permeability transition 
pore (mPTP).  
VDAC= voltage dependent anion channel, ANT= adenine nucleotide translocase, Cyp-D= 
cyclophilin D.   
 
1.3.4. Inflammation 
 
Inflammation is an important contributor to the pathophysiology of myocardial 
I/R injury and hypotheses pertaining to pathological mechanisms are an evolving 
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area of intense research and debate. The classic inflammatory response to acute 
ischaemia is predominantly an innate immune response (Entman and Smith, 
1994). Polymorphonuclear cells have been shown to be the major leukocytes 
found in necrotic tissue following ischaemic injury with neutrophils the early 
cellular mediators of local microvascular changes and parenchymal damage 
(Engler et al., 1986a; Engler et al., 1986b; Vinten-Johansen, 2004). Monocytes and 
macrophages infiltrate later and extend the early injury phase (Ysebaert et al., 
2000). The complement system is also activated and contributes to tissue 
destruction (Hill and Ward, 1971; Vakeva et al., 1994).  
 
More recently a role for an adaptive immune response has also been implicated 
in the pathogenesis of I/R injury with recent data suggesting that lymphocytes 
have a significant role in the response to I/R injury in a variety of organ systems 
(Linfert et al., 2009). Lymphocyte-related cytokines are upregulated in the post-
ischaemic heart, (Herskowitz et al., 1995; Squadrito et al., 1999) and leukocyte 
adhesion molecules and chemokines, such as P-selectin glycoprotein ligand-1, 
CD11/CD18, intercellular adhesion molecule-1 (ICAM-1), and monocyte 
chemoattractant protein-1 (MCP-1), mediate experimental myocardial I/R injury 
(Entman et al 1992; Herskowitz et al., 1995; Birdsall et al., 1997) and lymphocyte 
adhesion, migration, and signaling (Loetscher et al 1996; Siveke and Hamann, 
1998). 
 
The initiating stimulus activating the immune system is the myocardial damage 
(Taqueti et al., 2006). Shortly after ischaemia as a consequence of cell necrosis 
and apoptosis, the damaged tissue exposes ligands (e.g. non-myosin heavy chain 
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type IIA and C) that are recognised by components of the innate immune system 
and leads to its activation (Zhang et al., 2004). After the restoration of coronary 
blood flow, the activation of complement, release of cytokines and secretion of 
ROS from endothelial cells promote the infiltration of neutrophils into the 
myocardium. Complement fragments (e.g. C5a) (Ivey et al., 1995) and cytokines 
(Tumour necrosis factor-α (TNF-α) (Richter et al., 1990), Interleukin (IL)-1, 6 and 
8 (Kukielka et al., 1995; Smith et al., 2006), platelet activating factor (PAF) 
(Montrucchio et al., 1993), CXCL-1 (also known as KC) (Miura et al., 2001; 
Tarzami et al., 2003; Mersmann et al., 2010), CXCL-2 (also known as macrophage 
inflammatory protein-2 (MIP-2) (Chandrasekar et al., 2001; Tarzami et al., 2003) 
and CXCL-5 (Chandrasekar et al., 2001)) act as activating or chemoattractant 
factors that stimulate neutrophils to accumulate within the ischaemic-reperfused 
myocardium (Vinten-Johansen, 2004).  Cytokine generation in the myocardium is 
regulated at the transcriptional level by NF-κB, which is activated by cytokines 
themselves or by ROS (Chandrasekar and Freeman, 1997; Fan et al., 2002) 
(Figure 1.6).  
 
Animal models show that neutrophil accumulation in the reperfused area at risk 
is most rapid during the first hour with landmark data (Zhao et al., 2000a) 
demonstrating an abundance of neutrophils accumulating in the myocardium, 
localized in the intravascular space during the first six hours of reperfusion, 
followed thereafter by a shift into the parenchyma as they migrate 
transendothelially over the ensuing 24 hours. This process is facilitated by up-
regulated cell-adhesion molecules P-selectin (Davenpeck et al., 1994), 
CD18/CD11 (Entman et al., 1990), and ICAM-1 (Kukielka et al., 1993; Youker et 
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al., 1994), which aid the migration of neutrophils into the myocardial tissue. The 
upregulation of ICAM-1 on cardiomyocytes is stimulated by cytokine release, and 
activated neutrophils adhere to cytokine (IL-1, IL-6, TNFα) stimulated 
cardiomyocytes by a CD11b/CD18-ICAM-1 dependent mechanism (Entman et al., 
1990). 
 
Neutrophils can contribute to the cell death in ischaemic-reperfused myocardium 
directly or indirectly by a number of mechanisms: (1) the release of ROS during 
the early interactions with the coronary endothelium which precedes significant 
transendothelial migration (Albertine et al., 1994); (2) the release of proteases 
such as elastase and collagenase (Weiss, 1989); (3) embolization in microvessels 
leading to no-reflow and secondary ischaemia (Mehta et al., 1988; Siminiak et al., 
1995); (4) damage to the coronary vascular endothelium and upregulation of 
adhesion molecules implicated in amplification of neutrophil adhesion and 
emigration (Jordan et al., 1999); (5) release of lipoxygenase products such as 
leukotriene B4 (LTB4) which acts synergistically with thromboxane A2 causing 
intense vasoconstriction (Nichols et al., 1988) and also acts as a potent 
chemoattractant (Perlman et al., 1989); 6) promotion of the interaction with 
platelets that may further potentiate ischaemia–reperfusion injury (Alloatti et al., 
1992); (7) extension of infarct size and the degree of apoptosis during later 
phases of reperfusion (Zhao et al., 2001; Zhao et al., 2000b). 
 
The wave of neutrophil infiltration is followed by the mobilization and 
recruitment of monocytes. Recent studies have shed light on the mechanisms by  
which monocytes are recruited to the heart and the life cycle of the recruited 
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monocytes in the setting of AMI. These studies have suggested that Ly-6Chi 
(mouse equivalent of human inflammatory ‘CD14hiCD16-‘ monocytes), and Ly-
6Clo (mouse equivalent of human resident ‘CD14loCD16+‘ monocytes) monocytes 
have pathogenic and protective roles, respectively, in cardiac remodeling and 
preservation of heart function (Nahrendorf et al., 2007) (Leuschner et al., 2012). 
 
Figure 1.6. Temporal events of the inflammatory response following myocardial infarction  
The inflammatory response following reperfusion therapy for myocardial infarction is 
characterized by the sequential infiltration of the injured myocardium with neutrophils, 
monocytes and lymphocytes. This is a dynamic process: recruitment or proliferation of each cell 
type is followed by activation. Various cell populations have distinct but overlapping functions.  
 
After migration of monocytes into the myocardial tissue, they become active 
macrophages, releasing a variety of inflammatory substances, cytokines, and 
growth factors (Wan et al., 1997). Mast cells are also actively implicated in the 
post-MI inflammatory response and cardiac remodeling as they are stimulated by 
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the complement 5a (C5a)-adenosine-reactive oxygen complex, a necessary 
element for the development of the myocardial stunning process, part of I/R 
injury. In fact, by degradation, they may release vascular endothelium growing 
factors, fibroblast growing factors, and histamine, all promoting elements of 
myocardial fibrosis (Serini and Gabbiani, 1999; Kereiakes 2003). 
 
It had been felt that that adaptive immune system played little role in the 
inflammatory contribution to I/R injury however recent studies have suggested a 
key involvement for lymphocytes in reperfusion injury. T lymphocytes have been 
demonstrated to be pathogenic during myocardial I/R injury. Yang et al (Yang et 
al., 2006b) evaluated myocardial infarct size in wild type control and RAG1 
knockout (KO) mice (RAG1 plays an important role in VDJ recombinase, a 
complex of enzymes that work to join gene segments of B and T cell receptor 
genes, therefore RAG1 KO mice contain no mature B and T lymphocytes 
(Mombaerts et al., 1992) following 45 minutes of left anterior descending (LAD) 
coronary artery occlusion. RAG1 KO mice had significantly smaller infarct sizes 
compared to that of control mice.  After reconstitution of RAG1 KO mice by 
adoptive transfer with CD4+ T cells, the infarct size of the reconstituted RAG1 KO 
mice was significantly greater than that of the RAG 1 KO. They also examined T-
cell depletion and its effect on myocardial infarct size. CD4+ depleted mice, but 
not CD8+ depleted mice had a significantly decreased infarct size compared to 
control mice again implicating CD4+ T cells in a deleterious role in I/R injury 
(Yang et al., 2006b). Further support for CD4+ T cells comes from data 
demonstrating a cardioprotective effect of interleukin-10, a cytokine that 
suppresses interferon-γ secreting CD4+ T cell levels 4 days after AMI in a mouse 
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model (Burchfield et al., 2008). Little data exists assessing the T cell contribution 
to I/R injury in humans however a recent study looking at circulating T cell 
populations following primary PCI for STEMI identified a depletion of 
CCR7+/CD4+ T cells from peripheral blood during the first 30 min of reperfusion 
following primary PCI (Hoffmann et al., 2012). CCR7 has been identified as a key 
regulator of T-cell trafficking to secondary lymphoid organs and can also be 
involved in the abnormal recruitment of T cells from the peripheral blood to sites 
of acute inflammation (Forster et al., 2008). Therefore, it is conceivable that T 
cells could be migrating to infarcted myocardium via a CCR7 dependent 
mechanism. Although it should be noted that despite the ‘disappearence’ of T-
cells from the peripheral blood it cannot be concluded that the remaining cells 
have entered the myocardium (Hoffmann et al., 2012).  
 
Increasing evidence is emerging suggesting a role for systemic B cells in the 
immune responses leading to tissue damage after AMI (Chen et al., 2009; 
Zouggari et al., 2013). A recent study using mouse models demonstrated that 
after AMI (in vivo ligation of the left coronary artery) in mice, mature B 
lymphocytes selectively produce Ccl7 and induce Ly6Chi monocyte mobilization 
and recruitment to the heart, leading to enhanced tissue injury and deterioration 
of myocardial function (Zouggari et al., 2013). Reversing this effect using either 
models of Baff receptor deficiency (Baff signaling/receptor is required for the 
maintenance of mature B lymphocytes) or antibodies against CD20- or Baff 
resulting in depletion of mature B lymphocytes impeded Ccl7 production and 
monocyte mobilization, limited myocardial injury and improved heart function. 
These effects were also recapitulated in mice with B cell–selective Ccl7 deficiency. 
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In separate experiments it has been shown that high circulating concentrations of 
Ccl7 and Baff in patients with AMI predict increased risk of death or recurrent 
myocardial infarction (Zouggari et al., 2013). This suggests an interaction 
between mature B lymphocytes and monocytes after AMI that contributes 
significantly to I/R injury.  Further study is required to assess the exact 
contribution of both B and T lymphocytes in I/R injury.  
 
Various approaches have been used to inhibit the inflammatory component of I/R 
injury, ranging from strategies that specifically target the cellular components of 
inflammation by physically or chemically removing neutrophils from the 
systemic or coronary circulation, and systemic anti-inflammatory agents. These 
studies have shown reductions in infarct size of up to 50%. Specific interventions 
targeting cellular recruitment include leukocyte depleted blood (Litt et al., 1989); 
antibodies against the cell-adhesion molecules P-selectin (Hayward et al., 1999), 
CD11 and CD18 (Ma et al., 1991) and ICAM-1 (Zhao et al., 1997) and 
pharmacologic inhibitors of complement activation (Vakeva et al., 1998). 
However, despite these promising results a number of experimental studies have 
also reported a lack of reduction of infarct size with systemic anti-inflammatory 
therapy (e.g. using non-steroidal anti-inflammatory drugs such as ibuprofen or 
indomethacin) in animal models (Allan et al., 1985; Reimer et al., 1985). In the 
study by Reimer et al, (Reimer et al., 1985) in a canine model with 3 hours of 
coronary artery occlusion followed by 3 days of reperfusion ibuprofen treatment 
did not reduce infarct size. Anti-inflammatory effects have been proposed to 
underlie the benefical effects of adenosine in mice following its administration 
with experiments using intravenous, intra-coronary or topical administration 
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yielding positive results (Kaminski and Proctor, 1989; Babbitt et al., 1989). 
However using the intravenous approach adenosine has also been shown to be 
ineffective in a separate study, with the short half-life being proposed to be 
responsible for this lack of effect (Vander Heide and Reimer, 1996). 
 
Based on these promising pre-clinical results several agents have been proposed 
as potential therapies for translation into human subjects including adenosine 
however caution is warranted. The ‘prototype’ infarct size reduction study tested 
high-dose methylprednisolone (eight 30-mg/kg doses every 6 hours) as an anti-
inflammatory treatment in patients with AMI (Roberts et al., 1976), this showed 
an augmentation of infarct size (measured enzymatically), accentuation of 
malignant arrhythmias and in some cases ventricular aneurysm formation and 
rupture. This trial highlighted the double-edged sword of anti-inflammatory 
therapy, in that long-term treatment can attenuate the healing process as well as 
the acute inflammatory response in post-myocardial infarction. Studies assessing 
steroid therapy in AMI have subsequently not shown such damaging effects but 
have also not shown benefit (Heikkila and Nieminen, 1978; Madias and Hood, 
1982). Many other studies aimed at reducing the inflammatory response post 
AMI have also been negative, either with therapies aimed at specific targets; 
antibodies against CD18 (Baran et al., 2001b; Faxon et al., 2002), antibodies 
against P-selectin (Alfonso and Angiolillo, 2013), Anti-C5 antibody (pexelizumab) 
(Mahaffey et al 2003; Armstrong et al., 2007) or systemic therapies; NSAIDS 
(Gibson et al., 2009), or either intravenous or intracoronary adenosine (Ross et 
al., 2005; Desmet et al., 2011).    
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In concert, these mechanisms produce irreversible damage to cardiomyocytes 
that are severely ischaemic but still salvageable at the time of reperfusion. 
Consequently, these pathways have been the therapeutic targets in experimental 
and clinical studies. Importantly, these interventions do seem to translate better 
than the pharmacological interventions with recent trials of both remote 
conditioning (Botker et al., 2010; Sloth et al., 2014) and post conditioning (Thuny 
et al., 2012) demonstrating benefits. Additional endogenous pathways, which 
may be potentially cardioprotective, have also been identified which are 
discussed below.  
 
1.3.6 Survival Kinase pathways  
 
The reperfusion injury salvage kinases (RISK) are a group of proteins that are 
activated during myocardial reperfusion, conferring cardioprotection (Hausenloy 
and Yellon, 2004). They emerged as a concept in the late 1990s with the 
recognition that apoptotic cell death contributed to lethal reperfusion injury 
(Gottlieb et al., 1994; Freude et al., 2000), and the knowledge that certain pro-
survival anti-apoptotic protein kinases, such as Akt and extraregulated kinase 1 
and 2 (Erk1/2) existed, which when specifically activated at the time of 
myocardial reperfusion conferred powerful cardioprotection (Yellon and Baxter, 
1999; Hausenloy and Yellon, 2004). Subsequent study has further identified this 
pathway and it is now known to include other cardioprotective reperfusion 
salvage kinases such as protein kinase C (PKC) (primarily the PKC-e isoform) 
(Wolfrum et al., 2002), protein kinase G (PKG) (Han et al., 2001), p70s6K (Tsang 
et al., 2004), and glycogen synthase kinase-3beta (GSK-3b) (Tong et al., 2002). 
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There is extensive preclinical evidence that activation of the RISK pathway by 
either pharmacological agents such as atorvastatin (Bell and Yellon, 2003), 
erythropoietin (Bullard et al., 2005), and atrial natriuretic peptide (ANP) (Yang et 
al., 2006a) or by mechanical interventions such as postconditioning (Hausenloy 
et al., 2005) reduces myocardial infarct size by up to 50%. It is believed that 
activation of the RISK pathway confers cardioprotection by blocking calcium 
overload (Abdallah et al., 2006), upregulating anti-apoptotic pathways (Yellon 
and Baxter, 1999) and via inhibition of mPTP opening (Davidson et al., 2006), 
mechanisms all suggesting that the different proposed mechanisms involved in 
cardioprotection are interconnected, sharing common final pathways.  
 
However the RISK pathway is not critical to all cardioprotective agents. TNF-α 
has been shown to mimic postconditioning in isolated murine hearts in the 
absence of Akt activation, with its protective effect unaffected by the PI3K 
inhibitor, Wortmannin (Lacerda et al., 2009). Similarily ischaemic 
postconditioning in pigs in vivo (Skyschally et al., 2009) has also been shown to 
be independent of RISK activation. Taken together, these data support the 
existence of an alternative pro-survival signal transduction pathway for 
protecting the ischaemic myocardium against lethal myocardial I/R injury. 
Mechanistic studies have demonstrated that TNF-α initiates the activation of a 
novel and alternative protective path which has been termed the Survivor 
Activating Factor Enhancement (SAFE) pathway (Lecour, 2009) which involves 
the activation of Janus kinase (JAK), signal transducer and activator of 
transcription 3 (STAT-3), rather than the RISK pathway (Lecour et al., 2005; 
Suleman et al., 2008). Further work is needed to elucidate the relationship 
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between these two signaling pathways with studies ongoing to investigate the 
interplay between the pathways. It has been suggested that both the RISK and 
SAFE pathways seem to converge on the mitochondria and the mPTP, which is 
believed to be the target or end effector for the protection (Heusch et al., 2008). 
 
1.4 Clinical translation of cardioprotective strategies  
 
Whereas many strategies have been shown to be effective in reducing I/R injury 
in pre-clinical models, the translation of these approaches into the clinical setting 
has been disappointing (Yellon and Hausenloy, 2007). Most strategies have 
attempted to address individual mechanisms underlying I/R injury such as ROS 
or inflammation. Examples of this include the targeting of ROS with free-radical 
scavengers or anti-oxidants (Flaherty et al., 1994; EMIP-FR Group, 2000), trials of 
inhibition of the Na+-H+ exchanger (Zeymer et al., 2001), and measures aimed at 
reducing inflammatory damage induced by neutrophils (Baran et al., 2001a; 
Mertens et al., 2006), all of which have been unsuccessful. Additionally clinical 
studies targeting the generalised inflammatory components of myocardial I/R 
injury with anti-inflammatory agents such as adenosine have failed to 
demonstrate any impact on clinical outcomes in reperfused-STEMI patients (Ross 
et al., 2005; Armstrong et al., 2007). Trials targeting metabolic function such as 
glucose-insulin-potassium infusions (Mehta et al., 2005) or magnesium therapy 
(Woods et al 1992; ISIS-4 Study Group, 1995) also have generated inconclusive 
results. The reasons for the failure in translation are multiple but key factors are 
thought to include:-  
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1) Several of the failed interventions, including anti-oxidants, calcium-channel 
antagonists, adenosine, and erythropoietin had not shown conclusive 
cardioprotection in the pre-clinical animal studies, which may in part explain why 
they failed in the clinical setting 
 
2) Many of the study interventions were designed to target only one component 
of myocardial I/R injury such as ROS, calcium channel accumulation, apoptosis, 
and inflammation and not effect either all pathways or a final common one such 
as the mPTP. 
 
3) The design of the clinical cardioprotection study: it is essential that the design 
of the clinical study take into consideration the findings of previously published 
pre-clinical and clinical studies. This includes factors such as dose, mode of 
delivery and measurement of effect. 
 
Recently, improved understanding of the pathophysiological mechanisms 
underlying I/R injury such as identification of the mPTP have resulted in the 
design of therapies no longer directed at individual pathways. This coupled with 
excellent pre-clinical evidence and improved trial design has resulted in the 
identification of several promising mechanical (ischaemic post-conditioning 
(Staat et al., 2005) and remote ischaemic pre-conditioning (Botker et al., 2010) 
(Sloth et al., 2014), and pharmacological (cyclosporine (Piot et al., 2008), 
exenatide (Lonborg et al., 2012b)) therapeutic strategies, for preventing 
myocardial I/R injury.  
 61 
1.4.1 Mechanical Therapies 
 
In 2003, Zhao and coworkers demonstrated that short periods of ischaemia and 
reperfusion applied immediately after the reopening of an occluded LAD could 
reduce I/R injury and infarct size in open chest anaesthetized dogs, a concept 
referred to as ischaemic postconditioning (Zhao et al., 2003). In animal studies, 
ischaemic postconditioning involves all major contributors to reperfusion injury 
including the RISK pathway and the mPTP. This therapeutic approach was 
rapidly translated into the clinical setting of primary PCI in 2005 (Staat et al., 
2005) where the cumulative creatine kinase (CK) release measured over 72 
hours following reperfusion was reduced by a protocol of four cycles of 1 min 
angioplasty balloon inflation followed by 1 min deflation after reopening of the 
infarct related artery. The cumulative 72-hour CK release vs. the area at risk, as 
determined using ventriculography before reperfusion from the abnormally 
contracting myocardium, was also reduced. However the results of studies 
performed since have been inconsistent, with debate ongoing as to the 
effectiveness of this therapy (Freixa et al., 2012; Hahn et al., 2013). 
 
Remote Ischaemic conditioning: The phenomenon of remote ischaemic 
conditioning (RIC) allows the therapeutic intervention (transient episodes of 
ischaemia and reperfusion) to be applied to an organ or tissue distant from the 
heart, thereby facilitating its clinical application. In 1993, it was first 
demonstrated in a canine model that applying four 5-minute cycles of occlusion 
and reflow to the circumflex coronary artery could reduce infarct size generated 
by a sustained occlusion in the LAD (Przyklenk et al., 1993) This study 
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demonstrated for the first time that cardioprotection could be transferred from 
one region of the heart to another. This concept was quickly extended beyond the 
heart with the demonstration that the myocardium could be protected against MI 
by applying the preconditioning stimulus to either the kidney or intestine (Gho et 
al., 1996), confirming that the heart could be protected at a distance.   
 
Two independent clinical studies have been performed investigating the effect of 
RIC in STEMI patients undergoing primary PCI. In the 1st study (Rentoukas et al., 
2010), 96 STEMI patients were randomised at the hospital to receive control, RIC 
(3 cycles of blood pressure cuff placed on the upper limb to 20 mm Hg above 
systolic arterial pressure for 4 min and deflating the cuff for 4 minutes), or RIC + 
morphine (5 mg intravenous infusion initiated 5 minutes before reperfusion). In 
those STEMI patients who received RIC alone, there was a non-significant trend 
to benefit when compared to control patients. In the 2nd larger study (Botker et 
al., 2010) STEMI patients were randomised in the ambulance to receive control (a 
deflated cuff placed on the upper arm for 40 minutes) or RIC (four 5-minute 
inflations to 200 mmHg and deflations to 0 mmHg of upper arm cuff). Patients 
were randomised in the ambulance prior to coronary angiography and the 
primary endpoint was myocardial salvage index at 30 days post primary PCI. 
Although 333 patients were randomised, only 142 patients were analysed for the 
primary endpoint of myocardial salvage index as others were unsuitable. Those 
patients randomised to RIC had a greater myocardial salvage index when 
compared to control (0.75 vs. 0.55, p=0.0333), although there was no significant 
difference in final infarct size at 30 days (4% vs. 7% of LV, p=0.1). However, in 
those patients with greater AAR (LAD infarcts and complete occlusion in the 
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infarct-related coronary artery (TIMI 0 flow)) there was a greater reduction in 
final infarct size at 30 days in those patient treated with RIC when compared to 
control (8% vs. 16% of LV with LAD STEMI, p=0.01 and 9% vs. 13% of LV with 
TIMI 0, p=0.06), despite there being little difference in the myocardial salvage 
index. However, it is important to note there were no significant differences in 
secondary outcomes including peak troponin T, ST-segment resolution and LVEF 
at 30 days (Botker et al., 2010). The mechanisms underlying RIC cardioprotection 
remain unclear but have been attributed to neurohormonal pathways conveying 
the cardioprotective signal from the limb to the heart (Hausenloy and Yellon, 
2008) 
 
1.4.2 Pharmacological Therapies 
 
The first pharmacological agent to show promise in translating into patients 
undergoing primary PCI for STEMI was cyclosporine. The rationale behind its use 
is that cyclosporine is a potent inhibitor of mPTP opening (Nazareth et al., 
1991a). This inhibition of opening is via its binding to the cyc-D located in the 
mitochondrial matrix (Woodfield et al., 1998). In a proof of concept trial 
cyclosporine, was injected intravenously at a dose of 2.5mg/kg in 58 patients (28 
placebo, 30 cyclosporine) before primary PCI for AMI, and was shown to 
significantly reduce infarct size as assessed by CK profile over 72 hours. No 
difference was seen in the troponin T profile over the same time-period. In 
addition, in a sub-group of 27 patients it was demonstrated, by CMR imaging 5 
days post-primary PCI, that cyclosporine treatment was associated with a 
reduced area of hyper-enhancement (infarcted tissue) (Piot et al., 2008). An 
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additional follow-up sub-study of the patients who underwent CMR showed a 
persistent reduction in infarct size at 6 months in the cyclosporine group 
compared with the control group of patients (29 ± 15 g vs. 38 ± 14 g; p = 0.04). 
There was also a significant reduction of LV end-systolic volume (and a trend for 
LV end-diastolic volume; p = 0.07) in the cyclosporine group compared with the 
control group, both at 5 days and 6 months after infarction (Mewton et al., 2010).   
  
The other promising pharmacological therapy is exenatide, a synthetic analogue 
of exendin-4, also known as “lizard spit” which is found in the salivary secretions 
of the Gila monster, Heloderma suspectum. Importantly this 39-residue reptilian 
peptide is pharmacologically similar to mammalian glucagon-like peptide (GLP)-
1 (Treiman et al., 2010). Receptors for GLP-1 have been found in the heart and in 
rat (Sonne et al., 2008) and pig (Timmers et al., 2009), GLP-1 or its analogues 
protect against reperfusion injury-induced cell death in these species. This has 
subsequently been shown in 2 studies to have a cardioprotective effect in clinical 
studies of patients undergoing primary PCI for STEMI. Lønborg and co-workers 
showed that a 6-hour continuous exenatide infusion (at a rate of 26 mL/h (0.043 
μg/min), to achieve a plasma concentration of 0.03 and 0.3 nmol/L) during 
reperfusion therapy in patients presenting with STEMI resulted in an 
improvement in myocardial salvage in a group of 105 patients with reduction of 
infarct size in a subgroup with short systemic delay (≤132 minutes) (Lonborg et 
al., 2012b). More recently a smaller study (Woo et al., 2013) assessing 58 patients 
with STEMI who received either exenatide (10 μg subcutaneous and 10 μg 
intravenous bolus 5 minutes before reperfusion with further 10 μg twice daily 
doses for 2 days) or placebo (received an equivalent volume of normal saline 
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with the same treatment regimen) showed a reduction in infarct size (assessed 
by CK-MB and troponin I) in the exenatide group compared to placebo. There was 
also a significant reduction in CMR assessed infarct size in the exenatide group 
(12.8±11.7 versus 26.4±11.6 g; P<0.01). However, patients with left ventricular 
systolic dysfunction were excluded from the study and the use of exenatide was 
associated with significantly higher rates of nausea (56%), vomiting (33%) and 
loss of appetite (28%) with 1 patient experiencing symptomatic hypoglycemia 
requiring glucose infusion to complete the study (Woo et al., 2013).  
 
Despite the potential of these promising strategies limitations exist either with 
regard to route of administration, potential side-effects and complications and 
inconsistent results in clinical trials.  The intravenous route of administration 
utilized with exenatide/cyclosporine will possibly result in a delay in reperfusion. 
In trials of both agents the intervention was administered following confirmation 
of TIMI flow ≤1. Additionally the intra-venous administration may result in 
greater side-effects due to systemic drug delivery. For example with exenatide 
(Woo et al., 2013) higher rates of adverse effects in the exenatide group have 
been shown compared to control (although this did not result in subject 
withdrawal).  Similarly mechanical therapies come with additional risks such as 
ischaemic postconditioning where consecutive occlusions using a balloon 
catheter after the opening of the culprit vessel carries a potential risk of 
damaging the vessel or inducing peripheral embolization, similar risks exist with 
RIC if performed locally in a non-culprit coronary vessel. For both mechanical 
therapies currently clinical benefit is debated with inconclusive results in current 
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attempts at translation with large studies ongoing assessing the effectiveness of 
both techniques.  
 
 A new potential solution to the problem of I/R injury may exist in the form of 
inorganic nitrite (NO2-). Over the last decade evidence has accumulated 
supporting the view that nitrite, which is abundant in blood and tissues (Bryan et 
al., 2005; Webb et al., 2008; Li et al., 2008; Feelisch et al., 2008), represents a 
significant stable intravascular endocrine reservoir and tissue storage form of NO 
that exerts a number of beneficial effects (Lundberg JO and Weitzberg E, 2008). 
Importantly, a deficit of bioavailable NO contributes to the pathological events 
associated with both I/R injury and the long-term outcomes post-PCI. Therefore 
strategies that might improve NO delivery during PCI and post PCI may offer 
therapeutic benefit and this might be provided in the form of inorganic nitrite.  
 
1.5 NO and the cardiovascular system 
 
1.5.1 Discovery 
 
Since its discovery 25 years ago, NO has emerged as an important signaling 
molecule in a myriad of pathways, involving the nervous, immune, and most 
relevant to this thesis, the cardiovascular system.  NO was initially discovered in 
an attempt to reconcile the apparent conflict in the actions of acetylcholine (ACh) 
in vivo and in vitro. Although ACh is normally a potent vasodilator in vivo, it was 
often found to have little vasorelaxant effect in isolated vessel preparations. 
However it was Furchgott and Zawadzki in 1980, who discovered that during 
 67 
preparations of vessels for in vitro studies, accidental denuding of the endothelial 
layer caused loss of responsiveness to ACh, yielding the conflicting results 
(Furchgott and Zawadzki, 1980). In this paper Furchgott and Zawadzki suggested 
that the endothelial cells were releasing a substance that was crucial for the ACh-
induced vasodilation. The term endothelial-derived relaxation factor (EDRF) was 
used to describe this unknown entity (Furchgott and Zawadzki, 1980). 
Eventually, NO was identified as the EDRF responsible for mediating vasodilation 
in response to ACh (Palmer et al., 1987). Upon its synthesis, endothelial NO was 
shown to be a potent stimulator of soluble guanylate cyclase (sGC) to form cyclic 
guanylate monophosphate (cGMP) and cause relaxation of vascular smooth 
muscle cells (VSMC) (Arnold et al 1977; Ignarro et al., 1981). These investigations 
into the role of NO as a signaling molecule in the cardiovascular system earned 
Drs Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad a Nobel Prize in 
Physiology and Medicine in 1998 (Furchgott, 1993; Ignarro et al., 1999).  
 
1.5.2 Conventional pathway of NO generation 
 
Under normal conditions, within the cardiovascular system, basal endogenously 
generated NO, produced from the amino acid L-arginine by a family of enzymes 
known as NOSs, plays an essential role in maintaining homeostasis and, of 
particular relevance to this thesis, in sustaining normal healthy cardiac function, 
perfusion and cardioprotection (Bredt, 2003; Mount et al., 2007).  There are three 
isoforms of NOS that have been characterized; the endothelial isoform (eNOS, 
also known as NOSIII), the neuronal isoform (nNOS, also known as NOSII) and the 
inducible isoform (iNOS, or NOSI)(Bredt and Snyder, 1990; Stuehr, 1999). It is 
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eNOS however, that is of particular importance for cardiovascular physiology and 
pathophysiology as it maintains basal vascular NO production that exerts a range 
of beneficial effects (anti-platelet, anti-inflammatory, vasodilatation) that sustain 
cardiovascular health (Moncada and Higgs, 1993). eNOS is constitutively 
expressed and regulated by calcium, calmodulin and by post-translational 
modification (Michel et al., 1997).  
 
The NO synthases catalyze the five-electron oxidation of L-arginine to NO and L-
citrulline using NADPH as the electron source (Figure 1.7). This reaction is 
dependent on oxygen and the enzymes require several co-factors for proper 
function, including BH4, nicotinamide-adenine-dinucleotide phosphate (NADPH), 
flavin adenine dinucleotide, and flavin mononucleotide (Moncada and Higgs, 
1993) (Figure 1.7) Therefore, NO synthesis is significantly influenced by the 
presence of these co-factors, as well as substrate and oxygen availability (Michel 
and Feron, 1997).  
 
NO is a free radical with a biological half-life in the millisecond range (Borland, 
1991; Liu et al., 1998). This short half-life makes its detection in vivo difficult and 
therefore the end products of NO reaction pathways are usually measured to 
quantify NO production and metabolism.  As with many substances NO has a very 
rapid metabolism pathway. The predominant pathway is through a reaction first 
described nearly 150 years ago in 1865 by Hermann (as cited by Gladwin et al 
2005) where binding with oxyhaemoglobin (oxyHb) generates methaemoglobin 
(metHb) and nitrate (NO₃⁻) (Equation 1.1).  
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Equation 1.1. Oxidative termination of NO activity with Hb (Hb=haemoglobin, NO= nitric 
oxide) 
 
This incredibly fast and rapid reaction (6-8 x 107 M-1 s-1) represents the major 
pathway for the destruction of NO (Feelisch and Noack, 1987; Herold et al., 2001).  
 
Additionally NO rapidly reacts with species that possess unpaired electrons (e-) 
such as O2, which is the main oxidative mechanism to form nitrate in aqueous 
solutions and radicals such as O2. In pure aqueous solutions, this oxidation of NO 
occurs slowly and the primary product is nitrite (Ignarro et al., 1993), however, 
with the addition of oxyhaemoproteins, such as oxyHb, then the predominant 
product is NO3- (Ignarro et al., 1993) and thus nitrate is the predominant 
oxidative metabolite of NO in biological systems. 
 
NO reacts with a variety of metals to form nitrosyl complexes, most commonly 
with iron (Fe) but also copper (Cu) (Fukuto et al., 2000). One classic Fe nitrosyl 
reaction that occurs is the activation of haem containing protein sGc. Other 
haem‐containing proteins that have important interactions with NO, include 
cytochrome P450 and Hb itself (Fukuto et al., 2000).  
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Figure 1.7. Coupled Dimeric eNOS and co-factors.  
Diagrammatic representation of the domains and cofactors required for coupled eNOS synthesis 
of NO. (CAM=calmodulin; eNOS= endothelial  nitric  oxide  synthase;  FAD=flavin  adenine  
dinucleotide;  Fe=iron;  FMN=flavin  mononucleotide;  BH4=tetrahydrobiopterin;  
NADPH=nicotinamide  adenine dinucleotide phosphate). The red arrows depict electron flow 
eNOS. Electron flow starts from NADPH to flavins FAD and FMN of the reductase domain, which 
delivers the electrons to the Fe of the haem (oxygenase domain) and to the BH3· radical generated 
as an intermediate in the catalytic cycle. BH4 is essential to donate an electron and proton to 
versatile intermediates in the reaction cycle of L-arginine/O2 to L-citrullin/NO. Calmodulin (CAM) 
controls electron flow in eNOS.  
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The majority of the beneficial effects of NO in the cardiovascular system are 
mediated by cGMP (for review see Murad, 2006). NO diffuses through the lipid 
phase of cell membranes and into the cytosol where it meets its target protein, 
the enzyme sGC, binding to its haem group and causes a 100-200-fold increase in 
its activity (Ignarro et al., 1982; Stone and Marletta, 1996; Friebe and Koesling, 
2003). Activation of sGC converts the nucleotide guanosine triphosphate (GTP) 
into cGMP (Waldman and Murad, 1988; Furchgott and Jothianandan, 1991). 
cGMP itself has a molecular target identified nearly 40 years ago as a cGMP-
dependent protein kinase (now known as PKG) (Greengard, 1975). Activation of 
PKG leads to a series of signaling events with diverse consequences, including 
vascular smooth muscle relaxation (Moncada and Higgs 1993; Schmidt and 
Walter, 1994; Tang et al., 2003). 
 
The NO-induced cGMP signal also has effects on other intracellular effector 
molecules; cGMP-regulated phosphodiesterases (PDEs), and cGMP-gated ion 
channels. In the cardiovascular system, the primary cGMP–PDEs with known 
activity are PDE1, PDE2, and PDE5 (of 11 so far discovered) (Kass et al., 2007) 
(Figure 1.8). 
 
NO has cGMP independent effects; it exerts widespread signaling through the 
post-translational modifications of proteins and small molecules via S-nitrosation 
of sulfhydryl groups (Gow et al., 1997), which has been demonstrated in well 
over 100 proteins in multiple cells and tissues, including the heart (Stamler, 
1995; Gow et al., 2002; Hess et al., 2005). Various proteins involved in the 
regulation of myocardial contractility are modified by protein S-nitrosation (Xu et 
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al., 1998). For example in cardiac muscle, NO S-nitrosylates the ryanodine 
receptor on the sarcolemmal membrane, which is required for its normal activity 
(Xu et al., 1998). NO has also been shown to regulate gene expression and 
messenger ribonucleic acid (mRNA) transcription via binding to Fe response 
elements (Pantopoulos and Hentze, 1995; Khan et al., 1996).  
 
Figure 1.8 NO/cGMP signaling cascade 
NO produced by eNOS activates sGC and leads to increased synthesis of cGMP. This intracellular 
messenger in turn modulates the activity of cGMP-dependent protein kinase G, cGMP-gated ion 
channels and cGMP-regulated phosphodiesterases. These effectors are involved in the regulation 
of multiple physiological functions in the cardiovascular system.  
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1.5.3 NO and I/R injury 
 
The cardioprotective effects of NO relate to a number of actions including its 
potent vasodilator action in the ischaemic myocardium (Johnson G III et al., 
1991), which allows for essential perfusion of injured tissue. In addition NO 
exerts its anti-inflammatory effects with respect to inhibition of leukocyte 
recruitment (Kubes et al., 1991; Ahluwalia et al., 2004) which reverses the 
inflammatory cell driven injury to the endothelium and perivascular myocardium 
that plays a major role in determining infarct size post myocardial I/R injury 
(dPalazzo et al., 1998). NO also exerts anti-platelet effects, inhibiting platelet 
adhesion (Queen et al., 2000), aggregation (Radomski et al., 1990), recruitment 
(Freedman et al., 1997), and the formation of leucocyte-platelet aggregates 
(Chung et al., 2004). These anti-platelet effects, combined with the anti-leukocyte 
actions of NO helps to attenuate capillary plugging (Jones and Bolli, 2006). 
Additionally, in the long term following acute myocardial I/R injury it is thought 
that deficient NO generation contributes to delay in re-endothelialisation of blood 
vessels following primary PCI, enhances cardiomyocyte death and apoptosis 
during I/R injury, contributes to cardiomyocyte hypertrophy post-infarct and 
decreases the impact of strategies that might facilitate new cardiomyocyte 
generation (Razavi et al., 2005; Dorn, 2009).  Importantly and crucially for 
cardioprotection, NO prevents the opening of the mPTP (Brookes at al 2000; 
Heusch et al., 2008) which as discussed earlier is a critical and final common step 
in reperfusion injury (Griffiths and Halestrap, 1995) (section 1.3.5).  
 
During an I/R insult the activity of NO is compromised. The ability of eNOS to 
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make NO is severely attenuated as a result of inadequate delivery of oxygen and 
co-factors (Giraldez et al., 1997). This was first shown in isolated rat hearts 
where eNOS activity (assayed by L-[14C]arginine to L-[14C]citrulline conversion) 
although shown to be preserved after 30 minutes of ischemia with a value of 1.1 ± 
0.1 pmol of L-citrulline/min x mg of protein,was decreased by 77% after 60 
minutes and became nearly undetectable after 120 min. Reperfusion resulted in 
only a partial restoration of activity. Haemodynamic studies showed that the 
onset of impaired vascular reactivity paralleled the loss of functional eNOS 
(Giraldez et al., 1997). In addition, reperfusion generates ROS particularly 
generation of O2−, which binds avidly to NO generating ONOO-. This scavenging 
further reduces the bioavailability of NO, removing its cardioprotective effects 
(Bolli, 2001) (Moens et al., 2005). In addition, ONOO- is a short-lived oxidant, 
which is thought to be significantly more reactive and damaging than its 
precursors and is thus more toxic to cells than H2O2, O2−, or NO alone (Murphy et 
al., 1998).  Together, such pre-clinical observations are consistent with a 
protective role for NO (Jones and Bolli, 2006) and support the concept of 
pharmacotherapy focused on replacing the protective NO ‘lost’ during myocardial 
I/R injury. 
 
1.6 Use of organic NO-releasing compounds on I/R injury  
 
Strategies that provide exogenous, synthesized sources of NO have been used for 
medical purposes for more than 120 years before the discovery of endogenous 
NO synthesis. As a result it was organic nitrates that were first used to attempt to 
replace deficiency of NO in I/R injury. The effects of different organic nitrate 
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treatments in patients with AMI have been tested in 2 large scale trials of over 
80,000 patients, receiving recommended therapies (90% aspirin, 70% 
fibrinolysis). Both trials showed that routine organic nitrate use did not produce 
an improvement in survival either in the total population or in subgroups (GISSI-
3, 1994; ISIS-4, 1995). In the ISIS-4 study, 58, 050 patients were randomized 
within 24 hours of AMI in a 2 x 2 x2 factorial design to either isosorbide 
mononitrate (ISMN) (1 month of oral controlled-release mononitrate-30 mg 
initial dose titrated up to 60 mg once daily) versus matching placebo, oral 
captopril (6.25mg bd for 1 month) versus matching placebo or 24 hours of 
intravenous magnesium sulphate (8mmol). In those treated with ISMN, there was 
no significant reduction in 5-week mortality, either overall (2129 [7.34%] 
mononitrate-allocated deaths vs 2190 [7.54%] placebo) or in any subgroup 
examined (including those receiving short-term non-study intravenous or oral 
organic nitrates at entry). Further follow-up did not indicate any later survival 
advantage and there was an increase of 15 (SD 2) per 1000 events of hypotension 
(ISIS-4, 1995). The 2nd large study GISSI-3 trial, randomized 19,394 patients to a 
24-hour infusion of glyceryl trinitrate (GTN) starting within 24 hours of pain 
onset, followed by topical GTN (10mg daily for 6 weeks) or to control. No 
difference in mortality was seen at 6 weeks in the group randomized to GTN 
therapy compared to control (6.52% vs 6.92%), with a similar result in the pre-
specificed combined endpoint of death plus left ventricular dysfunction or clinical 
heart failure (15.9% vs 16.7%) (GISSI-3, 1994). Further smaller trials assessing 
nicorandil and the NO donor molsidomine also failed to show any benefit 
(ESPRIM 1994; Kitakaze et al., 2007). The J-WIND study of 545 patients with AMI 
undergoing reperfusion therapy, randomized to receive either intravenous 
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nicorandil (0.067 mg/kg as a bolus, followed by 1.67 μg/kg per min as a 24-h 
continuous infusion) or placebo (0.9% saline). No reduction in infarct size 
(assessed by CK) and no improvement in either LVEF or outcome (mortality or 
MACE) was seen in the nicorandil group (Kitakaze et al., 2007). A further trial, 
ESPRIM of the NO donor molsidomine also failed to show any mortality benefit in 
AMI patients. In this trial, patients were randomly assigned to receive 
linsidomine 1 mg/hour intravenously for 48 h, followed by 16 mg molsidomine 
by mouth daily for 12 days (n = 2007), or an identical placebo (n = 2010). The 
molsidomine and placebo groups showed similar all-cause 35-day mortality 
(8.4% vs 8.8%) and long-term mortality (mean follow-up 13 months; 14.7% vs 
14.2% p = 0.67) (ESPRIM Study group, 1994).  
 
Although both organic and inorganic nitrates/nitrites mediate their principal 
effects via NO, there are many important differences. Inorganic nitrate and nitrite 
have simple ionic structures, are produced endogenously and are present in the 
diet, whereas their organic counterparts are far more complex, and, with the 
exception of ethyl nitrite, are all medicinally synthesised products (Figure 1.9). In 
addition the use of the organic nitrates are limited by the development of 
tolerance (Mayer and Beretta, 2008). Both of these effects are attributed to the 
tendency of the organic nitrates to increase the formation of damaging ROS. 
Rabbit aortae from animals treated with transdermal GTN for 3 days have double 
the amount of O2- (as measured by lucigenin chemiluminescence) as control 
animals (Munzel et al., 1995) and elevated levels of ONOO- (assayed by 
nitrotyrosine accumulation) (Skatchkov et al., 1997). In marked contrast, pre-
clinical evidence using inorganic NO2- as a source of NO have been associated 
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with a reduction in markers of oxidative stress (Tripatara et al., 2007) and 
studies in primates demonstrate no evidence of development of tolerance with 
repeated use (Dejam et al., 2007). Using inorganic nitrite to replace the NO lost 
during I/R injury could therefore be a better option. 
 
Figure 1.9. Chemical structure of organic and inorganic nitrate showing the difference 
between the molecules. 
 
1.7 Inorganic Nitrite (NO2−) 
 
The biological role of the nitrite anion has undergone a significant transformation 
in recent years. For many decades, endogenous nitrite was considered simply a 
by-product of NO metabolism with limited functionally significant chemistry. 
However it is now recognized that it operates as a major storage form of NO in 
blood and tissues that can be reduced readily to NO to initiate cytoprotective 
signaling during pathological states including myocardial I/R injury (Zweier et al., 
1995; Webb et al., 2004; Bryan NS, 2007). Systemic nitrite levels (100–500 nM in 
plasma (Dejam et al., 2005; Webb and Ahluwalia, 2010) and from 1-20 μM in 
tissue (Bryan et al., 2005) are derived from both endogenous and exogenous 
sources with as much as 70% of plasma nitrite levels originating from the 
oxidation of eNOS-derived NO (Kleinbongard et al., 2003) and 30% proposed to 
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originate from dietary sources (Lundberg and Govoni, 2004; Lundberg et al., 
2004) In general, the dietary component of plasma nitrite levels derives from 
inorganic nitrate. Nitrate enters the oral cavity where it is converted into nitrite 
by commensal bacteria in the mouth although evidence suggests this can also 
take place in the gastrointestinal tract (Zobell, 1932; Tannenbaum et al., 1976; 
Spiegelhalder et al., 1976; Lundberg and Govoni, 2004). Both sources of nitrite i.e. 
via the enterosalivery circuit and through oxidation of NO are important for 
maintaining steady-state nitrite levels in the plasma and tissues (Lundberg JO and 
Weitzberg E, 2008; Kapil et al., 2013). 
 
 The functional effects of nitrite in the cardiovascular system were first shown in 
the 1950s when Robert Furchgott demonstrated that high supraphysiological 
concentrations (high mM) of nitrite exerted relaxant effects on vascular smooth 
muscle (Furchgott and Bhadrakom, 1953). Despite this finding being over half a 
century ago, it was felt for many years that at physiological concentrations, nitrite 
was biologically inert and may even have deleterious effects with putatively 
carcinogenic properties (Tannenbaum and Correa, 1985). In 1995, evidence 
challenging this view began to emerge. Zweier and colleagues suggested that 
bioactive NO could be produced from physiological concentrations of nitrite 
under ischaemic and acidotic conditions in tissue of the cardiovascular system 
(Zweier et al., 1995). They performed studies using rat myocardium that clearly 
demonstrated NOS independent generation of NO detected with EPR 
spectroscopy under ischaemic and acidotic conditions. Following this definitive 
evidence of nitrite activity at physiological levels was provided in 2001, in rat 
aortic rings where low µM concentrations of nitrite, whilst inactive under 
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physiological pH, were shown to relax contracted rat aorta under acidic pH (6.6) 
conditions (Modin et al., 2001). Confirmation that nitrite affected vascular tone 
under physiological conditions was provided by studies by Gladwin and 
colleagues where the infusion of physiological levels of sodium nitrite into the 
human forearm caused vasorelaxation with concomitant increased blood flow 
(Cosby K, 2003). Importantly this phenomenon was augmented by the mildly 
hypoxic conditions associated with exercise confirming the notion that nitrite 
bioactivation is increased in the acidotic and hypoxic environment (Cosby K, 
2003). More recently it has been suggested that endogenous NO2− reduction 
under physiological conditions does occur but that this is likely occurring to a 
greater extent on the venous side of the circulation where O2 tension is lower 
compared to the arterial side of the circulation (Maher et al., 2008).   
 
Since publication of the above findings substantial research effort has focused on 
identifying the biochemical pathways involved in mammalian nitrite reduction. It 
is now clear that the conversion of nitrite to NO increases with increasing 
acidosis and hypoxia (van Faassen et al., 2009) environments in which the 
conventional L-arginine/eNOS pathway is dysfunctional (Giraldez et al., 1997; 
Abu-Soud et al., 2000). This particular finding has led to the proposal that this 
alternative pathway for NO generation may act as a complementary, back-up 
system when conventional NO generation has been compromised (Lundberg JO 
and Weitzberg E, 2008; Reutov, 2002). The exact mechanism and location for 
nitrite reduction in blood and tissues and its physiological role in regulation of 
cellular processes have not yet been pinpointed despite many possible targets, 
but it is clear from animal experiments that administration of nitrite (or its 
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precursor nitrate) has a therapeutic potential especially in I/R injury.  
 
1.8 Conversion of nitrite to NO 
 
The reductive conversion of nitrite to NO is thought to occur by a number of 
mechanisms, including the enzymatic reductive actions of a variety of mammalian 
enzymes such as xanthine oxidoreductase (XOR) and non-enzymatic acidic 
disproportionation (Zweier et al., 1995). Importantly, environmental conditions 
play a major role in determining the extent of nitrite reduction with the 
bioconversion of nitrite to NO favoured under the hypoxic and acidic conditions 
present during ischaemia.  
 
1.8.1 Non-enzymatic disproportionation 
 
NOS independent generation of NO was first described to occur in the stomach 
back in 1994 where two independent groups showed that NO and other reactive 
nitrogen oxides were generated non-enzymatically in large amounts following 
protonation in the stomach of nitrite in swallowed saliva (Lundberg et al., 1994; 
Benjamin et al., 1994). Soon after the discovery of gastric NOS-independent NO 
generation, Zweier and colleagues performed their landmark studies 
demonstrating profound NO generation in rat ischaemic heart muscle, which 
could not be effectively blocked by pharmacological NOS inhibitors (Zweier et al., 
1995). During global cardiac ischaemia tissue pH fell below 6 and Zweier & 
colleagues demonstrated that under these conditions reduction of nitrite to NO 
was greatly enhanced.  
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The chemical reduction of nitrite to NO follows several steps, including the 
intermediate nitrous acid HNO2 (Equations 1.2a-c) 
 
Equation 1.2a NO2- acidification to form HNO2  
 
Equation 1.2b. Dehydration of HNO2  
 
Equation 1.2c. N2O3 dissociation to NO  
 
1.8.2 Enzymatic conversion 
 
Haemoglobin (Cosby et al., 2003), myoglobin (Hendgen-Cotta et al., 2008), 
neuroglobin (Tiso et al., 2011), XOR (Webb et al., 2004), aldehyde oxidase (Li et 
al., 2008), eNOS (Gautier et al., 2006; Webb et al., 2008), and mitochondrial 
enzymes have all been identified with having a role in nitrite bioactivation. The 
relative contribution from these pathways varies between tissues based on the 
enzymatic composition within each tissue type. In the heart and specifically 
implicated in myocardial I/R injury there are two pathways that appear to reduce 
significant quantities of nitrite to NO, namely deoxymyoglobin (deoxyMb) (Shiva 
et al., 2007a; Rassaf et al., 2007) and XOR (Webb et al., 2004). This compares to 
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other compartments such as blood, where deoxyhaemoglobin (deoxyHb) has 
been implicated (Cosby et al., 2003). Interestingly in the heart, it has been shown 
that nitrite is still protective in a haemoglobin-free buffer isolated heart I/R 
model (Dezfulian et al., 2007) suggesting that haemoglobin likely plays a minor 
role in nitrite reduction in the myocardium despite its seemingly important role 
in the blood. The rest of this section will focus on the 2 key pathways that appear 
important in nitrite reduction in myocardial I/R injury, XOR and myoglobin. 
 
1.8.2.1 XOR as a myocardial nitrite reductase 
 
XOR is a molybdoflavin enzyme found in mammalian cells that is involved in the 
catabolism of purine and pyrimidines, oxidizing hypoxanthine to xanthine and 
xanthine to uric acid. Functional XOR is a homo-dimer of ~300 kD with each 
subunit consisting of four redox centers: a molybdenum cofactor (Mo), one FAD 
(Flavin adenine dinucleotide) site and two iron-sulfur (Fe2/S2) clusters with 
purine oxidation being shown to occur at the Mo site.  XOR also reduces oxygen to 
O2- and H2O2 at the FAD site and is acknowledged as one of the key enzymes 
responsible for 02--mediated cellular injury. As discussed previously in section 
1.3.1, XOR is a key generator of ROS in myocardial I/R injury significantly 
contributing to cellular damage, an association confirmed by models where XOR 
inhibition leads to a reduction in symptoms and measurable restoration of 
function. This long-standing paradigm has been challenged with the 
demonstration of a nitrite reductase function for XOR suggesting XOR to be a 
source of beneficial NO under these same hypoxic/inflammatory conditions.  
 
 83 
The reduction of nitrite to NO is catalyzed by XOR under hypoxic conditions, 
when electrons are supplied by either xanthine or NADH (Godber et al., 2000) (Li 
et al., 2001). This reduction occurs at the reduced Mo site and electrons driving 
this reaction can be supplied directly by xanthine or indirectly by NADH, via 
electron donation at FAD with subsequent retrograde flow to the Mo site (Li et al., 
2001). 
  
The role of XOR in nitrite reduction in the heart has been shown in several 
studies. Webb and colleagues showed that conversion of nitrite to NO was 
reduced by 50% with inhibitors of XOR, allopurinol (100µM) and BOF-4272 
(10µM) in rat/human heart homogenates and almost completely abolished in the 
working heart (Webb et al., 2004). These findings were substantiated by further 
studies in rat heart homogenates where nitrite derived NO production was 
inhibited by 30% by the active metabolite of allopurinol, oxypurinol (100µM) 
(Liu et al., 2007) and in rat kidney homogenates where allopurinol (100µM) 
inhibited nitrite reduction by 71% (Tripatara et al., 2007).  
  
1.8.2.2 Myoglobin as a NO2− reductase 
  
The monomer myoglobin is a small (17.6 kDa) but important intracellular oxygen 
binding haem protein. It is present at high µM concentrations in cardiac and 
skeletal muscle (Wittenberg and Wittenberg, 2003) and has been identified to 
have a role in nitrite bioactivation, specifically in myocardial I/R injury. 
Depending on ambient oxygen level, myoglobin is thought to act either as an NO 
scavenger under normoxic conditions or as a nitrite reductase under conditions 
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of hypoxia and ischaemia (Shiva et al., 2007a; Rassaf et al., 2007) Because 
myoglobin must be at least partially deoxygenated to act as nitrite reductase, this 
only occurs when the oxygen level falls below the P50 of myoglobin (Crawford et 
al., 2006). 
 
Myoglobin has a high affinity for oxygen and a low haem redox potential that 
contributes to rapid nitrite reduction to NO when deoxygenated; in fact, 
deoxymyoglobin will reduce nitrite to NO at a rate 30-times faster than 
haemoglobin (Shiva et al., 2007a). These chemical properties suggest that when 
myoglobin becomes deoxygenated, such as in the subendocardium of the heart or 
in exercising skeletal muscle, it will rapidly convert nitrite to NO. This is done in 
much the same way as haemoglobin has been described to bioactivate nitrite 
(Equation 1.2) (Huang et al., 2005; Shiva et al., 2007a).  
 
 
Equation 1.3. Reduction of NO2− by myoglobin or haemoglobin 
 
Studies in the heart have suggested that approximately 60%-70% of NO 
generation from nitrite may be mediated by the nitrite reductase activity of 
deoxymyoglobin, with the balance dependent on reduction by XOR (Shiva et al., 
2007a; Rassaf et al., 2007). In agreement with an important role for myoglobin, 
nitrite reduction to NO is abolished in the myoglobin knockout mouse (Hendgen-
Cotta et al., 2008). Hengden-Cotta and colleagues subjected myoglobin knockout 
mice to a MI via coronary artery occlusion in the presence and absence of nitrite. 
While nitrite treatment decreased infarct size and improved post-ischaemic left 
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ventricular developed pressure in wild-type mice, nitrite did not mediate 
cytoprotection in myoglobin deficient mice. These studies suggest that nitrite and 
myoglobin play an important role in regulating cardiac energetics and oxygen 
utilization under conditions of physiological hypoxia. Whether myoglobin is also 
critical in nitrite reduction in the human heart is not known.  
 
1.9 Pre-clinical evidence: Cytoprotective actions of nitrite in myocardial I/R 
injury  
 
Nitrite has now been shown to mediate a number of beneficial effects in the 
cardiovascular system. The most potent and reproducible of which is the ability 
of nitrite to mediate cytoprotection after I/R in a number of organs and species 
(Webb et al., 2004; Duranski MR et al., 2005; Pluta et al., 2005; Jung KH et al., 
2006; Tripatara et al., 2007). The first demonstration of the cytoprotective effects 
of nitrite came in 2004 by Prof Ahluwalia’s group (Webb et al., 2004) where 
administration of nitrite (10 or 100µm/l) either prior to or at reperfusion, in the 
isolated rat langendorff heart preparation improved both left ventricular function 
and coronary perfusion pressure as well as decreasing infarct size following an 
I/R insult. Several studies have followed confirming these beneficial effects in the 
heart using both in vitro (Baker JE et al., 2007; Hendgen-Cotta et al., 2008) but 
also in vivo pre-clinical rodent models of AMI (Duranski MR et al., 2005; Bryan 
NS, 2007). Duranski and colleagues in a model of AMI (left main coronary artery 
occlusion) administering the intra-ventricular injection of 2.4-1920nmol of nitrite 
5 minutes prior to reperfusion, following 30 minutes of ischaemia, observed a 
dose-dependent decrease in infarct size with a maximal protective effect at 48 
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nmol, although the administration of 1920 nmol of nitrite failed to exert any 
significant cardioprotective effect (Duranski MR et al., 2005). Bryan and 
colleagues used a mouse model of AMI (left main coronary artery occlusion) and 
demonstrated that dietary nitrite supplementation (50mg/l) for 7 days prior to 
ischaemia resulted in a 48% reduction in infarct size (Bryan NS, 2007).    
 
The functional benefits of nitrite have also been demonstrated in larger species. 
In a canine model of AMI induced by ligation of the LAD coronary artery in vivo, 
the intravenous administration of nitrite (0.2µmol/min/kg for 1st 20 minutes and 
then 0.17µmol/min/kg for 40 minutes) for the last hour of a 2 hour period of 
ischaemia, reduced infarct size by ~50% compared with control (Gonzalez et al., 
2008). Importantly for clinical translation, the intravenous administration of 
nitrite during the last 5 minutes (0.2µmol/min/kg) of the 2-hour occlusion 
reduced infarct size and apoptosis almost as much as the 60-minute infusion. 
Such observations suggest that nitrite delivered just prior to reperfusion at the 
time of primary PCI could result in infarct size reduction.  
 
Although the largest body of evidence demonstrating the cytoprotective 
properties of nitrite has accumulated in models of AMI, similar protective effects 
have been evidenced in other organs including the liver (Duranski MR et al., 
2005), brain (Pluta et al., 2005) and kidney (Tripatara et al., 2007)(Table 1). For 
example, in a murine model of hepatic I/R, the intraperitoneal administration of 
sodium nitrite (1.2-480 nmol) during the ischaemic period exerted dose-
dependent cytoprotective effects on hepatocellular necrosis and apoptosis as well 
as attenuating serum elevations of liver transaminases (Duranski MR et al., 
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2005). In a rat model of cerebral I/R, 48 and 480 nmol of nitrite, infused 
intravenously at the start of reperfusion, exerted dose-dependent 
neuroprotective effects, reduced cerebral infarct volume by 33% and 77%, 
respectively, and promoted neurologic functional recovery (Jung KH et al., 2006). 
Similarly, the topical administration of sodium nitrite (0.12nmol/g) in a rat 
model of renal I/R injury, 1 minute before reperfusion significantly attenuated 
renal dysfunction, reperfusion injury, glomerular dysfunction and tubular injury 
(Tripatara et al., 2007). Interestingly in this study the intravenous administration 
of the same dose of sodium nitrite at the same time-point (1 minute before 
reperfusion) did not lead to an improvement in renal dysfunction or reperfusion 
injury (Tripatara et al., 2007). In all of these studies the beneficial effects were 
shown to be due to the activity of NO and were most often specifically associated 
with the local application into or on the organ of interest. 
 
With the establishment of primary PCI as the gold standard treatment for AMI 
and evidence of the beneficial effect of the local administration of nitrite, this 
raises the question of the optimal route for the administration of nitrite therapy 
either intravenously like the canine AMI model (Gonzalez et al., 2008) or intra-
coronary at the time of balloon inflation during primary PCI. When the two routes 
have been directly compared i.e in the kidney; the local administration of nitrite 
was effective at reducing infarct size whereas the same intravenous dose was not, 
suggesting a superiority of local administration (Tripatara et al., 2007). The 
intravenous route was effective in models of myocardial I/R injury including the 
most relevant to primary PCI (Gonzalez et al., 2008) however the intra-coronary 
route has several advantages, in that it would achieve a high local concentration 
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of nitrite within the desired area only; the myocardium, minimising the potential 
systemic side-effects that could occur (hypotension, methaemoglobinaemia). 
Additionally, if agents are to be delivered at reperfusion i.e. following 
angiography to ensure TIMI flow ≤1 the intra-coronary route will not delay 
reperfusion. This is compared to intra-venous administration, which may result 
in a delay in reperfusion whilst administered and also might require the 
establishment of very high circulating levels to achieve sufficient levels of nitrite.  
Together these observations suggest that nitrite may have use in the treatment of 
acute STEMI in which nitrite could be delivered locally (intra-coronary) before 
balloon inflation at the time of primary PCI.  
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Table 
1.1 
 
Pre-clinical models of I/R injury 
   
Organ I/R model Species Placebo Dose of nitrite, route, timing of administration Timing of ischemia and 
reperfusion 
Outcome measures of cytoprotection Reference 
Heart Isolated perfused heart 
(Langendorff) 
Rat Saline -10 or 100 mol/L  
-infusion 
-15 min before 
30 min ischemia 
120 min reperfusion 
Infarct size 
Left ventricular pressure 
Rate of change of pressure during diastole 
Webb et al. 2004 
Left main coronary artery 
occlusion 
Mouse Nitrate or 
saline 
-2.4-1920 nmol 
-intraventricular injecton  
-5 min before reperfusion 
30 min ischemia 
24 reperfusion 
Infarct size Duranski et al. 2005 
Left main coronary artery 
occlusion 
Mouse Saline -48 nmol bolus  
-intraperitoneal injection  
-24 h or 5 min before reperfusion 
-200L of 100 mg/L  
– oral gavage  
-24 h before ischemia onset 
30 min ischemia 
24 reperfusion 
Infarct size Shiva et al 2007 
In vivo-left anterior descending 
coronary artery occlusion 
Rat Nitrate or 
saline 
In vivo- 
-0.04-10.0 mg/kg  
-bolus iv injection  
-15 min before ischemia onset 
In vivo- 
30 min ischemia 
Infarct size Baker et al 2007 
In vitro-isolated perfused heart 
(Langendorff) 
  In vitro- 
-1.0-300.0  mol/L  
-infusion   
-15 min before ischemia onset 
 Left ventricular developed pressure  
 Left main coronary artery 
occlusion 
Mouse Standard 
chow 
-Supplemented in drinking water (50 mg/L for 7 d) 30 min ischemia 
24 h reperfusion 
Infarct size Bryan et al. 2007 
 Left anterior descending coronary 
artery occlusion 
Dog Saline -0.20 mol/min per kg  infusion for 20 min followed by  
0.17 mol/min per kg infusion for 40 min or 0.20 
mol/min per kg infusion for 5 min  
-during last 60 min or 5 min of ischemia, respectively 
2 h ischemia 
6 h reperfusion 
Infarct size 
Microvascular perfusion  
Cardiomyocyte apoptosis 
Left ventricular ejection fraction 
Gonzalez et al. 2008 
Liver Hepatic artery/portal vein 
occlusion 
Mouse Nitrate or 
saline 
-1.2-960 of nmol  
-intraperitoneal injection  
-midway through ischemia 
45 min ischemia 5 (serum 
transaminase levels) or 24 h 
reperfusion 
AST or ALT  
Hepatocellular necrosis and apoptosis 
Duranski et al. 2005 
 Hepatic artery/ portal vein 
occlusion 
Mouse Saline -48 nmol of bolus  
-intraperitoneal injection  
-24 h before reperfusion or midway through ischemia  
-200 L of 100 mg/L  oral gavage  
-24 h before ischemia onset 
45 min ischemia 
5 h reperfusion 
AST or ALT Shiva et al. 2007 
Kidney Bilateral renal pedicle occlusion Rat 
 
 
 
Mouse 
Saline 
 
 
 
Saline 
-0.12 nmol/g  
-administered topically or intravenously  
-1 min before reperfusion 
60 min ischemia 
6 h reperfusion 
Serum creatinine, creatinine clearance, AST 
Renal injury (histology) 
Tripatara et al. 2007 
 
Milsom et al 2009 
Brain Middle cerebral artery occlusion Rat Nitrate -48-4800 nmol  
-intravenous infusion  
-1 min at start of reperfusion 
90 min ischemia 
3 h (LCBF) or 
24 h (infarct size) or 
2 h/1, 3, 7 d 
(neurologic testing) 
reperfusion 
Infarct size 
LCBF 
Neurologic scores 
Jung et al. 2006 
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1.10 Clinical evidence for inorganic nitrite 
 
Prior and during the tenure of this PhD, there had been no clinical trials of nitrite 
therapy for organ I/R injury conducted in man. However, the effects of nitrite 
have started to be translated into humans. Studies performed in healthy 
volunteers have shown that elevations in circulating nitrite levels (achieved 
through administration of a high dietary nitrate load) is associated with a 
number of beneficial effects including prevention of the development of transient 
endothelial dysfunction, in a model of I/R injury in the forearm (Webb et al., 
2008) (Kapil et al., 2010). This is in addition to other studies demonstrating that 
an intra brachial infusion of nitrite vasodilates the human forearm without the 
development of tolerance and with increased activity in hypoxia (Cosby et al., 
2003). Recently a study looking at the safety of sodium nitrite infusion in healthy 
subjects has demonstrated that it can be safely infused intravenously at defined 
concentrations for prolonged intervals (48 hours) (Pluta et al., 2011). Maximally 
tolerated doses for intravenous infusion were 267 mg/kg/hour with dose 
limiting toxicity occurring at 446 mg/kg/hour. Toxicity included a transient 
asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) 
and/or an asymptomatic increase of methaemoglobin level above 5% (Pluta et 
al., 2011). 
 
Currently sodium nitrite is an FDA-approved drug being the active ingredient in 
cyanide antidote kits; in this indication the dose of nitrite administered to 
humans (500-1000µmol) is significantly higher than doses thought to be 
required to reduce I/R injury (0.5-10µmol). The acute toxicity issues lie with 
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respect to methaemoglobinemia (National Institute of Environmental Health 
Sciences, 1970), which has been associated with high doses of ingested nitrite, 
and it is this reaction/process (nitrite reacting with haemoglobin to form 
methaemoglobin and nitrate (section 1.5.2, equation 1.1) by which nitrite has 
been used to treat cyanide poisoning. However, results from data in humans 
demonstrate that vasodilating concentrations of nitrite (Cosby et al., 2003) do not 
induce clinically significant methaemoglobinaemia (Pluta et al., 2011).  
 
1.11 Potential mechanisms for nitrite-induced cytoprotection in I/R injury  
 
While the exact mechanisms by which nitrite confers cyoprotection are not clear 
there are several potential theories that have been proposed.  It is clear the 
beneficial effects of nitrite are dependent upon its conversion to NO, as evidenced 
by the complete block of nitrite induced protection by the NO scavenger 
(carboxy-PTIO) (Webb et al., 2004; Duranski MR et al., 2005). The mechanisms 
also appear to be independent of NO-synthases as cytoprotection induced by 
nitrite is not prevented by NO-synthase inhibition (Webb et al., 2004; Duranski 
MR et al., 2005; Lu et al., 2005) or affected in eNOS knockout models (Duranski 
MR et al., 2005). Different nitrite reductases appear to be responsible for NO 
formation during hypoxia, depending on the tissue involved and the severity of 
hypoxia. In the myocardium as discussed earlier it appears that the 2 key nitrite 
reductases are XOR and myoglobin. The involvement of XOR in the reduction of 
nitrite to NO appears important in the myocardium on the basis of reduced 
efficacy after treatment with allopurinol (Webb et al., 2004) whilst it has also 
been shown that the protective effect of nitrite was lost in myoglobin knockout 
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mice (Shiva et al., 2007a; Shiva et al., 2007b).    
 
The derived NO or nitrite itself may modulate cellular proteins or lipids or may 
directly participate in actions which mitigate the injury occurring at reperfusion. 
Potential mechanisms for cytoprotection include the S-nitrosation of critical 
regulatory thiols on proteins such as caspase-3, a key constituent of the apoptotic 
pathway, this leads to its inactivation and prevents apoptotic cell death (Maejima 
et al., 2005), or the L-type calcium channel which results in reduced cytosolic Ca2+ 
and subsequent I/R injury (Sun et al., 2006).  
 
1.11.1 Improved mitochondrial function 
 
NO is a well-characterized regulator of mitochondrial function that stimulates 
mitochondrial biogenesis through the activation of sGC and the production of 
cGMP (Nisoli et al., 2005; Clementi and Nisoli, 2005). Therefore the 
mitochondrion has emerged as a major sub-cellular target of nitrite with 
accumulating evidence demonstrating that nitrite differentially regulates 
mitochondrial function through the modulation of specific proteins within the 
organelle in both physiology and pathology (for review see Murillo et al., 2011). 
The direct inhibition of complex 1 of the electron transport chain with resultant 
decrease in the amount of ROS formed, decreased Ca2+ influx and a reduction in 
cytochrome c release (Shiva et al., 2007b) has been implicated in nitrite mediated 
cytoprotection after I/R injury in both the heart and the liver (Gladwin et al., 
2005). This inhibiton of complex I may also prevent opening of the mPTP 
(Fontaine et al 1998; Nadtochiy et al., 2007) and appears to make mitochondria 
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more tolerant to Ca2+ overload (Nadtochiy et al., 2007). Nitrite via conversion to 
NO also results in the stimulation of sGC to form cGMP which in turn activates 
PKG resulting in stabilization of mitochondrial KATP channels (Sasaki et al., 2000). 
This stabilization is associated with decreased mitochondrial Ca2+ accumulation, 
and the prevention of mPTP opening (Takuma et al., 2001; Brown and Borutaite, 
2002).  The reversible inhibition of cytochrome c oxidase (complex IV of the 
electron transport chain) has also been implicated in nitrite mediated protection. 
NO is known to bind to this enzyme, in competition with oxygen, leading to the 
reversible inhibition of oxygen consumption (Poderoso et al., 1998). This 
inhibition of complex IV has consequences for the preservation of high-energy 
phosphate stores during I/R injury and may underlie the phenomenon of 
“myocardial hibernation” where metabolic activity of the heart is temporarily 
shut down during ischaemia in order to preserve high-energy phosphate reserves 
(Hendgen-Cotta et al., 2008; Murillo et al., 2011).   
 
As stated above it is clear that the beneficial effects of nitrite are dependent upon 
its conversion to NO, however recently in vivo and in vitro data has emerged to 
suggest that nitrite itself may also have independent effects on mitochondrial 
function (Mo et al., 2012; Kamga Pride et al., 2014). Mo and colleagues 
demonstrated in a rat model of carotid injury, that two weeks of continuous oral 
nitrite treatment post-injury prevented the hyperproliferative response of 
smooth muscle cells, accompanied by a nitrite-dependent upregulation of PGC1 
(the master regulator of mitochondrial biogenesis) and increased mitochondrial 
number in the injured artery. In vitro they demonstrated that this increase in 
mitochondrial number did not require activation of sGC and was due to nitrite 
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augmenting the activity of adenylate kinase, resulting in AMP kinase 
phosphorylation, downstream activation of sirtuin-1, and de-acetylation of PGC1 
(Mo et al., 2012).  Additionally and more specific to cardioprotection, Kamga-
Pride and colleagues using a model of hypoxia/reoxygenation in cultured rat 
H9c2 cardiomyocytes, demonstrated that a transient (30 minutes) normoxic 
nitrite treatment significantly attenuated cell death after a hypoxic episode 
initiated 1 hour later. As this was a normoxic treatment it is unlikely nitrite was 
converted to NO and mechanistically, it was demonstrated that this protection 
depended on the activation of PKA, which phosphorylated and inhibited 
dynamin-related protein 1, leading to the enhancement of mitochondrial fusion 
in normoxia. Functionally, this augmented mitochondrial O2- production, which 
oxidized and activated AMP kinase, an essential step in nitrite-mediated pre-
conditioning (Kamga Pride et al., 2014). 
 
By these proposed mechanisms nitrite has beneficial inhibitory effects on several 
of the key process implicated in reperfusion injury; ROS generation, Ca2+ 
overload and mPTP opening. Additionally nitrite also exerts a range of anti-
inflammatory and anti-platelet effects common to NO, two key processes known 
to play important roles in myocardial I/R injury. As such these effects are 
discussed in more detail in the following sections.  
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1.12 Nitrite/NO and platelet reactivity 
 
Platelet adhesion and aggregation are important in the pathogenesis of AMI. The 
role of platelets, in terms of activation and aggregation, is well recognized as a 
terminal event in the formation of thromboses which cause blockages of arteries 
and lead to stroke, AMI and other vascular events (Davi and Patrono, 2007). 
Therefore, inhibiting platelet reactivity is an important strategy in the prevention 
and treatment of AMI. It is widely accepted that NO suppresses the adhesion of 
platelets to intact vascular endothelium (Radomski et al., 1987;  Dangel et al., 
2010) and also platelet aggregation itself (Radomski et al, 1990).  The effect of NO 
has been attributed, primarily, to activation of sGC and consequent elevation of 
platelet cGMP levels (Moro et al., 1996; Dangel et al., 2010; Radomski et al., 1990) 
although, evidence also exists to suggest there may be sGC-independent effects of 
NO and NO donor drugs on platelets (Pawloski et al., 1998; Zhang et al., 2011).  
 
The exact mechanisms in which cGMP elevation inhibits platelet aggregation are 
uncertain however it has been hypothesised that the elevation of cGMP in 
platelets results in PKG activation and consequent phosphorylation of a range of 
proteins that influence platelet function including inositol triphosphate receptors 
and PDE-5 (Jones et al., 2012). The importance of PKG is exemplified by studies 
with PKG-deficient mice demonstrating increased platelet adhesion and 
aggregation in vivo and lack of response to NO in vitro (Massberg et al., 1999). 
Irrespective of the exact molecular pathways involved, NO has been shown to 
influence all major aspects of platelet function including Ca2+ mobilization, shape 
change, secretion and both integrin activation and outside-in signalling to ensure 
 96 
a coordinated modulation of platelet activity (Naseem and Roberts, 2011). 
Specifically NO is known to regulate P-selectin expression on activated platelets, 
an adhesion molecule important for inter-platelet aggregation (stabilizing the 
initial GPIIb/IIIa–fibrinogen interactions) and known to aid leukocyte and/or 
endothelial adhesion (Murohara et al., 1995; Michelson et al., 1996; Gries et al., 
1998). The ability of NO to control such a diverse range of events is explained by 
the capacity of cGMP/PKG signaling pathways to interact with a plethora of target 
proteins. 
 
A growing weight of evidence suggests that nitrite via its conversion to NO 
reduces platelet aggregation (Johnson et al., 1990; Richardson et al., 2002; Webb 
et al., 2008; Velmurugan et al., 2013). Ex-vivo incubation of platelet rich plasma 
with supraphysiological nitrite concentrations (60μM) reduced the aggregatory 
response to adenosine diphosphate (ADP), arachidonic acid and collagen whilst 
similar concentrations of inorganic nitrate had no effects (Schafer et al., 1980), as 
measured by light transmission aggregometry (Srihirun et al., 2012). In humans, 
oral supplementation with either 2mmol inorganic potassium nitrate (KNO3) 
(Richardson et al., 2002) or 500ml beetroot juice (providing ~22.5mmol nitrate) 
(Webb et al., 2008) reduced platelet aggregation to ADP and collagen. The 
importance of the bioactivation of nitrate to nitrite was confirmed with both the 
antiplatelet effect and rise in serum nitrite levels abolished by interruption of the 
entero-salivary circuit (Webb et al., 2008). In another study, acidified sodium 
nitrite has been demonstrated to significantly inhibit platelet aggregation in a 
concentration dependent manner in cat platelet-rich plasma (Johnson et al., 
1990). Recent in-vitro experiments with human platelet rich plasma have also 
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demonstrated decreased platelet reactivity (as measured by P-selectin and 
GPIIb/IIIa expression) in response to sodium nitrite (0.1-1.0 μM) treatment at 
oxygen levels lower than 49 mmHg. The inhibitory effect of nitrite was 
augmented by decreasing oxygen saturation and the platelet inhibiton prevented 
by the addition of an NO scavenger (carboxy-PTIO) (Akrawinthawong et al., 
2014). The precise mechanism(s) of this inhibition has still to be clarified. 
Nevertheless, the above studies have shown that nitrite has inhibitory effects on 
platelet activation, which could contribute to the potential beneficial effects of 
nitrite in AMI.    
 
1.11 Nitrite/NO and inflammation 
 
NO plays an important role in modulating many aspects of the inflammatory 
response. In particular NO inhibits leukocyte recruitment (Kubes et al., 1991) 
(Ahluwalia et al., 2004), which is a key element in reducing the inflammatory cell-
driven injury to the endothelium and perivascular myocardium (dPalazzo et al., 
1998) associated with I/R injury. Leukocyte recruitment is a dynamic cellular 
and molecular process and constitutes leukocyte tethering, rolling, adhesion and 
ultimately emigration from the microvasculature (Petri et al., 2008). Previous 
work has demonstrated that NO is key in the regulation of interactions of the 
leukocyte with endothelial cells within the circulation (Kubes et al., 1991). 
Inhibition of endogenous NO production in postcapillary venules by L-NMMA or 
L-NAME increased leukocyte adhesion to the endothelium by 15-fold and 
reduced wall shear rate by half shown in a cat mesentery study. Additionally 
leukocyte adhesion was completely reversed by the addition of L-arginine and by 
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an antibody specific for the leukocyte adhesion molecule glycoprotein CD18 
(Kubes et al., 1991).  
 
NO appears to play an important role in regulation of P-selectin expression. NO 
reduces P-selectin expression, while inhibitors of NOS elicit an increase in P-
selectin expression, and a corresponding increase in leukocyte adherence to the 
endothelium (Kubes et al. 1991; Armstead et al. 1997). As in the case of relaxant 
effects of NO on vascular smooth muscle, down-regulation of P-selectin 
expression by NO is mediated via sGC/cGMP (Ahluwalia et al. 2004). 
 
To date there has been limited research investigating whether nitrite might 
influence inflammatory cell recruitment. In mice fed a high cholesterol diet, signs 
of inflammation were shown to be evident in intra-vital microscopy studies 
assessing leukocyte adhesion and emigration through the cremaster venular 
endothelium (Stokes et al., 2009). In these studies, nitrite supplementation (33 
and 99mg/l in drinking water) inhibited leukocyte adhesion and emigration as 
well as reversing endothelial dysfunction. These results assessed in ex vivo organ 
bath experiments suggest a beneficial effect of nitrite administration in 
hypercholesterolaemia-induced inflammation. Jadert et al. studied the effects of 
both dietary nitrate and nitrite supplementation on acute microvascular 
inflammation (Jadert et al., 2012). In 2 separate experiments, they demonstrated 
that a dietary nitrate load (0.85 g/L or 2.0 mmol/kg/day for 7 days, given in the 
drinking water of mice) or intravenous sodium nitrite (1.3 mg/kg) decreased 
leukocyte recruitment after the induction of a predominantly neutrophil-
mediated inflammatory response induced by the intra-peritoneal administration 
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of the neutrophil chemokine CXCL-2.  Both the intravenous nitrite treatment and 
dietary nitrate intake affected various stages of leukocyte recruitment.  
Intravenous nitrite had significant effects on adherence and emigration but no 
effect on rolling whereas the dietary nitrate treatment affected emigration and 
rolling but not adherence.  Both treatments were partly cGMP-dependent 
indicating a role for NO (Jadert et al., 2012).  The study suggested that 
intravenous nitrite therapy (or oral nitrate) could potentially be a way to mitigate 
the detrimental effects of an acute inflammatory process. 
 
There is sparse data assessing the effect of NO therapy on the inflammatory 
response in humans. A recent study using a human model of I/R injury showed 
an attenuation of the inflammatory response secondary to inhaled NO therapy 
(Mathru et al., 2007). In this study patients undergoing knee surgery were 
recruited and a tourniquet was applied during surgery to the upper portion of the 
leg for 2 hours to create a period of ischaemia. Inhaled NO (80 ppm) or placebo 
was administered before tourniquet application and continued throughout 
reperfusion until the completion of surgery. Reperfusion resulted in an 
inflammatory response locally in the skeletal muscle characterized by NF-κB 
activation and increased oxidative stress accompanied by enhanced systemic 
expression of adhesion molecules CD11b/CD18 and soluble P-selectin in 
peripheral blood. These alterations were significantly attenuated in patients who 
received inhaled NO (Mathru et al., 2007), suggesting a potential benefit in 
replacing NO in I/R injury.      
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1.12 Outcomes after PCI 
 
Patients undergoing the treatment of AMI with opening of the culprit (occluded) 
coronary artery have endovascular stents placed during the angioplasty 
procedure to prevent the vessel from collapsing or closing up again. A major 
limitation of this technique is re-growth of the tissue within the stented part of 
the artery, known as in-stent restenosis (ISR). Developments in the field of 
endovascular stents have substantially reduced the rates of ISR from 30% (with 
the use of bare metal stents) to 10% (with drug eluting stents (DES)) (Jukema et 
al., 2012b). However, in addition to these residual rates of ISR, concern has arisen 
about the potential for late or very late stent thrombosis after DES implantation, 
with extended-duration dual anti-platelet therapy now recommended in these 
patients {(Hamm et al., 2011; Nakazawa et al., 2008). After injury caused by 
balloon angioplasty or stent deployment in PCI the endothelium is partially or 
completely denuded (Harnek et al., 1999; Otsuka et al., 2012), triggering 
inflammatory mechanisms like platelet aggregation and formation, vascular 
smooth muscle cell (VSMC) migration and proliferation, extra cellular matrix 
(ECM) formation, and finally ISR (Jukema et al., 2012b). The significance of 
delayed re-endothelialization, inhibition of vascular repair and late stent 
thrombosis is particularly important following implantation of DES because the 
anti-proliferative agents used to prevent VSMC proliferation also delay re-
endothelialization in the stented segment (Finn et al., 2007; Nakazawa et al., 
2008). Importantly it has been shown that a deficiency in NO contributes to the 
delay in re-endothelialization following PCI and therefore the replacement of this 
could be beneficial.  Recent evidence suggests that the ISR rate (assessed by late 
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loss and target vessel revascularisation) can be reduced by additional 
pharmacotherapy such as NO that is anti-inflammatory and anti-platelet in 
activity (Lee et al., 2008). If NO, which is known to have anti-inflammatory and 
anti-platelet effects (as discussed above) also has effects on endothelial cell 
growth promoting re-endothelization and VSMC growth inhibiting proliferation 
this could have important effects on long-term outcomes after PCI potentially 
reducing ISR and stent thrombosis.  
 
1.13 NO, nitrite and cell growth 
 
NO is believed to play different roles in regulating the growth of different cell 
types involved in arterial injury. While it is believed to inhibit smooth muscle cell 
proliferation (Zuckerbraun et al., 2007; Zuckerbraun et al., 2010) it is thought to 
stimulate endothelial cell proliferation (Ziche et al., 1997; Cooke and Losordo, 
2002; Metaxa et al., 2008). Thus nitrite derived NO might also be useful in 
modulating these cellular responses to injury.  
 
1.13.1 Endothelial cells 
 
NO is thought to stimulate endothelial cell proliferation and the regeneration of 
healthy endothelium (Ziche et al., 1997; Cooke and Losordo, 2002; Metaxa et al., 
2008), however not all studies have shown a stimulating effect. There are studies 
suggesting NO inhibits endothelial cell growth (Heller et al., 1999), however these 
effects have been shown at very high (>100 μM) concentrations of an NO donor 
with the consensus that at lower physiological levels NO not only enhances 
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endothelial cell proliferation but also promotes migration, angiogenesis (Cooke 
and Losordo, 2002), and inhibits endothelial cell apoptosis (Rossig et al., 1999). 
Convincing evidence of the effect of NO on cell growth is provided by the 
impairment of cell growth resulting from its inhibition. In lung epithelial and 
pleural mesothelial cells, the depletion of endogenous NO by the NO scavenger 
carboxy-PTIO stops cell proliferation by arresting the cell cycle at the late S or 
G2/M phases, events that are mediated by a cGMP-dependent pathway (Janssen 
et al 1998). Recently an in-vivo study showed that eNOS deficiency causes 
collateral vessel rarefaction, impairing the activation of a cell cycle gene network 
during arteriogenesis; suggesting a role for eNOS in maintaining native collateral 
density during growth to adulthood and in collateral remodeling in obstructive 
disease through regulation of cell proliferation (Dai and Faber, 2010).   
 
Various mechanisms have been implicated in NO induced endothelial cell 
proliferation. In coronary venular endothelial cells, exogenous and endogenous 
NO both induce a proliferative response by a mechanism implicating basic 
fibroblast growth factor (bFGF) as an anti-bFGF antibody blocks NO-mediated 
proliferation (Ziche et al., 1997). In addition, the proliferative action of exogenous 
NO, via activation of the mitogen-activated protein kinase (MAPK) pathway, was 
also demonstrated in foeto-placental artery endothelial cells (Zheng et al 2006) 
suggesting a positive role of NO in angiogenesis. VEGF-mediated proliferation of 
umbilical vein endothelial cells and activation of Raf-1, the first kinase of the 
MAPK cascade are NO dependent processes controlled by cGMP and its target 
PKG (Hood and Granger 1998). NO enhances endothelial migration (Ziche et al., 
1994; Murohara et al., 1999) by stimulating endothelial cell podokinesis (Noiri et 
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al., 1998), enhancing the expression of αvβ3 (Murohara et al., 1999), and 
increasing dissolution of the extracellular matrix via the bFGF–induced 
upregulation of urokinase-type plasminogen activator (Ziche et al., 1997). 
 
High levels of NO as well as inhibiting endothelial cell growth have also been 
shown to induce apoptosis however lower levels of NO function as an important 
inhibitor of apoptosis by interfering with signal transduction pathways that 
control apoptotic cell death (Dimmeler and Zeiher, 1997). Using cultured human 
umbilical vein endothelial cells (HUVECs) that had been subjected to shear stress 
in the presence of NO, Dimmeler et al demonstrated that NO (sodium 
nitroprusside [SNP] 10 μM) prevented apoptosis (Dimmeler et al., 1997), and 
similar effects have also been demonstrated in porcine endothelial cell models 
(DeMeester et al., 1998). Tzeng et al showed that an adenoviral vector 
overexpressing iNOS caused an inhibition of lipopolysaccharide induced 
apoptosis in cultured sheep arterial endothelial cells by reducing caspase-3-like 
protease activity (Tzeng et al., 1997). Further clarification regarding this 
mechanism was provided by studies in human endothelial cells where NO 
supplied by exogenous NO donors (SNP or PAPA NONO-ate [50 μM]) served as an 
anti-apoptotic regulator of caspase activity via S-nitrosation of the Cys-163 
residue of caspase-3 (Rossig et al., 1999). Taken together, these results suggest 
that NO production favors healing of injured vasculature by inhibiting further 
apoptosis of endothelial cells in order to rapidly cover the injured site and 
therefore the provision of NO to these areas could be beneficial.   
 
Data suggests that the provision of NO in the form of nitrite has beneficial effects 
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on endothelial cell proliferation and protection under hypoxia. Nitrite has been 
shown to protect endothelial barrier function against hypoxic challenge by 
regulating caspase-3 activity. Studies in zebrafish and murine endothelial cells 
showed that nitrite promotes S-nitrosation and consequent inactivation of 
caspase-3, leading to a sustained barrier function through better maintenance of 
cadherin junctions (Lai et al., 2011) Other studies have demonstrated that nitrite-
mediated cell proliferation is via the induction of the S phase of the cell cycle 
(Kumar et al., 2011). Using human neutrophilic HL-60 cells it was also shown that 
nitrite induced augmentation in the S phase. In the same study, up-regulation of 
cell cycle regulators, efficient Cdk2/cyclin E interaction, and augmented Cdk2 
activity were observed in nitrite-treated cells with the proliferative effect of 
nitrite blocked by roscovitine, a Cdk2 inhibitor (Kumar et al., 2011). Overall this 
suggested that that the proliferative effect of nitrite on HL-60 cells seemed to be 
NO mediated, redox sensitive and Cdk2 activation dependent.   
 
Despite the majority of evidence existing to suggest that nitrite exerts effects on 
endothelial cells under hypoxic conditions there has been at least one study 
demonstrating the effects of nitrite on cell growth under normoxic conditions. A 
recent study by Wang and colleagues (Wang et al., 2012) showed that sodium 
nitrite (1-100µM) enhances cell proliferation and subsequent wound healing of 
human airway epithelial cells in normoxic physiological conditions.  Interestingly 
they also found that intracellular signaling after stimulation with nitrite under 
normoxia was independent of NO and cGMP generation, and involved oxidative 
reactions with hydrogen peroxide and downstream ERK1/2 activation. This 
suggests that nitrite may have a direct effect on endothelial cells rather than by 
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conversion to NO. Further data is required to assess whether nitrite has an effect 
on cellular proliferation in normoxia.  
 
1.13.2 Smooth muscle cells 
 
NO has been shown to conversely limit smooth muscle cell proliferation and 
migration via both cGMP-dependent and independent mechanisms (Zuckerbraun 
et al., 2007) (Zuckerbraun et al., 2010). Early studies demonstrated that NO 
donor agents inhibit the proliferation of isolated rat and rabbit VSMCs in tissue 
culture (Kariya et al., 1989; Garg and Hassid, 1989; Assender et al., 1992; 
Mooradian et al., 1995). In several studies, the effects of low, but not high 
concentrations of NO-donors were mimicked by 8-Br-cGMP (Assender et al., 
1992) indicating the involvement of cGMP-dependent protein kinases. However, 
NO can also directly inhibit the synthesis of RNA and proteins in VSMCs (Jeremy 
et al., 1999) and directly inhibit mitochondrial respiration, which, in turn, may 
influence cell growth (Giuffrè et al., 1996). Sarkar and colleagues (Sarkar et al., 
1997b) suggested multiple sites for the effect of the NO donors, SNP and S-
nitroso-glutathione (SNOG) on the cell cycle in rat aortic VSMCs. Individually, 
these elicited a 50% reduction in the fraction of cells in the S and G
2 1M phases 
and a corresponding increase in the G1 fraction, suggesting that NO inhibits S-
phase entry of VSMCs. Addition of both donors together, however, immediately 
blocked replication reversibly in the S-phase, an effect that was not mimicked by 
exogenous cGMP. These experiments intimate that NO inhibition of VSMC 
proliferation is associated with two distinct and reversible cell cycle arrests, an 
immediate cGMP-independent S- phase block and a cGMP-dependent shift back 
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from the G
1
– S boundary to a quiescent G
0 
-like state (Sarkar et al., 1997a; Sarkar 
et al., 1997b).  
 
Subsequently, Ishida and colleagues used SNP-treated VSMC to demonstrate that 
NO halted the G1/S transition by a p21-mediated inhibition of the 
phosphorylation of the retinoblastoma protein by cyclin-dependent kinase 2 
(Ishida et al., 1997). Further evidence for a role of p21, has been provided by 
studies using the gene transfer of iNOS into VSMC that demonstrated p53-
independent and cGMP-independent increases in expression of p21 (Kibbe et al., 
2000). Further verification has been provided by studies (Tanner et al., 2000) 
demonstrating that NO alters the expression or activity of many cell cycle 
regulatory proteins, including cyclin A, cyclin-dependent kinase 2, and p21. NO 
also retards VSMC migration, with the NO donor SNP shown to inhibit 
angiotensin II–induced rat VSMC migration in vitro, as measured by a modified 
Boyden Chamber (Dubey et al., 1995). In addition other NO donors, including 
diethylamine NONO-ate (DETA/NO), spermine NONO-ate (SPER/NO), and S-
nitrosoglutathione, have all been shown to exhibit concentration-dependent 
inhibition of both the number of and distance migrated by VSMC, with the 
inhibition reversible upon removal of the NO donors (Sarkar et al., 1996). 
 
It has been demonstrated that low dose sodium nitrite given prior to balloon 
injury in vivo prevents vascular intimal hyperplasia in both rat and mouse injury 
models (Alef et al., 2011). Moreover, it has been shown that nitrite delivered after 
the establishment of intimal hyperplasia could reverse the pathological process 
(Alef et al., 2011). In these studies sodium nitrite, was shown to be metabolized to 
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biologically active NO by XOR and to limit VSMC proliferation via a p21Waf1/Cip1 
dependent-mechanism. However not all studies have found an inhibitory effect of 
nitrite on VSMC growth. A study by Vavra and colleagues. demonstrated that  
neither nitrite nor nitrate inhibited rat aortic VSMC proliferation in vitro (Vavra 
et al., 2011). However both these studies did suggest a benefit of sodium nitrite in 
the treatment of/protection from restenosis in vivo (Alef et al 2011; Vavra et al., 
2011) 
 
Whether the effects of nitrite on cell growth might be of use in improving 
outcomes after stent placement in humans is unknown. If it can be demonstrated 
that nitrite protects endothelial cells from the effects of ischaemia and I/R injury 
promoting re-endotheliasation after PCI and also exert an opposing repressive 
influence over smooth muscle cell growth, it would suggest that in an 
environment where improved endothelial cell growth but repressed smooth 
muscle cell growth is desired, such as in restenosis following stent implantation, 
raising circulating nitrite levels may be of therapeutic utility.  
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1.14. Aims and Hypotheses 
 
The primary aim of my PhD is to test the hypothesis that inorganic nitrite 
protects patients undergoing primary PCI for the treatment of AMI against the 
effects of I/R injury.   
 
Specific aims are: 
 
(i). To determine whether intra-coronary nitrite is safe, tolerable and reduces 
infarct size during primary PCI in patients with AMI. 
(ii). To understand the mechanisms by which nitrite reduces reperfusion injury, 
focusing specifically on inflammation and platelet activity. 
(iii). To investigate whether prolonged nitrite treatment might prove useful in 
promoting endothelial and vascular smooth muscle cell growth under normoxia, 
hypoxia and I/R injury and may therefore affect restenosis after PCI.  
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Chapter 2.0  
 
 
General Methods 
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2.1 Clinical Trial 
 
The study performed employed a double-blind, randomized, single-centre, 
placebo-controlled trial design to determine whether intra-coronary nitrite 
injection reduces infarct size in patients with myocardial infarction undergoing 
primary angioplasty (NITRITE-AMI). Subjects were randomized to receive either 
an intracoronary bolus (10 ml) of sodium nitrite (1.8 μmol in normal saline) or 
normal saline distal to the occlusion site before initial balloon inflation during 
primary PCI. The dose was chosen to achieve a local tissue concentration of 2.5-
10 μmol/L following bolus administration (Cosby et al 2003); a concentration 
associated with cardioprotection in pre-clinical studies (Webb et al 2004; 
Duranski et al 2005; Gonzalez et al 2008). 
 
2.1.1 Study Protocol 
 
The study was performed with ethical approval from the National Research 
Ethics Service London – West London (Reference: 11/LO/1500) for ethical 
human research and sponsored by Barts Health NHS Trust Research and 
Development Department. MHRA approval was also obtained (EudraCT No:2011-
000721-77). The trial was performed in accordance with the Declaration of 
Helsinki (revised version, 1996) and the principles of the International 
Conference on Harmonization–Good Clinical Practice (ICH-GCP) guidelines. All 
subjects gave written informed consent before being included in the study. Any 
serious adverse event or reaction during the course of the study was reported to 
the Barts Health NHS Trust Joint Research Office as per adverse event guidelines. 
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The study was registered with the United Kingdom Clinical Research Network 
(Study ID 12117) and ClinicalTrials.gov (NCT01584453) 
 
2.1.2 Patient selection 
 
All consecutive patients presenting to Barts Health Heart Attack Centre, based at 
The London Chest Hospital, suspected of an acute STEMI and candidates for 
primary PCI were considered eligible for participation. Potentially eligible 
patients were approached at the time of their acute admission with STEMI. Due 
to limited time available a rapid assessment of preliminary eligibility was made 
and consent taken at the time of consent for the primary angioplasty procedure. 
Patients were given approximately 5-10 minutes to consider their participation 
and further opportunity was given to the patient to reconsider any decisions 
made at this time during the procedure. As a consequence of the short 
consideration time, patients with limited English were excluded. Members of staff 
obtaining this consent were GCP trained and aware of the Mental Capacity Act 
2005 being able to assess the patient’s capability to give consent in an emergency 
situation. The initial information provided to the patient included a summary 
patient information sheet (PIS) (see appendix 8.1), which provided adequate 
explanation of the aims, methods, anticipated benefits and potential hazards of 
the study.  A detailed PIS (see appendix 8.2) was provided following the 
procedure. Entry into the trial was not confirmed until diagnostic angiography 
and the patient had fulfilled the pre-specified inclusion criteria (section 2.1.3) 
and did not meet any exclusion criteria (section 2.1.4).  
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2.1.3 Inclusion criteria 
 
Inclusion criteria were:  
1. Patients aged between 18 and 80 years  
2. Acute STEMI with ECG showing ST-segment elevation of 1mm or more in   
    two adjacent limb leads or 2mm or more in at least two contiguous  
    precordial leads or new left bundle branch block 
3. Haemodynamically stable 
4. Estimated symptom to balloon or thrombus aspiration time < 6 hours 
5. Signed and dated written informed consent prior to study admission  
6. Angiographically  
i. Primary PCI indicated for revascularisation 
ii. Single epicardial artery to be treated 
iii. Expected ability to use over the wire balloon 
 
2.1.4 Exclusion criteria 
 
Exclusion criteria were: 
1. Inability to consent (including inability to speak English) 
2. Patients on organic nitrate treatment (Nicorandil, ISMN) 
3. Previous history of AMI, systolic dysfunction or CABG 
4. Subjects presenting with cardiogenic shock (systolic blood pressure <80 
mmHg for >30 minutes, or requiring inotropes or emergency intra aortic 
balloon pump for hypotension treatment) or cardiopulmonary 
resuscitation  
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5. Current diagnosis of or treatment for malignancy, other than non-
melanoma skin cancer.  
6. Current life-threatening condition other than vascular disease that may 
prevent a subject completing the study.  
7. Use of an investigational device or investigational drug within 30 days 
or 5 half-lives (whichever is the longer) preceding the first dose of study 
medication. 
8. Patients considered unsuitable to participate by the research team (e.g., 
due to medical reasons, laboratory abnormalities, or subject’s 
unwillingness to comply with all study-related procedures). 
9. Severe acute infection, or significant trauma (burns, fractures).  
10.  Pregnancy.  
11.  Contra-indications to CMR scanning 
i. Pacemakers, intracranial clips or other metal implants  
ii.  Claustrophobia  
iii.  Renal failure (eGFR<30mls/min) 
12. History of alcohol or drug abuse within the past 6 months 
13. History of congenital methaemoglobinaemia 
14. Angiographically, severe vessel tortuosity, diffuse disease or severe 
calcification is present which may impede successful delivery of the over 
the wire balloon 
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2.1.5 Randomisation 
 
After coronary angiography, patients were randomized (1:1) to a bolus injection 
of intracoronary sodium nitrite (1.8 μmol in 10 mL of 0.9% NaCl) or placebo (10 
mL of 0.9% NaCl). Manufacture of the nitrite and placebo, blinding, coding and 
randomisation were conducted by the pharmacy manufacturing unit at Ipswich 
Hospital prior to transfer of stock to the London Chest Hospital Pharmacy. The 
randomisation list was computer-generated based on blocks of ten to assign 
patients to treatment or placebo group and kept in a sealed envelope in the 
hospital pharmacy. A total of 80 indistinguishable vials of sodium nitrite and 
placebo were provided. All study personnel were blind to treatment allocation 
until the study had been completed and all analyses performed.  
 
2.1.6 Investigational medicinal product (IMP) 
 
The experimental intervention was a bolus of sodium nitrite solution (1.8μmol in 
10 ml (pre-diluted in 0.9% sodium chloride in a syringe) which was delivered 
over 30-60 seconds via intracoronary injection initiated during the re-
establishment of antegrade epicardial flow with primary PCI. The control 
intervention was a bolus of 0.9% sodium chloride solution (prepared with an 
identical appearance to the sodium nitrite). This dose of nitrite (1.8 μmol) was 
chosen since studies in the forearm of healthy volunteers demonstrates that this 
dose results in a local concentration of 2.5-10μmol/l (Cosby et al., 2003; Dejam et 
al., 2007; Maher et al., 2008). This dose sits within the range associated with 
cardioprotection in reperfusion injury achieved through bolus dose 
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administration in pre-clinical studies (Gonzalez et al., 2008; Duranski MR et al., 
2005) and provides levels of nitrite that are approximately 10-100 times higher 
than circulating physiological levels which are thought to be between 0.02-0.4 
μmol (Webb and Ahluwalia, 2010)  
 
The IMP was stored in the pharmacy at the London Chest Hospital with 6 vials 
stored in the controlled drug (CD) cupboard in catheterization laboratory one at 
the London Chest Hospital. This was done so that the IMP was readily deliverable 
to patients on their arrival to the hospital in the emergency setting. When the 
stock level fell to below 3 vials in the cupboard, a further 3 vials were obtained 
from the pharmacy. The CD cupboard was temperature monitored so that the 
IMP was kept between 15-25oC. No deviations from this range were noted during 
the trial period.  
 
Following patient consenting and fulfilling of inclusion and no exclusion criteria 
the patient was randomized to receive the next sequential vial of IMP (i.e. Patient 
010 received vial 010). The sodium nitrite was stored in volumes of 10ml at a 
concentration of 0.435M equating to 4350μmol in normal saline. Therefore it 
required serial dilutions to generate the correct delivery dose (1.8μmol). Initially 
2.1ml (913.5μmol) was removed from the vial and made up to 50ml with normal 
saline, resulting in a concentration of 18.27μmol/ml (syringe A). Of this solution 
0.5ml (9.135μmol) was then removed and made up to 50ml with normal saline to 
give a concentration of 0.18μmol/ml (syringe B). Following this 10ml of this 
solution was then taken into a sterile 10ml syringe (C) (1.8μmol in 10ml) ready 
for delivery to the patient. The same dilution steps were performed for both 
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nitrite and placebo as the vials were indistinguishable from each other and the 
study personnel were blinded to treatment allocation.  
 
Figure 2.1. Example labels of study IMP  
 
2.1.7 Percutaneous Coronary Intervention 
 
After crossing the obstruction of the infarct-related coronary artery with a guide 
wire, an over-the-wire balloon (Emerge, Boston Scientific, Natick, MA, USA) was 
positioned beyond the obstruction (Figure 2.2). The guide wire was removed and 
the study drug solution injected by hand through the central lumen of the balloon 
catheter into the distal vascular bed over 30 seconds. The guide wire was then 
reinserted through the balloon catheter and advanced to a distal position. The 
procedure was then continued as per operator preference with no restriction 
placed on vascular access route, type of stent or method of stenting (pre-
dilatation or direct). Patients undergoing non-culprit PCI were excluded from the 
FOR CLINICAL TRIAL USE ONLY 
EudraCT reference: 2011-000721-77 
Placebo/Active Nitrite Dilution 
Subject Number: 
Date: 
Syringe: A 
Syringe A for dilution use only 
FOR CLINICAL TRIAL USE ONLY 
EudraCT reference: 2011-000721-77 
Placebo/Active Nitrite Dilution 
Subject Number: 
Date: 
Syringe: B 
Syringe B contains final Injectable 
product 
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trial. Staging  of non-culprit PCI was allowed.  
 
Figure 2.2. Delivery of investigational medicinal product  
Panel A: Fluroscopic image demonstrating an occluded right coronary artery. Panel B. Fluroscopic 
imaging shoing a standard 0.014 guide-wire passed across the obstruction as depicted by the 
black arrow. Panel C: Fluroscopic imaging displaying the position of the over-the-wire balloon 
(OTW) (white arrow) for the infusion of the IMP. Here the OTW balloon has been advanced over 
the wire, the wire removed and the IMP injected through OTW balloon over 30 seconds. Panel D: 
Fluroscopic imaging displaying the end result of the procedure where the artery has been opened 
with stent implantation. Here the wire was re-advanced through the balloon, the balloon removed 
and the procedure continued as normal with balloon pre-dilatation and stent implantation.   
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2.1.8 Study Endpoints 
 
2.1.8.1 Primary endpoint 
 
The primary endpoint was myocardial infarct size, assessed by 48-hour area 
under the curve (AUC) plasma creatine kinase (CK). The area under the curve 
(AUC) (expressed in arbitrary units) for CK was measured in each patient by 
computerised planimetry (GraphPad prism version 5.0 for mac, San Diego, 
California). We chose to assess CK rather than CK-MB as this matches previous 
studies (Staat et al., 2005) and since CK measurement is part of the routine 
clinical assessments made in the UK following PCI. Moreover, whilst CK-MB might 
be considered more specific for cardiac injury recent evidence suggests that CK 
AUC is comparable to CK-MB, Troponin T or Troponin I for the assessment of 
infarct size (Chia et al., 2008).  
 
2.1.8.2 Secondary endpoints-infarct size 
 
The principal secondary end point was the size of the infarct as measured by 
troponin T AUC and the area of delayed hyperenhancement evident by cardiac 
magnetic resonance imaging (CMR), assessed on day two and six months after 
infarction. The CMR scan was offered as a sub-study with separate consent to 
participants and therefore this estimation of infarct size was only performed in 
those patients consenting to the procedure. Additional CMR related secondary 
endpoints were left ventricular volumes, ejection fraction, and the myocardial 
salvage index. 
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2.1.8.3 Secondary endpoints-Mechanistic 
 
 Mechanistic endpoints included plasma nitrite and nitrate levels (collectively 
termed NOx) and plasma cGMP concentrations. These provide an indication of 
systemic NO levels and NO bioactivity (Ignarro et al., 1993). Markers of 
inflammation (flow cytometric assessment of circulating inflammatory cells and 
plasma levels of high-sensitivity C-reactive protein (hs-CRP), monocyte 
chemoattractant protein-1 (MCP-1), CXCL-1, and CXCL-5) and platelet reactivity 
(P-selectin expression and whole-blood aggregometry (WBA)) were measured at 
baseline, post procedure, at 4 hours, 24 hours and 6 months post-PPCI).  
 
2.1.8.4 Secondary endpoints-Safety 
 
Safety endpoints included the acute safety and tolerability of intra-coronary 
nitrite in STEMI (haemodyamics and in-patient major adverse events occurring 
after reperfusion, including death, heart failure, AMI, stroke, recurrent ischaemia, 
need for repeat revascularization, renal/hepatic insufficiency, vascular 
complications, and bleeding. Additional safety endpoints included an assessment 
of ventricular rhythm disturbance for 24 hours post primary PCI and an 
assessment of major adverse cardiac events (MACE) at 6 and 12 months (death, 
MI, stroke, heart failure, need for repeat revascularization (PCI or CABG). MI was 
defined as new ischaemic pain with new ST elevation or ECG changes, and further 
elevation of enzymes, whether treated with further revascularisation therapy or 
not), (PCI or emergent CABG). Stroke was defined according to World Health 
Organization criteria, which defines a stroke as a focal deficit that lasts for more 
 120 
than 24 hours. Heart failure was defined as dyspnoea accompanied by both 
physical signs of heart failure (pulmonary crackles/rales, peripheral oedema, 
jugular venous distension, S3 gallop, radiological evidence of pulmonary oedema) 
and a need for increased heart failure therapy (diuretic or other oral heart failure 
therapies e.g. ACEi or mechanical/surgical intervention).  
 
2.1.9 Blood sampling 
 
Blood samples were taken by standard venepuncture into pre-chilled vacutainer 
tubes containing 1.8mg EDTA (for NOx), 0.1 mmol/L 3-isobutyl-1-
methylxanthine (IBMX: added to cGMP samples to prevent cleavage of cGMP) 
silica (separate tubes for CK/trop T, chemokine and N-terminal-pro-brain 
natriuretic peptide (BNP) analysis) or 3.2% buffered sodium citrate (for 
aggregation and flow cytometry analysis)  (Becton, Dickinson & Co, Franklin 
Lakes, USA). NT-pro-BNP levels have been shown to identify patients post AMI 
who are at risk of LV dysfunction, heart failure, and death and is complementary 
to the measurement of LVEF (Omland et al., 1996; Richards et al., 1998). All 
samples aside from citrate containing tubes and samples sent to Barts Health 
laboratory were immediately centrifuged (Heraeus Megafuge 16R, Thermo 
Scientific, Karlsruhe, Germany) (1300g, 4oC, 10 min). Plasma was separated and 
stored at ‐80oC until measurement of NOx (see section 2.1.17) cGMP (section 
2.1.16) or chemokine (section 2.1.15) levels were undertaken. Bloods taken for 
Urea and elctrolytes, CK and troponin T analysis were sent to Dr Sally Benton, 
Consultant in Clinical Biochemistry, Department of Biochemistry, Barts Health 
NHS Trust and were processed as per standard clinical laboratory methods. 
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Samples taken for mean platelet volume (MPV) were sent to Jyoti Farren, Chief 
Biomedical Scientist, Department of Haematology, Barts Health NHS Trust and 
were processed as per standard clinical laboratory methods. MPV was measured 
on baseline samples for 60 patients and was measured as baseline levels have 
been linked to impaired angiographic reperfusion and mortality after primary 
PCI for STEMI (Huczek et al 2005). Samples for BNP were sent to the Doctors 
laboratory (60 Whitfield Street, London, W1T 4EU).   
 
Blood samples for Troponin-T and CK were taken prior to primary PCI and at 4, 8, 
12, 18, 24, 36 and 48 hours post-procedure. AUCs were measured over 48 instead 
of 72 hours as in other studies (Piot et al., 2008) as it was routine practice at the 
trial institution for patients to remain in hospital for 48 hours after a successful 
PPCI, unless there was a reason for a longer stay i.e. cardiogenic shock. Therefore 
the trial was designed to best fit with Barts Health Trust’s clinical 
policies/pathways and neither delay the patient’s discharge nor necessitate their 
return for further blood tests after discharge.  
 
Arterial blood gases were taken pre and post-primary PCI to assess levels of 
methaemoglobin. This was performed to assess for one of the main potential side 
effects of nitrite infusion:  methaemoglobinaemia.  NT-pro BNP was measured at 
baseline, 48 hours and 6 months. Blood samples for markers of inflammation 
(CXCL-5, CXCL-1, MCP-1 and Hs-CRP), platelet reactivity (P-selectin expression, 
WBA), and nitrite/nitrate/cGMP levels were taken at baseline, 30 minutes, 4, 24 
hours and 6 months post primary PCI. 
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2.1.10 CMR imaging 
 
CMR imaging was performed on a 1·5 T Philips Achieva scanner with a cardiac 
32-channel phased array coil. Each examination used cine-CMR for ventricular 
volumes and function, T2-weighted imaging for myocardial oedema and delayed 
enhancement CMR for infarct size assessment and evaluation of microvascular 
obstruction (MVO). Cine CMR is considered the gold standard of the evaluation of 
cardiac volumes, mass, and systolic function since it does not apply geometric 
assumptions and has excellent reproducibility and accuracy (standard error for 
left ventricular, LV, mass and volume is approximately 5%) (Grothues et al., 
2004; Hundley et al., 2010). Balanced steady-state free precession cine imaging 
was used to acquire 10-12 short axis slices (8 mm slice thickness, 2mm gap) with 
one slice per breath-hold. Sequence parameters were 1.5 ms echo time (TE), 3.1 
ms repetition time (TR), and acquired voxel size was 1.8 x 1.86mm with a typical 
field of view (FOV) of 360mm in the phase encode direction. 45 phases were 
acquired with 25% phase sharing.  Parallel imaging (SENSE) was used with an 
acceleration factor of 2.0.  
 
Delayed gadolinium enhancement (DE) images are T1-weighted inversion 
recovery sequences acquired about 10 minutes after the intravenous 
administration of gadolinium with an inversion time chosen to null the 
myocardial signal (Simonetti et al., 2001) using an ‘inversion time scout’ or ‘look 
locker’ sequence. Gadolinium is an extracellular agent, which enhances its 
distribution volume in certain conditions such as necrotic myocardium, assuming 
a bright signal (hyperenhancement), opposed to dark viable (normal) 
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myocardium (Judd et al., 1995). CMR highlights the region of scar as small as 0.16 
g (Wu et al., 2001) and the reproducibility is high with a coefficient of 
reproducibility reported equal to+2.4% of LV mass in the chronic setting 
(Mahrholdt et al., 2002). Delayed enhancement images were acquired ten 
minutes after injection of a dose of 0.2 mmol/kg of gadoterate meglumine 
(Dotarem) for delayed gadolinium enhancement. A T1-weighted segmented 
inversion-recovery gradient echo pulse sequence (TR 3.9ms TE 1.9ms, flip angle 
15o, voxel size of 2 x 2mm, typical FOV 360mm) was used to obtain 10-12 short 
axis slices (matched with short-axis cine images) with one slice per breath-hold. 
The inversion time was adjusted individually according to a T1 scout sequence 
(Look-Locker). Images were acquired every other heart beat with 2 signal 
averages.  
 
Myocardial oedema is one of the earliest manifestations of ischaemia and occurs 
before the development of definitive and irreversible damage, T2-weighted 
imaging may be used to visualise the ischaemic area at risk (AAR) (Beek and van 
Rossum, 2010). Increased myocardial water content increases signal on T2-
weighted images due to a prolongation of the T2 relaxation time (Higgins et al., 
1983). Myocardial oedema in the acute phase of AMI can therefore be visualized 
as a bright signal on T2-weighted images, defining the ‘myocardium or area at 
risk’ (Aletras et al., 2006). Myocardial oedema was assessed using fat suppressed 
T2-weighted triple inversion turbo spin echo STIR (Short tau inversion recovery) 
imaging (TE 80ms, TR 2 heart beats, TSE factor 31, voxel size 1.8 x 1.8mm). 10-12 
slices were obtained (8mm per slice, 2mm gap matched to DE/cine slices) with 
one slice per breath-hold.   
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Images were anonymised, batched and analyzed in blinded fashion by two 
experienced operators. Scar and oedema volumes were calculated by manually 
drawing endocardial and epicardial contours followed by semi-automated 
selection of normal remote myocardium per slice (Figure 2.3). Myocardial 
oedema was described as >2SD in signal intensity from remote normal 
myocardium. Infarct size was calculated using the full-width half maximum 
method as previously described (Flett et al., 2011). In case of discordance 
between operators, blinded review by a level III accredited CMR reader was 
performed (Dr Mark Westwood). Analysis was performed using dedicated 
software (CVI42, Circle Cardiovascular Imaging Inc, Calgary, Alberta, Canada). 
Interobserver variability was calculated. 
 
Figure 2.3. LV function analysis in short axis images using long axis views as a cross-
reference.  
Left panel: Diastolic mid-ventricular short axis view with contours. Right upper panel: Example 
long axis reference view in a 4-chamber orientation. Right lower panel: Example long axis 
reference view in a 2-chamber orientation. The orange lines represent the location of the cross-
sectional long axis views used for measurements. 
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2.1.11 Determining the myocardial salvage index 
 
When assessing the efficacy of a reperfusion treatment strategy, it is essential to 
express myocardial infarct size as a percentage of the area-at-risk (AAR). In this 
study, the AAR was quantified using both coronary angiography (modified 
Bypass Angioplasty Revascularisation Investigation [BARI] (Alderman and 
Stadius, 1992) (Figure 2.4) and the modified Alberta Provincial Project for 
Outcome Assessment in Coronary Heart Disease [APPROACH] (Ortiz-Perez et al., 
2007) (Figure 2.5) jeopardy scores) and the acute (2 day) CMR scan (Myocardial 
oedema-T2 imaging). Myocardial salvage index was calculated from the CMR scan 
according to (AAR-Infarct size)/AAR. 
 
Figure 2.4 Diagram to show the BARI angiographic myocardial risk score 
 (Alderman and Stadius, 1992)  
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Figure 2.5 The modified- Alberta Provincial Project for Outcome Assessment in Coronary 
Heart Disease (APPROACH) angiographic myocardial risk score (Ortiz-Perez et al., 2007) 
 
2.1.12 Angiographic analysis 
 
Coronary angiograms obtained before and after primary PCI were reviewed by 
two experienced observers blinded to treatment allocation and clinical data. 
From these angiograms an assessment of Thrombolysis In Myocardial Infarction 
(TIMI) flow grade (Table 2.1) and area at risk using both the modified BARI and 
modified APPROACH jeopardy scores were made. The TIMI flow grade was 
developed by TIMI study group for grading coronary blood flow based on visual 
assessment of the rate of contrast opacification of the infarct artery. The TIMI 
flow grade has become the standard for semi-quantitative evaluation of 
myocardial perfusion before and after coronary reperfusion therapies (TIMI 
Study Group, 1985) (TIMI Study Group, 1989).  
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Table 2.1. Thrombolysis in myocardial infarction (TIMI) flow grade classification 
 
Syntax scores were calculated using http://www.syntaxscore.com. This is a 
scoring system used to quantify the complexity of coronary artery disease taking 
into account not only the number of significant lesions and their location but also 
the complexity of each lesion independently.  
 
2.1.12 Measurement of whole blood aggregometry 
 
Whole blood aggregation was determined using an impedance aggregometer 
(Multiplate® analyser, Dynabyte Medical, Munich). Impedance aggregometry is 
based on the principle that platelets are non-thrombogenic in their resting state, 
but expose receptors on their surface when they get activated which allow them 
to attach on vascular injuries and artificial surfaces. The device has five channels 
TIMI 0 Flow = no penetration of contrast beyond stenosis   
             (100% stenosis, occlusion) 
TIMI 1 Flow = penetration of contrast beyond stenosis 
             but no perfusion of distal vessel 
   (99% stenosis, sub-total occlusion) 
TIMI 2 Flow = contrast reaches the entire distal vessel but either  
             at a decreased rate of filling or clearing versus 
             the other coronary arteries (partial perfusion) 
TIMI 3 Flow = contrast reaches the distal bed and clears at an  
             equivalent rate versus the other coronary arteries 
   (complete perfusion) 
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for parallel tests, and a single-use test cell with duplicate impedance sensors, 
each consisting of two straight silver coated electrode wires (blood contacting 
area: 3 mm length, 0.3 mm diameter for each sensor wire) (Figure 2.6). When 
platelets stick on the Multiplate® sensor wires, they enhance the electrical 
resistance (impedance) between the two electrodes, which is continuously 
recorded (Figure 2.7). This delivers automated quality control of measurements 
by comparison of the two simultaneously recorded single analyses. The method 
has been described previously (Tóth et al., 2006).  
 
In the test cuvette, whole blood (300 μL) is diluted, 1:1, with 0.9% NaCL with 3 
mmol/L CaCL2 (Sigma, UK) solution maintained at 37°C for 3 minutes. At the end 
of this time, 12µl of agonist was added to give end concentrations of ADP of 10µM 
(ChronoLog, Havertown, PA) and 3µg/ml of collagen (Nycomed, Munich, 
Germany). Phosphate buffered saline (PBS) was added to one test-cell as a 
control. The increase of impedance due to the attachment of platelets to the 
electrodes was detected for each sensor unit separately and transformed to 
arbitrary aggregation units (AU) that were plotted against time (AU*min). The 
aggregation measured with this device was quantified as area under the curve 
(AUC) of AU*min. (Figure 2.7) 
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Figure 2.6. How the multiplate cell works 
A. Disposable test cell with duplicate sensor electrodes 
B. Activated platelets adhere on the surfaces of the sensor. The impedance between the       
     electrodes rises as the adhered platelet aggregates form an insulation layer 
 
 
Figure 2.7. Screenshot depicting AUC measurement for Whole-blood aggregometry 
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2.1.13 Measurement of Platelet P-selectin expression 
 
Two-colour whole blood flow cytometry was used to measure platelet P-selectin 
using a previously published protocol (Janes et al., 1993). Whole blood was 
collected from individuals at the specified time-points (baseline, 30 minutes, 4 
hours, 24 hours and 6 months post IMP).  
 
Five μL of citrated blood was immediately added to 45μL of HEPES-buffered 
saline containing appropriate concentrations of antibodies (isotype control of IgG 
or IgM; or platelet markers CD42b and CD62P) and agonists: ADP 10 µmol/L, 
collagen 3µg/ml or PBS as a control sample (Figure 2.8). All samples were run in 
duplicate.  After gentle mixing, the samples were incubated at room temperature 
for 20 minutes, and then fixed using 1% paraformaldehyde (Sigma, UK) stored at 
4oC and then analysed using flow cytometry within 48 hours.  
 
Figure 2.8 Sample make-up for P-Selectin expression 
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2.1.13.1 Flow cytometry 
 
Flow cytometry is a widely used technique, which enables detailed quantitative 
information to be gathered on cells in a large cell population.  Samples were 
acquired and recorded on the LSR Fortessa II Cell Analyzer (BD Biosciences, San 
Jose, CA, USA) using BD FACSDiva Software (BD Biosciences, San Jose, CA, USA).  
The flow cytometer analyses deflected light from each individual cell, which is 
recorded as forward-scatter (FSC; proportional to the size of the cell) and side-
scatter (SSC; relative to granularity and internal complexity of the cell) on a 
FSC/SSC dot-plot graph.  Fluorochromes conjugated to antibodies bind to specific 
cell surface markers and the presence of these markers can be quantified by 
measuring the fluorescence emission. For the assessment of the platelet 
population in blood samples, platelets were first identified preliminarily based on 
their forward and side-scatter properties, then further delineated via labeling 
with CD42b monoclonal antibody conjugated to allophycocyanin (APC) 
(Biolegend, San Diego, USA) Gates were used to isolate this population, and CD62 
(P-selectin) (Serotec Canada Ltd) monoclonal antibody conjugated to fluorescein-
nisothiocyanate (FITC) was used to determine P-selectin expression. Selectivity 
of populations were further confirmed by use of antibody negative iso-types to P-
selectin and CD42b (Biolegend, San Diego, USA). 10,000 platelets were acquired 
in the CD42b region, and results were expressed as the percentage of platelets 
positive for P-selectin (Figure 2.9). 
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Figure 2.9. Flow cytometry assessment of P-selectin expression  
A. Platelets were first identified based on their forward and side-scatter properties (P1)  
B. Then further delineated via labelling with CD42b monoclonal antibody conjugated to 
allophycocyanin (APC) (P2)  
C. CD62 (P-selectin) monoclonal antibody was used to determine P-selectin expression (P3)  
 
2.1.14 Measurement of circulating cell populations and their activation 
state 
 
The systemic inflammatory response post myocardial infarction was assessed 
using monoclonal antibodies conjugated to fluorochromes to identify 
lymphocytes, monocytes and neutrophils in the systemic circulation followed by 
the expression of CD162, CD62L and CD11b on their surfaces as indices of cell 
activation (see table 2.2). 
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2.1.14.1 Preparation of samples for flow cytometry 
 
A total of 50μL of citrated blood was added to tubes containing specific 
antibodies (CD14, CD16, CD16b, CD3, CD4, CD8, CD11b, CD62L, CD162 and 
isoytpe controls for CD11b, CD162, and CD62L, see table 2.2 for dilutions), mixed 
gently and then allowed to incubate for 30 minutes. Excess antibody was washed 
off by adding 2ml of PBS to each tube and centrifuged for 5 minutes, 400g at 4°C. 
After decanting the supernatant, 500μL of a working solution of a whole blood 
lysing reagent (Beckman Coulter Inc.) was added to each tube. The samples were 
washed twice using 2mL of PBS and centrifuged for 5 minutes, 400g at 21°C. To 
the supernatant 500μL of 1% paraformaldehyde (Sigma, UK) was added to the 
tubes. All samples were then analysed using BD LSR Fortessa Cell Analyser (BD; 
flow cytometer) and recorded with BD FACSDiva software. 
 
2.1.14.2. Flow cytometry and analysis 
 
The principles of flow cytometry were described in section 2.1.13.1 and the same 
principles apply to the analysis of the cell types and activation markers. 
Combined with FSC and SSC data used to identify cell types (Figure 2.10) the 
staining pattern of each leukocyte was used to calculate the relative percentage of 
cells expressing each inflammatory marker. In addition, in each case the 
respective median fluorescence intensity (MFI) was determined and provides a 
measure of the number of markers present on each cell type.  To ensure that the 
fluorescence recorded was due to specific primary antibody binding to the 
desired marker, and not due to non specific binding (i.e. Fc receptors), isotype-  
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Antigen 
Role Of Surface 
Marker 
Cells/inflammatory 
marker identified 
using antibody 
Fluorochrome 
Conjugated 
With Antibody 
Source Dilution 
CD14 
Pattern recognition 
receptor which binds 
bacterial 
lipopolysaccharide 
Monocytes 
Fluorescein 
isothiocyanate 
(FITC) 
Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
20μL 
CD16 
Low affinity Fc 
receptor found on 
natural killer cells, 
neutrophils and 
monocytes 
Monocytes, 
neutrophils 
Phycoerythrin 
(PE) 
Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
2 μL 
CD16b 
Fc receptor (FcyRIIIb) 
which binds to Fc 
portion of IgG 
antibodies 
Neutrophils 
(Granulocytes) 
PE 
Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
20μL 
CD3 
Forms part of the T-
cell co-receptor 
required for T-cell 
activation 
Lymphocytes FITC 
eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD4 
Glycoprotein 
expressed on T-helper 
cells which interact 
with MHC-II molecules 
CD4+ Lymphocytes 
Combined PE & 
cyanine dye (Cy7 
(PE-Cy7) 
eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD8 
Glycoprotein 
expressed on cytotoxic 
T-cells which interact 
with MHC-I molecules 
CD8+ Lymphocytes 
Combined 
peridinin 
chlorophyll 
protein & 
cyanine dye 
(PerCP-Cy5.5) 
eBioscience 
Inc, San 
Diego, USA 
2.5μL 
CD162 
Expressed by 
activated leukocytes, 
PSGL-1 is the high 
affinity receptor for P-
selectin (expressed by 
platelets and 
endothelial cells, 
important for 
leukocyte rolling) 
P-Selectin 
Glycoprotein Ligand-
1 
Allophycocyanin 
(APC) 
eBioscience 
Inc, San 
Diego, USA 
5μL 
CD62L 
Expressed by 
activated 
macrophages, 
monocytes and 
neutrophils. Important 
for leukocyte rolling 
L-Selectin APC-eFluor 780 
eBioscience 
Inc, San 
Diego, USA 
5μL 
CD11b 
Expressed by 
activated leukocytes. 
Aids in leukocyte 
adhesion and 
migration 
Integrin alpha M 
(ITGAM) or 
Macrophage-1 
antigen (MAC-1) 
Pacific blue (PB) 
Beckton, 
Dickinson 
& company, 
New Jersey, 
USA 
10μL 
 
Table 2.2. The fluorochrome conjugated antibodies used to identify specific cell surface 
markers 
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matched control antibodies were used.  MFIs were recorded in absolute values  
 
Flow cytometry data were analysed using the BD FACSDiva 6.0 software. During 
flow cytometry the fluorochromes are excited by light, which causes the emission 
of fluorescent light at a longer wavelength.  The fluorochromes do not emit light 
at a specific wavelength but over a fairly wide range known as emission spectra.  
Overlapping of emission spectra between fluorochromes can occur therefore 
when using multiple fluorochromes, the emitted light from the leading and 
trailing tails from a neighbouring fluorochrome is registered. 
 
Figure 2.10. Dot plot showing the FSC vs. SSC characteristics of leukocyte subpopulations 
derived from human blood.   
Lymphocytes are the smallest leukocytes with little granularity in the cytoplasm.  They are 
identified by having a low FSC and SSC (P1 gate; green).  Monocytes (P2 gate; red) are larger in 
size and therefore distinguished by a higher FSC.  Granulocytes (predominantly neutrophils) are 
the largest cell type according to size and contain many granules within their cytoplasm and 
therefore have a higher FSC and SSC (P3 gate; blue).  The black dots with low FSC and SSC 
represent dead cells and/or debris. 
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Since 7 different fluorochromes were used for cell type and activation marker 
analysis, spectral overlap had to be accounted for by manual compensation to 
allow accurate data analysis.  In order to manually compensate, single staining of 
samples with each antibody conjugated fluorochrome was recorded on the flow 
cytometer. 
 
Analysis of cell population size and fluorescent intensities of the different 
leukocytes were achieved by constructing dot plots and histograms.  In order to 
segregate leukocyte populations accurately, gates had to be established on the 
dot-plots.  The quadrant boundaries between cells that stained positive and 
negative for a particular leukocyte population was determined according to the 
fluorescence distribution of positively stained cell relative to the unstained 
sample. MFIs were reported as ratios relative to the MFI of the iso-control 
antibodies. (Figure 2.11) 
Figure 2.11: Calculation of the relative Fluorescence Intensity (RFI)  
Example histograms staining positive for CD62L and the isotype control for CD62L.  Panel shows 
the MFI for the CD62L iso-type control and a histogram of cells positively stained for CD62L. The 
relative fluorescence intensity (RFI) was calculated by dividing the MFI for the positive antibody 
by the MFI for the iso-type control for each marker.  
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2.1.15 Measurement of circulating inflammatory mediators 
 
2.1.15.1 MCP-1/CRP (Flowcytomix) 
 
Levels of the chemokine MCP-1 and Hs-CRP were determined by flow cytometry. 
A FlowCytomix five-plex-assay (eBioscience, Vienna, Austria) was performed. 
Each FlowCytomix contains antibodies carrying beads of different sizes that bind 
free mediator. These bead complexes are then labelled with a fluorescent dye and 
are then detected by a flow cytometer.  
 
For each mediator 25μl of each standard (S1-7: Concentration range for MCP-1: 
41-30000pg/ml; hs-CRP:0.1-70ng/ml), blank assay buffer and serum samples 
were transferred into flow cytometry tubes and mixed with 25μl of bead mixture 
and 50μl biotin-conjugate-mix. The tubes were then incubated for 2 hours at 
room temperature. The samples were then washed twice using 1ml of assay 
buffer. Following this 50μl of phycoerythrin (PE) conjugated streptavidin 
solution was added to the samples and further incubated for 1 hour at room 
temperature. Samples were then washed twice and 400μl of assay buffer added 
to the tubes. Sample data were then acquired by multiparameter flow cytometric 
analysis using a BD LSR Fortessa Cell Analyser (BD; flow cytometer) and 
recorded with BD FACSDiva software (Figure 2.12).  The detection limit of the 
assay was 18.2 pg/mL and 0.067 ng/mL for MCP-1 and hs-CRP respectively. The 
mean inter-assay and intra-assay coefficients of variation for MCP-1 were 12.5% 
and 3.4% respectively whereas for hs-CRP the inter-assay coefficient variation 
was 3.4% and the intra-assay 9.6%. 
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Figure 2.12 Flowcytomix Flow cytometry  
The antibody bead population (P1) was gated according to the FSC/SSC and the variable signal 
from the 700nm excitation probe (R670/14-A). This allows differentiation between MCP-1 and 
hs-CRP (B). The amount of cytokines for numerous data-points vary in the amount of reporter 
fluoresecence PE (YG 582/15-A). This allows standard curves to be generated from the MFI of the 
standards (S1-7). Test sample MFI values are then read off the standard curves.   
 
2.1.15.2 CXCL-1/CXCL-5 (ELISA) 
 
Circulating serum CXCL-5 (ENA-78) or CXCL-1 chemokine levels were assessed 
using 100μl frozen serum per direct sandwich ELISA in duplicate using the 
Human CXCL-5/ENA-78 DuoSet kit DY254 or the Human CXCL-1/Gro alpha 
duoset kit DY275 (R&D Systems, USA). In each case, a standard curve was 
generated (Figure 2.13) with the provided standards and utilized to calculate the 
quantity of chemokine in the sample tested. Ninety-six–well plates (R&D systems, 
USA) were coated overnight with capture antibodies at room temperature. After 
blocking of plates, supernatant samples and standard proteins were added to the 
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wells. After a 2 hour incubation period and a washing step, a biotin-labelled 
antibody was added to each well and incubated for an additional 2 hours. Plates 
were washed and streptavidin-horseradish peroxidase was added. Colour 
reaction was achieved using a tetramethylbenzidine substrate solution (TMB; 
and was stopped by a 1N sulphuric acid stop solution. Immediately thereafter, 
optical density values were measured at 450 and 570 nm on a 
spectrophotometric plate reader (MRX-TC Revelation, Dynex Technologies, UK). 
Optical values were corrected for the 96 well plate, by subtracting the 570nm 
values from the 470nm.     
 
Figure 2.13. Example standard curves for CXCL-1 and CXCL-5 
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2.1.16 Measurement of plasma nitrite and nitrate concentration 
 
To measure plasma nitrite and nitrate concentration the technique of ozone 
chemiluminescence; a powerful quantitative analytical technique for measuring 
NO species in biological fluids, was used as previously described (Ignarro et al., 
1993). Prior to chemiluminescence, plasma samples were filtered to remove 
proteins by centrifugation  at  15000g  for  60 minutes  at  4°C,  using  Microcon®  
Ultracel  YM\3  (3  kDa)  (Millipore  Corporation,  Billerica,  USA)  filters  that  had  
been  double-washed  in  NOx free  water  to  remove  any potential  nitrate/ 
nitrite contamination.   
 
The chemiluminescence apparatus consists of two distinct components the purge 
vessel (reaction chamber) and the NO chemiluminescence analyser. Within the 
purge vessel, gaseous N2 is continuously bubbled to render the chamber anoxic. 
Here, standards and biological samples containing NOx are reduced to NO in an 
equimolar fashion. The NO produced by these reactions is carried in the gaseous 
phase through the vessel into the NO chemiluminescence analyser (NOA 280i, 
Sievers, Manchester, UK), where it reacts with ozone. Light is emitted as a result 
of the chemical reaction (Equation 2.3), and is detected by the analyser, 
producing a digital signal corresponding to NO concentration (therefore NOx 
levels as appropriate).  
 
NOx levels were calculated by comparison to a standard curve generated daily 
from known standards, concentration range of sodium nitrite (0.1-10µM) and 
sodium nitrate (1-100µM) (see figure 2.14 and 2.15).   
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Equation 2.3. Reaction of ozone and NO to chemiluminescent light (*=nitogen dioxide in an  
excited state) 
 
To determine total [NOx], samples were incubated in a strongly reducing 
environment using 0.1 mol/L vanadium (III) chloride in 1M hydrochloric acid 
refluxing at 95°C under N2 which results in a sequential reduction of all NO3- to 
NO2-, and then all NO2- to NO (Equations 2.4-2.5) 
 
Equation 2.4 Reduction of NO3- by vanadium (III) chloride to produce NO. 
  
Equation 2.5 Reduction of NO2- by vanadium (III) chloride to produce NO. 
Concentration of nitrite from samples was determined by addition of samples to 
milder reducing conditions, 1.5 % potassium iodide in glacial acetic acid under N2 
at room temperature (equation 2.6), which is unable to reduce nitrate.  
 
Equation 2.6 Reduction of NO2- by potassium iodide to produce NO. 
Concentrations of nitrate were calculated by subtraction of nitrite from NOx 
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values. Nitrate/nitrite concentrations were calculated by comparison to the 
standard curves.    
 
Figure 2.14 An example trace that is produced when standards of known concentration are 
injected into the purge vessel. 
 
Figure 2.15 A typical standard curve produced prior to the measurement of nitrite in liquid 
samples (slope=8.6; intercept=-8.4; R²=0.9996) 
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2.1.17 Measurement of plasma cGMP 
 
On collection of plasma for cGMP determination, samples were incubated with a 
competitive non-selective phosphodiesterase (PDE) inhibitor, 3-isobutyl-1-
methylxanthine (IBMX, 100μm) to prevent cleavage of cGMP during storage at -
80oC. The concentration of cGMP in samples was determined using an enzyme 
immunoassay (cGMP Enzymeimmunoassy Biotrak System RPN226, GE 
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions 
(www.gelifesciences.com). The assay is based on competition between unlabeled 
cGMP and a fixed quantity of peroxidase labeled cGMP for binding sites on a 
cGMP-specific antibody (Figure 2.16). Samples measured were compared to a 
standard curve generated from known standards (Figure 2.17). 
 
Figure 2.16 Schema of enzyme immunoassay for measurement of cGMP levels 
(cGMP=cyclic Guanosine monophosphate) 
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Samples were diluted 1:20 in assay buffer (0.05M sodium acetate buffer pH 6.0 
containing 0.002% (w/v) bovine serum albumin and 0.01% (w/v) preservative). 
Using a 96-well plate, 100μl of cGMP antibody was added to each well that had 
been pre-coated with donkey anti-rabbit IgG. To each well 20μl of acetylation 
reagent (2:1 of triethylamine and acetic acid) was added with 50μl of each 
sample or standard. Following a 2-hour incubation at 4oC, 100μl of lyophilized 
cGMP conjugated to horseradish peroxidase was added to each well and 
incubated at 4oC for 1 hour. Each well was then washed 4 times with wash buffer 
(0.01 M phosphate buffer pH 7.5 containing 0.05% (v/v) Tween™ 20) and 200μl 
of enzyme substrate 3,3’,5’5’- tetramethylbenzidine (TMB) was added to each 
well and incubated at room temperature for 30 minutes. The colourless substrate 
TMB is converted into blue by the peroxidase and then 100μl of 1M sulphuric 
acid was added, turning the blue colour into yellow, and the plate was read at 
450nm using a spectrophotometric plate reader (MRX-TC Revelation, Dynex 
Technologies, UK). The colour change depends on the amount of enzyme linked 
to the well and is inversely proportional to the cGMP concentration.  Each sample 
and standard were analysed in duplicate.  
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Figure 2.17 Standard curve for determination of cGMP levels.  
(%B/B0=% bound; cGMP=cyclic guanosine monophosphate). 
 
2.1.18. Data and statistical analyses 
 
Analysis was performed using GraphPad™ Prism software version 5.0 for Mac 
OsX and SPSS version 19, (SPSS Inc, Chicago, Ill). All p values are 2 sided and 
significance accepted as p<0.05. Power calculations were performed using 
Graphpad statmate (Graphpad Software) and are represented in the 
experimental protocols in each chapter. For the clinical trial analysis was based 
on the intention-to-treat principle. Baseline demographic and clinical variables 
were summarised for each arm of the study. Descriptive summaries of the 
distributions of continuous baseline variables are presented in terms of 
percentiles (e.g. median, 25th and 75th percentile), while discrete variables are 
summarised in terms of frequencies and percentages. Comparisons are between 
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the sodium nitrite-treated and placebo control-treated group for the primary and 
secondary outcomes. Statistical analyses were conducted blind to the treatment 
groups. The statistical comparisons of the treatment arms with respect to the 
primary endpoint was performed using the Wilcoxon rank-sum test. For 
comparisons between normally distributed data statistical comparisons were 
performed using unpaired T test, for parametric data either the Mann-Whitney or 
Wilcoxon rank sum tests were used.    
 
For comparisons between treatment groups assessing platelet reactivity, white 
cell counts and chemokine levels are expressed as mean ± SEM and analysis was 
performed using two-way repeated measures ANOVA, including Bonferroni 
adjustment for multiple comparisons as appropriate.  
 
Determination of correlations were performed using the Pearson’s correlation 
coefficient analysis of least-squares and are expressed as 95% confidence 
intervals. 
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2.2 Cell culture experiments 
 
2.2.1 Human Endothelial Cell Culture 
 
Human coronary artery endothelial cells (HCAECs, Lonza, UK) and human 
umbilical vein endothelial cells (HUVECs, Lonza, UK) were cultured in endothelial 
growth medium (HCAECs: EGM-2 MV, HUVEC: EGM-2. Lonza, UK) containing 
endothelial growth factors, 5% fetal bovine serum (FBS), 100 U/mL of penicillin, 
and 100 μg/mL of streptomycin at 37°C in humidified air (5% CO2). Cells 
passaged 3 times to 80%-90% confluency were used (Figure 2.16). 
 
2.2.2 Human Coronary Artery Smooth Muscle cell culture 
 
Human Aortic Smooth muscle cells (HmCASMCs, Lonza, UK) were cultured in 
smooth muscle growth media (SmGM-2, Lonza, UK) containing smooth muscle 
cell growth factors, 5% fetal bovine serum (FBS), amphotericin and streptomycin 
at 37°C in humidified air (5% CO2). Cells passaged 3 times each to 80-90% 
confluency were used (Figure 2.18).  
 
2.2.3 Cell Treatments 
 
2.2.3.1 Hypoxia  
 
For hypoxia, confluent HCAECs/HUVECs and HmCASMCs were initially treated 
with various concentrations of sodium nitrite (0.1-10µM) and  
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HCAECs 
HUVECS     
HmCASMCs 
 
 
1 Ampoule of primary ECs (from Lonza company) 
 
 
 
 
 
 
 
 
 
 
P2 = 1 x T75 flask (» 2x106 cells/flask) 
 
 
 
P3  = 6 x T75 flasks 
Cells stored in N2  
FREEZE in N2 
THAW = 1 ampoule only 
4 x (6 wells/ plates » 20,833 cells/well) for HCAEC 
 
 
 
 
CALCULATION & SET UP of vessels Þ cf Chart 
1 
SUBCULTURE 
STORAGE 
THAWING & ADDING OF CELL IN FLASK 
P4 = 1 x T75 flask (» 2x106 cells/flask) 
HUVEC = P1 
 
 
 
 
 
HmCASMC = P3  
HCAEC = P3  
 
 
 
 
 
 
P5 = 4 x T75 flasks 
HUVEC = Human Umbelical Vein Endothelial Cells 
HmCASMC = Human Coronary Artery Smooth Muscle Cells 
HCAEC = Human Coronary Artery Endothelial Cells 
 
24- 26 vials for HUVEC 16 vials for HCAEC and HmCASMC 
Figure 2.16. Diagram depicting method of cell passaging ready for experimentation 
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then exposed to hypoxia (5% or 1% O2) by incubation in a Coy hypoxic glove box, 
(Coy Laboratory Products Ltd, Figure 2.19) at 37°C that subjected the cells to a 
controlled gas mixture consisting of N2 and 5% CO2 for 24 hours. For normoxic 
controls, cells were incubated in the standard CO2 incubator under normoxic 
conditions (21% O2, 5% CO2, and 74% N2).   
 
 
 
Figure 2.19. Coy hypoxic glove box 
 
2.2.3.2 I/R injury experiments 
 
For the I/R injury simulation studies, 70% confluent HCAECs and HmCASMCs 
were exposed to anoxia (0.1% O2) by incubation in a Coy Hypoxic Glove Box, (Coy 
laboratory products Ltd) at 37°C that subjected the cells to a controlled gas 
mixture consisting of N2 and 5% CO2 for 24 h. Cells were then reoxygenated by 
being returned to the standard CO2 incubator under normoxic conditions (21% 
O2, 5% CO2, and 74% N2) with the replacement of fresh oxygenated EBM media 
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(to simulate reperfusion) or oxygenated EBM media containing nitrite (1 µM or 3 
µM). Cells were then analysed at 8, 24h and 48h after reperfusion. For normoxic 
controls, cells were kept at 21% O2 in the standard CO2 incubator (5% CO2, and 
74% N2) for 24h and then the EBM media replaced as above.   
 
2.2.4 Flow cytometry analyses of cell apoptosis and death 
 
Flow cytometry is a validated and effective method of identifying apoptosis with 
comprehensive reviews of its use, detailing descriptions of cell features that can 
be measured (Darzynkiewicz et al 1992; Vermes et al., 2000; Wlodkowic et al., 
2012). During apoptosis phosphatidyl serine (PS) residues, which are normally 
located on the internal surface of the plasma membrane, redistribute to the 
external surface. PS binds the protein Annexin V and the change can be observed 
by incubating unfixed cells with fluorochrome labelled Annexin V. Combining 
detection using directly-conjugated Annexin V with viability exclusion using 
Propidium Iodide (PI) or 7-AAD (7-aminoactinomycin D) allows for assessment 
of non-apoptotic vs. early and late apoptotic cells. Viable cells will contain neither 
stain, apoptotic cells with intact plasma membrane are stained only by Annexin 
V-FITC, whereas cells in secondary necrosis, consecutive to apoptosis, contain 
both stains. This method is well established and has the advantage that Annexin 
V-FITC will bind immediately to cells which have surface exposed PS and can 
therefore be analysed almost instantaneously  
 
Following treatment as described in section 2.2.3, HCAEC, HUVEC and HmCASMC 
cultures were washed with PBS, trypsinised and centrifuged at 1000 rpm for 5 
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min. The cell pellets were then re-suspended in PBS to remove any trace of 
trypsin and re-centrifuged at 700 g for 5 min.  Cells were treated with 
recombinant annexin V antibody conjugated to Alexa Fluor 488 (Trevigen, 
Gaithersburg, USA) for determination of apoptosis. Necrotic cells were shown by 
binding of the red-fluorescence PI nucleic acid binding dye (Trevigen, 
Gaithersburg, USA).  PI is impermeable to live cells and apoptotic cells, but stains 
necrotic cells with red fluorescence, binding tightly to the nucleic acid in the cell. 
All samples were then analysed using BD LSR Fortessa Cell Analyser (BD; flow 
cytometer) and recorded with BD FACSDiva software (Figure 2.20). 
 
Figure 2.20 HUVEC Viability assessed by flow cytometry under 5% hypoxia  
Representative flow cytometry dot plots of HUVECs exposed to 24 hours 5% hypoxia.  
Representative FSC versus SSC and the annexin V-FITC (B-530/30-A) versus propidium iodide 
(PI) (YG-710/50-A) plots are shown. Values in Q1 are positive for PI and negative for annexin and 
are necrotic cells. Q2 are cells positive for annexin V and PI and are apoptotic. Q3 are negative for 
both PI and annexin V (Viable), Q4 are early apoptotic (annexin positive and PI negative).   
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2.2.5 Cell counting 
 
A haemocytometer consists of a special glass slide with an accurately ruled 
etched grid of precise dimensions. Originally developed for counting blood cells, 
hence the name haemocytometer, it can also be used for counting 
cells/microorganisms in a liquid medium. It not only allows the counting of cells 
in suspension, but the percentage of viable (intact) cells can be determined using 
the dye exclusion method. Dead cells take up the dye trypan blue and appear blue 
under the microscope. Living cells exclude trypan blue, and appear white. Thus, 
the percentage of viable cells can be calculated.  
 
Confluent HCAEC, HUVEC and HmCASMc cultures were washed with PBS, 
trypsinised and then centrifuged at 700g for 5 minutes to form cell pellets. The 
cell pellets were then resuspended in 200μl of growth medium to disaggregate 
the cells. Of this cell suspension 50μl was taken and mixed with 50μl trypan blue 
solution (0.4% w/v trypan blue in PBS) such that approximately 50-100 cells 
were observed over each of the 9 large squares of the haemocytometer chamber. 
The large squares in the haemocytometer have an area of 1 mm2. When the 
coverslip is passed over the grid, the depth of the chamber is 0.1 mm. Thus, the 
total volume over each large square = 1 x 1 x 0.1=0.1 mm3 = 1x10-4ml.  Cells were 
counted from 5 large squares and the mean cell number (n) was calculated. Since 
the cell suspension was mixed with the same volume of trypan blue, i.e. diluted 2-
fold: the number of cells per ml in the suspension= n x 104 x 2 
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From the cell number obtained from the haemocytometer the cell viability was 
calculated: 
 
%Viability =  Total number of viable cells             X  100 
  Total number of viable and nonviable cells 
 
2.2.6 Scratch-test assay 
 
The scratch assay is a valuable tool for studying multi-cell migration in vitro and 
was conducted as a measure of cell growth (Liang et al., 2007). In this assay, 
which was first developed almost 50 years ago (Todaro et al., 1965), contact-
inhibited cells are grown on a 2D surface until they form a confluent monolayer. 
A strip of cells is then removed by mechanically scraping the monolayer. 
Molecules of interest as potential therapeutics are added to the wells and images 
of cell movement are captured at regular intervals within a 24 hour period for 
data analysis (Yarrow et al., 2004; Yarrow et al., 2005). The monolayer responds 
with cell spreading and migration into the denuded region until the wound is 
closed. 
 
HCAECs and HCASMCs were plated in 6 well plates in EGM-2 MV and SmGM-2 
growth media respectively and allowed to grow to approximately 90% 
confluence.  EGM-2 complete culture media was then removed and replaced with 
starvation media for 8 hours. A uniform scratch in the monolayer was then 
produced using a sterile pipette tip approximately 500 µm in width. Starvation 
media was replaced with 2ml of either complete growth media (EGM-2 MV for 
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HCAEC/SmGM-2 for HCASMC) or growth media containing 1 or 3μM nitrite and 
incubated in 1% hypoxia for 24 hours. Microscopic images were taken at 10x 
magnification after the scratch was made and then after 24 hours of treatment. 
Images were analyzed by determining the distance between cells on either side of 
scratch measured at baseline and at 24 hours. The absolute difference in scratch 
closure was then calculated for each treatment comparing 24 hours to baseline 
(Figure 2.21).  
 
Figure 2.21. Scratch Assay.  
A scratch was introduced into a confluent monolayer of cells (A) by drawing a tip across the cell 
layer (B). The denuded area is imaged to measure the boundary of the wound at pre-migration 
(C) and after cells have migrated inward to fill the gap (D). 
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2.2.7 Identification of potential nitrite reductases involved in nitrite-
induced effects of cell growth/survival  
 
To investigate the role of specific nitrite reductases in 5% and 1% hypoxic 
conditions, HCASMCs, HCAECS and HUVECS were all incubated with the selective 
XOR inhibitor allopurinol (100μM) (Millar et al., 1998) both in the absence and 
presence of 3μM nitrite.  To investigate the role of eNOS, HCAECS and HUVECS 
were treated with the NOS inhibitor L-nitro monomethyl arginine (L-NMMA; 
300μM).  All drug pretreatments were for 30 min prior to nitrite incubation. 
Additionally to test whether the effects of nitrite were cGMP mediated the 
selective soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ, 1 mM) (Garthwaite et al., 1995) was added to a 
selection of 1% hypoxia experiments for both HCAECs and HCASMCs.  
 
2.2.8 Determination of the expression of potential nitrite reductases and 
markers of cell growth 
 
To determine whether any of the treatments alter the expression of key nitrite 
reductases western blotting was conducted. In particular this technique was 
utilized to assess levels of eNOS, phosphorylated-eNOS (p-eNOS) and XOR in 
endothelial cells (HCAEC, HUVEC) and XOR in HmCASMCs. Additionally cell cycle 
markers (p21 and cyclin D1) were measured to see if the treatments altered their 
expression.  This technique comprises 3 main steps; sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), gel transfer and incubation and 
detection of proteins with the appropriate antibodies. 
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2.2.8.1 Sample Preparation for western blotting 
 
After treatments, HCAEC, HUVEC and HmCASMc cultures subjected to various 
treatments were washed with PBS, trypsinised (0.25%) and centrifuged at 700 g 
for 5 min. The supernatant was removed and the cell pellets snap frozen in liquid 
nitrogen and stored at -20oC until analysis. Following defrosting cell pellets were 
lysed using a stock solution of tissue lysis buffer (10mM Trix-HCL, 50mM NaCL, 
30mM NaPPi and 2mM EDTA) and 0.5 M NaF, 1 % Triton X-100, 0.2 M Na₃VO₄ as 
well as 1 µg/ml each of the protease inhibitors benzamidine, aprotinin, antipain, 
leupeptin, pepstatin A and AEBSF (Table 2.3). 
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2.2.8.2 Protein determination 
 
To quantify the amount of protein in each sample a Bradford Assay (Bradford, 
1976) was performed. A standard curve was generated from bovine serum 
albumin (BSA, 2mg/ml) by serial dilution at 0.125-2 mg/ml (figure 2.23).  10 µL 
of each standard and 10 µL of each sample was loaded in duplicate on a 96-well 
plate.  200 µL of reagent (Bio-Rad, UK; diluted 1:5 in MQ H₂O) were added to each 
of the wells.  The light absorbance was measured using a spectrophotometric 
plate reader (MRX-TC Revelation, Dynex Technologies, UK) at wavelength 570 
nm.  The protein concentration was determined by comparing the light 
absorbance of the unknown samples to the standards. The protein concentration 
of each sample was then adjusted to 20 µg/µl in tissue lysis buffer.  
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Inhibitor Source Mechanism of action Final conc. 
Benzamidine Sigma 
#B6506 
Potent inhibitor of thrombin and trypsin 
 
1 mg/l  
(5.7 µM) 
Antipain Sigma 
#A6191 
Reversible inhibitor of serine and cysteine proteases. Inhibits 
papain and trypsin more specificity than leupeptin. Plasmin is 
inhibited only slightly.  
1 mg/l  
(1.5 µM) 
Aprotinin Sigma 
#A1153 
Basic single-chain polypeptide that inhibits numerous serine 
proteases by binding to the active site of the enzyme, forming 
tight complexes. It inhibits above all plasmin, kallikrein, trypsin, 
chymotrypsin and urokinase, but not carboxypeptidase A and B, 
papain, pepsin, subtilisin, thrombin and factor X. Used in cell 
culture to prevent proteolytic damage to cells and to extend 
lifetime of cells. 
1 mg/l 
(0.15 µM) 
    
Leupeptin Sigma 
#L0649 
Tripeptide aldehyde. Reversible competitive inhibitor of serine 
and cysteine proteases. 
2 mg/l 
(4.2 µM) 
Pepsatin A Sigma 
#P5318 
Pentapeptide derivative. Reversible inhibitor of aspartic 
proteases, e.g. pepsin, cathepsin D, chymosin, renin 
0.7 mg/l 
(1.5  µM) 
AEBSF Sigma 
#76307 
Irreversible inhibitor of Thrombin and other serine proteases. 
Inhibits by acylation of the active site of the enzyme. Much less 
toxic than PMSF and DFP 
100mg/l 
(400 µM) 
 
Table 2.3 List of Protease inhibitors with their respective mechanism of action.  
 
Figure 2.23 Typical standard curve generated from the Bradford protein assay. 
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2.2.8.3 SDS-PAGE 
 
Samples were diluted 1 in 5 in Laemmli’s loading buffer (final concentration 0.05 
M Tris-HCl, 6 % glycerol, 0.002 % bromophenol blue, 1.7 % SDS and 1.55 % DTT) 
and denatured by boiling at 95°C for 5 min. 10 % Mini-PROTEAN® TGX™ precast 
gels (Bio-Rad, Hertfordshire, UK) were used.  The precast gel was securely locked 
in to a casting stand.  From the gel, the comb was removed and the casting stand 
was placed inside a Mini-PROTEAN® TGX™ Tetra System gel tank.  Running 
buffer (25 mM Tris-Base, 192 mM glycine, 0.1 % SDS) was then added to the gel 
tank until all wells were fully submerged and no air bubbles were present inside 
any well.  10 µl of protein marker (Precision Plus Protein™ Dual Colour 
Standards, 10 kDa – 250 kDA, Bio-Rad, Hertfordshire, UK) was loaded in to the 
first well followed by 30 µl of each diluted sample into subsequent wells 
providing an equal protein loading of each well. The proteins in the samples were 
then separated at 200 V for 90 min, i.e. until the dye was visible at the bottom of 
the gel. 
 
2.2.8.4 Protein transfer 
 
A piece of blot paper (PROTEAN®XL Size extra thick, Bio-Rad, Hertforshire, UK) 
and a Hybond™ Enhanced Chemiluminescence (ECL)™ nitrocellulose membrane 
(Amersham Biosciences, UK) was soaked in positive buffer (100 ml methanol + 
18.3 g Tris-base, made up to 500 ml with water) for 20 min.  A further piece of 
blot paper was soaked in negative buffer (100 ml methanol + 1.5 g Tris-base + 2.6 
g 6-amino-n-caprioic acid, made up to 500 ml with water) for 20 min. The 
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positive blot paper was placed on a platinum anode followed by the nitrocellulose 
membrane, then the gel and finally the negative blot paper.  In order to ensure 
homogenous transfer the ‘stack’ was rolled to ensure removal of air bubbles.  A 
cathode was then placed on to the ‘stack’ and the proteins were then transferred 
from the gel to the membrane by electrotransfer at 100 mA using a Trans-Blot® 
SD semi-dry transfer cell (Bio-Rad, Herforshire, UK) for 75 min.  Following this 
the membrane was stained with 0.1 % Ponceau S Solution.  Ponceau S reversibly 
stains proteins so that the membrane can be visually inspected to ensure equal 
loading and transfer.  With distilled water the Ponceau S was washed 3 - 5 times 
with gentle agitation on a Luckham R100 Rotatest Shaker (Ecomat, Reading, UK) 
for 3 min per wash step. 
 
2.2.8.5 Identification of proteins 
 
To determine the expression of proteins of interest the nitrocellulose membranes 
were then exposed to specific antibodies. Firstly, to prevent non-specific binding, 
each membrane was blocked for 1 hour at room temperature with gentle 
agitation with 5 % non-fat milk (Marvel®, Dublin, Republic of Ireland) in Tween-
20 buffer (150 mM NaCl, 10 mM Tris-HCl pH 7.6 and 0.05 % (w/v) Tween-20) 
and then washed with Tween-20 buffer.  The membranes were then incubated 
overnight at 4°C with the primary antibody of interest (Table 2.4) diluted in 0.05 
% (w/v) Tween-20 buffer.  The following day, the membranes were washed 
again with Tween-20 buffer and incubated with the secondary antibody for an 
hour (Table 2.6).   
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2.2.8.6 Detection and quantification of proteins 
 
In order to visualise the antibody-bound proteins on the membrane the Clarity™ 
Western ECL kit was used (Bio-Rad, Hertfordshire, UK).  Solution A (peroxide 
solution) and solution B (Luminol / enhancer solution) were mixed in a 1:1 ratio 
and the membrane incubated in the mixture for 5 min.  The excess was then 
drained and bands were visualized using a FluorChem E digital imager 
(proteinsimple, Santa Clara, CA, USA). 
 
 
Table 2.4. Primary and secondary antibodies used for western blot analysis.  
XO-Xanthine Oxidoreductase, e-NOS-endothelial nitric oxide synthase, P-eNOS- Phosphorylated 
endothelial nitric oxide synthase 
 
Antibody Concentration 
eNOS 1O Ab: 1:2000 Rabbit Anti-human (Santa Cruz, Germany) 
20 Ab: 1:5000 Goat Anti-rabbit (Abcam, UK) 
p-eNOS 1O Ab: 1:1000 Rabbit Anti-human (Cell signalling, UK)  
20 Ab: 1:2000 Goat Anti-rabbit (Abcam, UK) 
Anti-XOR 1O Ab: 1:2000 Rabbit Anti-human (Abcam, UK) 
20 Ab: 1:3000 Goat Anti-rabbit (Abcam, UK) 
p21  1O Ab: 1:1000 Mouse Anti-human (BD Bioscience, UK ) 
2O Ab: 1:2000 Goat Anti-mouse (Abcam, UK) 
Cyclin-D1 1O Ab: 1:1000 Rabbit Anti-human (Cell signalling, UK) 
20 Ab: 1:2000 Goat Anti-rabbit (Abcam, UK) 
Anti-β-actin 1O Ab: 1:2000 Mouse monoclonal (Millipore, UK) 
20 Ab: 1:2000 Goat anti-mouse (Abcam, UK) 
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Image J (National Institute of Health) was used to quantify the integrated density 
of protein on Western blots. For each blot the background signal was subtracted 
from experimental integrated densities to obtain sample values. Background 
subtracted values for nitrite reductase (eNOS, p-ENOS, XOR) or cell cycle (p21, 
cyclin D1) signal were then divided by background subtracted actin signal to 
obtain the HA/actin ratio. 
 
2.2.9 Measurement of cGMP  
 
Levels of cGMP in cell samples was determined using an enzyme immunoassay 
(cGMP Enzymeimmunoassy Biotrak System RPN226, GE Healthcare, Little 
Chalfont, UK) according to the manufacturer’s instructions 
(www.gelifesciences.com), using a 96 well plate optical density reader. This 
process has been described previously in section 2.1.17 for the analysis of plasma 
cGMP. The main difference in the steps for the analysis, was the preparation of 
the pellets prior to analysis.  For the cell pellets the samples were 1st lysed to 
enable analysis. Lysis reagent 1 (Dodecyltrimethylammonium bromide) was used 
to hydrolyse cell membranes releasing intracellular cGMP with the 2nd lysis 
reagent sequestering the key component in lysis reagent 1 and ensuring cGMP is 
free for subsequent analysis. Lysis reagent 1 was added to cultured cells followed 
by a 5 minute incubation before assay (fig 2.20). The antiserum is reconstituted 
with lysis reagent 2 rather than assay buffer as performed in section 2.1.17. 
Samples measured were then compared to a standard curve generated from 
known standards. 
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Figure 2.22.  Cell lysis protocol 
A. Cultured cells present in 6 well plates were decanted and washed 
B. Cells were lysed using lysis reagent 1. 
C. Cells were transferred to new plate 
D. Assay was performed 
 
2.2.10 Data and statistical analyses  
 
All data were analysed using GraphPad Prism version 5.0 for Mac OsX (GraphPad 
Software, San Diego, CA; www.graphpad.com). All p values are 2 sided and 
significance accepted as p<0.05.  All values are expressed as mean ± standard 
error of the mean (SEM) with the n value representing the experiments in that 
particular treatment group. For cell number, viability, cGMP levels and 
expression of nitrite reductases/cell cycle markers one-way ANOVA with 
Bonferroni post-hoc tests for individual group comparisons was used.  
Determinations of correlations were performed using the Pearson’s correlation 
coefficient analysis of least-squares.   
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Chapter 3.0 
 
 
Investigation of the safety and 
efficacy of intracoronary nitrite 
infusion during primary PCI for 
acute myocardial infarction 
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3.1 Introduction 
 
Reperfusion injury remains a limitation to the beneficial effects of primary PCI for 
STEMI (Frolich et al 2013). A potential solution has emerged in the form of 
inorganic nitrite. The activity of nitrite resides in its propensity for conversion to 
NO under the optimal conditions of low pO2 and low pH (Gladwin et al 2005), 
conditions that prevail during ischaemic episodes.  NO exerts a number of actions 
(Moncada & Higgs 1993) that are thought to underlie its cardioprotective effects 
(Johnson et al 1991) including anti-inflammatory and anti-platelet actions (Jones 
& Bolli 2006) and the prevention of the opening of the mitochondrial 
permeability transition pore (Heusch et al 2008). Pre-clinical evidence has shown 
that nitrite administered either intra-ventricular, intra-coronary but also 
intravenously reduces infarct size (Webb et al 2004; Baker et al 2007; Gonzalez 
et al 2008). In these studies the beneficial effects of nitrite were shown to be due 
to the activity of NO and were often associated with local application of nitrite, 
prior to reperfusion, into or on the organ of interest. These observations support 
investigation of the potential of nitrite in the treatment of acute STEMI, 
particularly where it could be delivered locally before balloon inflation at the 
time of primary PCI.  
 
Thus the aim of the study described in this chapter is to assess whether intra-
coronary nitrite is safe, tolerable and reduces infarct size during primary PCI in 
patients with STEMI as per the study design described in chapter 2, section 1 and 
Figure 3.1.  
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3.2 Power analysis 
 
It was hypothesised that nitrite would reduce the AUC for creatine kinase release 
by 30%, the same amount as both cyclosporine (Piot et al., 2008) and 
postconditioning (Staat et al., 2005). For a statistical power of 80% and a 
probability of a type I error of 0.05 using a two-sided test, it was calculated that 
the sample size should be 70 subjects (35 per group). It was further estimated 
that 4-8% of patients would die by the time of the endpoint at 6 months and 10% 
would either not tolerate or fail to attend the CMR scan at 6 months so an 
additional 10 patients were recruited to account for these eventualities, giving a 
total of sample of 80 patients.  
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Figure 3.1. Flow diagram of Study design  
AMI: acute myocardial infarction, OTW: Over the wire balloon, PPCI: primary percutaneous 
coronary intervention, CMR: cardiac magnetic resonance imaging, MVO: microvascular 
obstruction, LVEF: Left ventricular ejection fraction 
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3.3 Results 
 
3.3.1 General characteristics of Study population 
 
Between April 2012 and December 2012, 430 patients were hospitalised for 
management of AMI at The Barts Health Heart Attack Centre. Of these patients 
353 underwent PCI. Among these 353 patients, 13 were not evaluated for 
enrollment because study personnel were not available. Another 251 were 
evaluated and excluded for the following reasons: onset of chest pain more than 6 
hours before presentation (30), greater than 80 years of age (53), preadmission 
cardiac arrest or cardiogenic shock before primary PCI (13), previous AMI in the 
same territory (39), previous CABG (15), recruitment to other research studies 
(32), unable to consent (19), angiographically unsuitable (34), and other 
(malignancy, renal failure, pregnancy (16)). This left 89 suitable patients, of 
which 9 declined. Data are thus presented for 80 patients (40 in the control group 
and 40 in the nitrite group, Figure 3.2). 
 
Patients randomised to nitrite infusion had a longer ischaemia time than those 
who received placebo (207.05±76.35 minutes vs 171.63±67.72 minutes). All 
other baseline characteristics were similar between the treatment groups (Table 
3.1). The mean age of the trial participants was 57 years, with 84% male. The two 
study groups were similar with respect to syntax score, culprit vessel, baseline 
TIMI flow and morphine use pre-PCI (Table 3.1).  
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Figure 3.2 Consort diagram.  
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         Table 3.1 Baseline characteristics by treatment group.  
Values shown as number (%) unless otherwise stated. (PCI, percutaneous coronary 
intervention; TIMI, Thrombolysis in myocardial infarction; DES drug-eluting stent)  
a The body-mass index is the weight in kilograms divided by the square of the height in 
meters.  
b Ischaemia time determined from symptom to balloon times for each patient. 
 Nitrite (n=40) Placebo (n=40) P Value 
Age (yr) (Mean±SD) 56.35±11.16 57.60±13.20 0.649 
Sex (M/F) 36/4 31/9 0.225 
Diabetes mellitus  3 (7.5%) 3 (7.5%) 1.000 
Body-mass index (kg/m2) (Mean±SD)a 28.97±5.14 28.58±5.17 0.740 
Hypertension  20 (50.0%) 14 (35.0%) 0.258 
Hypercholesterolaemia  16 (40.0%) 12 (30.0%) 0.482 
Heart rate (BPM) (Mean±SD) 72.68±18.62 77.35±21.31 0.299 
Systolic BP (mmHg) (Mean±SD) 124.48±29.92 136.13±26.99 0.071 
Ischaemia time (min) (Mean±SD)b 207.05±76.34 171.63±67.72 0.031 
    
Culprit Vessel   0.736 
Left anterior descending 9 (22.5%) 12(30%)  
Circumflex  5 (12.5%) 5 (12.5%)  
Right coronary  26 (65.0%) 23 (57.5%)  
    
TIMI flow before PCI    0.451 
0  30 (75.0%) 31 (77.5%)  
1 6 (15.0%) 3 (7.5%)  
2 2 (5.0%) 5 (12.5%)  
3 2 (5.0%) 1 (2.5%)  
0/1 36 (90.0%) 34 (85.0%)  
Treatment before PCI     
Morphine 26 (43.3%) 34 (56.7%) 0.070 
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Area at risk scores were non-significantly higher in the nitrite group (APPROACH: 
30.88 (95%CI: 28.30 to 33.47) vs 26.63 (95%CI: 23.28 to 29.99); BARI: 27.41 
(95% CI: 24.02 to 30.80) vs 25.17 (95%CI 22.20 to 28.13) (Table 3.2). Stenting of 
the culprit lesion was performed in 97.5% of all patients. Use of thrombectomy 
catheters, drug-eluting stents and anti-platelet therapy were similar between the 
2 groups. Mean contrast loads were similar between the 2 groups (nitrite 
261.2±15.61mls vs placebo 236.3±12.05mls, p=0.211). In five patients, TIMI 3 
flow was not achieved after PCI (3 in the nitrite group and 2 in placebo), however 
levels of ST segment resolution (>70%) were the same in the 2 groups (88.5%). 
 
3.3.2 Plasma NOx 
 
Measurement of nitrite levels locally post-intervention during angioplasty is 
difficult. In addition evidence indicates that induction of iNOS during I/R may 
interfere with measurement. However samples were collected for analysis at 30 
minutes post infusion. Figure 3.3 demonstrates that whilst there were no 
differences in plasma nitrate or nitrite at baseline, 30 minutes following 
angioplasty, circulating NO2- but not NO3- levels did rise indicating successful 
nitrite administration.  
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Figure 3.3 Plasma NO2- and NO3- levels pre and post study infusion 
Dot plots showing plasma NO2- and NO3- levels measured at baseline and 30 minutes after delivery 
of either intra-coronary nitrite or placebo in all patients.  Each line representing the difference 
between baseline and 30 minute plasma NO2- and NO3- levels is shown for each patient in the 
nitrite group in panel A and placebo in panel B. Error bars represent mean ± SD for each group. 
***P<0.0001 using paired T-test. (NO2- = Nitrite, NO3- = Nitrate) 
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 Nitrite (n=40) Placebo (n=40) P value 
Access site    
    Radial 31 (77.5%) 28 (70%) 0.612 
    
Syntax Score 13.41±5.50 13.58±6.20 0.893 
DES use 33 (82.5%) 30 (78.9%) 0.778 
Thrombectomy use 33 (82.5%) 31 (77.5%)  0.781 
Contrast use (mls) 261.20±15.61 236.30±12.05 0.211 
    
Angiographic AAR    
   APPROACH (Mean (95% CI)) 30.89 (28.30-33.47) 26.63 (23.28-29.99) 0.050 
   BARI (Mean (95% CI)) 27.41 (24.02-30.80) 25.17 (22.20-28.13) 0.316 
    
Treatment at time of PCI    
Heparin 40 (100%) 40 (100%) 1.000 
Aspirin 40 (100%) 40 (100%) 1.000 
Clopiodgrel/Prasugrel 35/5 37/3 0.712 
GPIIb/IIIa inhibitor 40 (100%) 40 (100%) 1.000 
GTN use 18 (45%) 18 (45%) 1.000 
    
ST segment resolution>70% 35 (88.5%) 35 (88.5%) 1.000 
Procedural Success  37 (92.5%) 38 (95.0%) 0.615 
Table 3.2. Procedural characteristics by treatment group.  
Values shown as number (%) unless otherwise stated. (AAR, area at risk; DES, Drug-eluting stent; 
GTN, Glyceryl Trinitrate; GP, glycoprotein) 
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3.3.3 Infarct size 
 
There was no evidence of difference in the AUC for serum CK release after 
reperfusion between the nitrite and control groups, with a median of 56,398 
arbitrary units (IQR: 31185 to 83,531) in the nitrite group versus 48,195 (IQR: 
27,726 to 82,841) in the control group (p=0.92) (Figure 3.4A). The median AUC 
for troponin T release was 140,782 arbitrary units (IQR: 84,949 to 218,133) in 
the nitrite group and 136,412 arbitrary units (IQR: 70,045 to 239,483) in the 
control group. This difference was also not conventionally statistically significant 
(p = 0.85) (Figure 3.4B).  Ischaemia time correlated significantly with infarct size 
(CK: r=0.256 and p=0.022, Troponin T: r=0.273 and p=0.014, Figure 3.5) 
 
3.3.4 CMR analysis 
 
Of the 80 patients recruited 12 declined consent for the CMR protocols. In the 
remaining 68 patients (33 in nitrite group and 35 in placebo) no evidence of 
difference in left ventricular volumes (end-diastolic volume, end-systolic 
volume), left ventricular mass or ejection fraction (LVEF) between the nitrite and 
placebo treated groups were evident (Table 3.3). There was a trend to smaller 
infarct size, incidence and amount of microvascular obstruction in the nitrite-
treated group compared to placebo. CMR assessed infarct size was positively 
correlated with cardiac biomarkers (CK, r=0.770, p<0.01: troponin T, r=0.787, 
p<0.01, Figure 3.6). There was a trend to a higher area at risk in the nitrite group 
compared to placebo  (Figure 3.7) but this was not significant. There was also a 
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trend to a higher MSI but again this difference was on the borders of statistical 
significance (p=0.05).    
 
Figure 3.4. Assessment of Infarct size by biomarker assessment  
Serum CK was measured at baseline, 4, 8, 12, 18, 24, 36 and 48 hours after coronary reperfusion. 
Curves for the nitrite and control group are shown in Panel A. There was no difference in infarct 
size as measured by CK release between the 2 groups. Serum troponin T was measured at the 
same time points as creatine kinase. Curves for the nitrite (n=40) and control (n=40) groups are 
shown in Panel B. Nitrite administration did not result in a significant reduction in infarct size as 
measured by troponin T release. T bars denote standard errors of the mean (SEM) (CK = Creatine 
Kinase). 
 176 
The CMR assessed area at risk correlated significantly with both angiographic 
risk scores (APPROACH:  r=0.678 and p<0.01, BARI: r=0.541 and p<0.01, Figure 
3.8). 
Table 3.3 Cardiac magnetic resonance data for study population  
Values shown as Mean (95% CI) unless otherwise stated. (LVEDVi, Indexed left ventricle end-
diastolic volume; LVESVi, Indexed left ventricle end-systolic volume; LVMi, Indexed left ventricle 
mass; LVEF, left ventricle ejection fraction; AAR, area at risk; MSI, myocardial salvage index; MVO, 
microvascular obstruction 
 
 Nitrite Placebo P value 
    
Baseline CMR (n=33) (n=35)  
LVEDVi 76.13 (71.11-81.14) 70.58 (65.22-75.94) 0.13 
LVESVi 36.16 (32.56-39.75) 35.71 (30.94-40.48) 0.88 
LVMi 63.02 (58.65-67.40) 58.23 (54.67-61.79) 0.09 
LVEF 52.87 (49.88-55.86) 50.07 (46.46-53.67) 0.23 
Infarct size (% LV) 17.10 (14.12-20.08) 19.55 (16.40-22.70) 0.25 
AAR 34.58 (31.62-37.55) 33.05 (29.40-36.72) 0.52 
MSI 0.52 (0.46-0.58) 0.44 (0.39-0.49) 0.05 
MVO    
  No. (%) 16 (48.5%) 23 (69.7%) 0.13 
 Amount (median (IQR) 2.98 (0-6.25) 3.47 (0-4.75) 0.34 
    
6 month CMR (n=29) (n=33)  
LVEDVi 82.13 (74.80-89.46) 75.62 (69.90-81.34) 0.15 
LVESVi 36.50 (31.48-41.52) 34.85 (30.53-39.17) 0.61 
LVMi 55.67 (51.66-59.68) 51.20 (48.17-54.24) 0.07 
LVEF 55.93 (52.71-59.15) 54.75 (51.62-57.87) 0.59 
Infarct size (% LV) 11.88 (9.52-14.24) 13.15 (10.75-15.56) 0.45 
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Figure 3.5 Associations between cardiac biomarker assessment of infarct size and 
ischaemia time  
There was a significant positive correlation between infarct size assessed by creatine kinase area 
under the curve (AUC) and ischaemia time (r=0.256), as shown in panel A. Panel B depicts a 
similar positive association between troponin T AUC and ischaemia time (r=0.273). Associations 
determined using Pearson’s correlation coefficient assessment. 
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Figure 3.6 Associations between cardiac biomarker assessment of infarct size and 
infarct size on cardiac magnetic resonance imaging  
There was a significant positive correlation between infarct size assessed by creatine kinase 
area under the curve (AUC) and LGE (late gadolinium enhancement) assessed infarct size 
on CMR (late gadolinium enhancement) (r=0.770), as shown in panel A. Panel B depicts a 
similar positive association between troponin T AUC and LGE CMR infarct size (r=0.787). 
Associations determined using Pearson’s correlation coefficient assessment. 
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Figure 3.7 Assessment of myocardial salvage index on CMR.  
The size of the myocardial salvage index on CMR is presented for 35 TIMI flow 0-3 patients 
in the control group and 33 patients in the nitrite group.  The mean index as assessed by 
CMR was larger in the nitrite group than in the control group and is on the margins of 
conventional statistical significance. Significance evaluated using unpaired t test and data 
shown as mean ± SEM.  
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Figure 3.8 Associations between angiographic area at risk scores and area at risk 
assessed by cardiac magnetic resonance imaging (CMR) 
There was a significant positive correlation between the angiographic area at risk as 
assessed by the modified APPROACH score and the area at risk assessed by T2 oedema 
imaging on CMR (r=0.678), as shown in panel A. Panel B depicts a similar positive 
association between the modified BARI score and the area at risk assessed by T2 oedema 
imaging on CMR (r=0.541).  Associations determined using Pearson’s correlation coefficient 
assessment. 
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3.3.5 Subgroup analysis (TIMI flow and successful procedures) 
 
We conducted a single sub-group analysis on the 66 patients with TIMI flow 
≤ 1 pre-procedure and a successful procedure i.e. drug delivered. In this sub-
group ischaemia time was the same between the two groups as were all 
other baseline characteristics (Table 3.4).  
 
3.3.5.1 Infarct size in subgroup 
 
Importantly, there was a significant reduction in myocardial infarct size 
assessed by CK AUC between the nitrite and control groups, with a median 
of 44,608 arbitrary units (IQR: 27,535 to 64,848) in the nitrite group versus 
55,666 (IQR: 41,591 to 93,659) in the control group (p=0.030). This 
represents a 19% reduction in infarct size (Figure 3.9A). The median AUC 
for troponin T release was 131,410 AU (IQR: 71,337 to 183,452) in the 
nitrite group and 176,492 AU (IQR: 89,831 to 245,094) in the control group. 
This difference is not conventionally statistically significant (p=0.158) 
(Figure 3.9B).  
 
In the nine patients with TIMI >1 flow at time of infusion, baseline 
characteristics were similar between the groups aside from a significantly 
longer ischaemia time in the nitrite group (286.80±96.70 vs 174.33±55.19 
minutes, p=0.038) (Table 3.5). There was no statistical difference in infarct 
size assessed by CK (78398 IQR: 30945-104752 vs 21196 IQR: 13864-
73887, p=0.413) or troponin T AUC (144798 IQR: 59452-207770 vs 83796 
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IQR: 55473-182372) seen in the patients with TIMI flow >1 treated with 
nitrite compared to placebo, although there was a trend to increased values 
in the nitrite group. 
 Nitrite  Placebo   
 (n=33)  (n = 33)  P value 
Age (yrs) (mean±SD) 57.30±11.29  56.94±13.48  0.90 
Sex (male/female) 29/4         28/5  0.99 
Diabetes mellitus  2 (6.1)  1 (3.0)  0.99 
Body-mass index (kg/m2) (mean±SD)a 29.27±5.30  29.06±5.17  0.87 
Hypertension  16 (48.5%)  8 (24.2%)  0.07 
Hypercholesterolaemia  13 (39.4%)  10 (30.3%)  0.61 
Heart rate (mean±SD) 70.94±18.97  79.06±22.10  0.11 
Systolic Blood pressure (mean±SD) 120.76±29.64  132.94±23.44  0.07 
Ischaemia time (minutes) (mean±SD)b 194.45±69.05  168.63±69.94  0.11 
Culprit Vessel      0.57 
Left anterior descending 8 (24.2%)  9 (27.3%)   
Circumflex 3 (9.1%)  5 (12.5%)   
Right coronary 22 (66.7%)  19 (57.6%)   
      
Syntax score (mean±SD) 13.29±5.42  13.68±5.42  0.77 
DES use  29 (87.9%)  26 (81.3%)  0.51 
Angiographic AAR      
   APPROACH (mean±SD) 30.72±7.75  26.94±10.73  0.11 
   BARI (mean±SD) 27.32±10.88  24.75±9.26  0.31 
      
Treatment before PCI       
Morphine 22 (66.7)  29 (87.9)  0.08 
Treatment at time of PCI      
Heparin  33 (100)  33 (100)  0.99 
Aspirin   33 (100)  33 (100)  0.99 
Clopidogrel/Prasugrel (no/no) 29/4  30/3  0.99 
Glycoprotein IIb/IIIa inhibitor  33 (100)  33 (100)  0.99 
   Table 3.4. Baseline characteristics of the TIMI <1 subgroup 
Values shown as number (%) unless otherwise stated. Abbreviations: PCI, percutaneous 
coronary intervention; TIMI, Thrombolysis in myocardial infarction; DES, drug-eluting 
stent. a The body-mass index is the weight in kilograms divided by the square of the height 
in meters. b Ischaemia time determined from symptom to balloon times for each patient. 
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Figure 3.9 Assessment of Infarct size by biomarker assessment in the TIMI flow ≤1 
subgroup  
Serum CK was measured at baseline, 4, 8, 12, 18, 24, 36 and 48 hours after coronary 
reperfusion. Curves for the nitrite and control group are shown in Panel A. Nitrite 
administration resulted in a significant reduction in infarct size of approximately 20% as 
measured by CK release. Serum troponin T was measured at the same time points as CK. 
Curves for the nitrite (n=33) and control (n=33) groups are shown in Panel B. Nitrite 
administration did not result in a significant reduction in infarct size as measured by 
troponin T release. T bars denote standard errors of the mean (SEM).
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 Nitrite Placebo  
 (n=4) (n = 5) P value 
Age (yrs) (mean±SD) 54.75±5.50 60.00±13.87 0.50 
Sex (male/female) 4/0 2/3 0.17 
Diabetes mellitus  1 (25.0) 2 (40.0) 0.99 
Body-mass index (kg/m2) (mean±SD)a 28.53±5.43 25.95±5.85 0.54 
Hypertension  3 (75.0%) 4 (80.0%) 0.99 
Hypercholesterolaemia 3 (75.0%) 1 (25.0%) 0.21 
Heart rate (mean±SD) 74.00±17.38 72.80±13.41 0.91 
Systolic Blood pressure (mean±SD) 131.50±26.90 135.80±33.82 0.84 
Ischaemia time (minutes) (mean±SD)b 286.80±96.70 174.33±55.19 0.04 
Culprit Vessel   0.49 
Left anterior descending 1 (25.0%) 2 (40.0%)  
Circumflex 1 (25.0%) 0 (0.0%)  
Right coronary 2 (50.0%) 3 (60.0%)  
    
Syntax score (mean±SD) 15.63±7.91 13.30±10.79 0.73 
DES use  1 (25.0%) 2 (40.0%) 0.99 
Angiographic AAR    
   APPROACH (mean±SD)  31.68±10.15 25.18±9.98 0.30 
   BARI (mean±SD) 26.35±6.06 24.24±4.69 0.57 
    
Treatment before PCI     
Morphine 3 (75.0) 4 (80.0) 0.99 
Treatment at time of PCI    
Heparin  4 (100) 5 (100) 0.99 
Aspirin  4 (100) 5 (100) 0.99 
Clopidogrel/Prasugrel  (No/No) 3/1 5/0 0.44 
Glycoprotein IIb/IIIa inhibitor (%) 4 (100) 5 (100) 0.99 
Table 3.5 Characteristics and infarct size of the TIMI >1 subgroup. 
Values shown as number (%) unless otherwise stated. Abbreviations: PCI, percutaneous 
coronary intervention; TIMI, Thrombolysis in myocardial infarction; DES, drug-eluting 
stent. a The body-mass index is the weight in kilograms divided by the square of the height 
in meters. b Ischaemia time determined from symptom to balloon times for each patient. 
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3.3.5.2 CMR analyses in subgroup 
 
In the TIMI flow ≤1 group for the CMR analysis nitrite treatment was 
associated with a 25% decrease in myocardial infarct size (15.31 vs 20.08, 
p=0.03) and a 30% increase in the myocardial salvage index (0.56 vs 0.43, 
p=0.002) (Table 3.6, Figure 3.10). There was also evidence of a reduction in 
both the presence (37% vs 72.4%, p=0.02) and median amount (1.0 vs 4.5G, 
p=0.002) of microvascular obstruction in the nitrite treated patients (Table 
3.6).  
 TIMI ≤1  
 Nitrite Placebo P value 
    
Baseline CMR (n=27) (n=30)  
LVEDVi 75.69 (69.93-81.44) 70.33 (64.31-76.34) 0.19 
LVESVi 35.16 (31.20-39.12) 35.41 (30.62-40.20) 0.94 
LVMi 61.07 (56.27-65.88) 58.07 (54.44-61.71) 0.31 
LVEF 53.86 (50.40-57.32) 50.00 (46.43-53.57) 0.12 
Infarct size (%) 15.31 (12.36-18.27) 20.08 (16.72-23.43) 0.03 
AAR 33.89 (30.54-37.24) 33.27 (29.12-37.42) 0.82 
MSI 0.56 (0.50-0.62) 0.43 (0.37-0.49) 0.002 
MVO    
  No. (%)) 10 (37.0%) 21 (72.4%) 0.02 
  Amount (median (IQR)  1.00 (0.80-5.87) 4.50 (1-7.50) 0.003 
    
6 month CMR (n=25) (n=29)  
LVEDVi 79.27 (72.01-86.54) 75.37 (69.20-81.53) 0.40 
LVESVi 33.80 (30.08-37.54) 34.94 (30.16-39.73) 0.71 
LVMi 54.21 (50.35-58.07) 51.09 (47.75-54.44) 0.21 
LVEF 57.19 (54.12-60.27) 54.51 (50.96-58.05) 0.25 
Infarct size (%) 10.69 (8.38-13.02) 13.70 (11.16-16.24) 0.08 
    
Table 3.6 CMR data for study population with TIMI ≤1 flow at presentation.  
Values shown as mean (95% CI) unless otherwise stated. Abbreviations: LVEDVi, Indexed 
left ventricle end-diastolic volume; LVESVi, Indexed left ventricle end-systolic volume; 
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LVMi, Indexed left ventricle mass; LVEF, left ventricle ejection fraction; AAR, area at risk; 
MSI, myocardial salvage index; MVO, microvascular obstruction. 
 
Figure 3.10 Assessment of myocardial salvage index in the TIMI ≤ 1 patients on CMR.  
The size of the myocardial salvage index on CMR is presented for 28 TIMI ≤ 1 patients in the 
control group and 27 patients in the nitrite group.  The mean index as assessed by CMR was 
significantly larger in the nitrite group compared to the control group (P=0.002). 
Significance evaluated using unpaired t test and data shown as mean ± SEM.  
 
 
There was no evidence of difference in infarct size, area at risk, MSI or 
microvascular obstruction seen in patients with TIMI flow >1 treated with 
nitrite compared to placebo (Table 3.7). 
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 TIMI >1  
 Nitrite Placebo P value 
    
Baseline CMR (n=4) (n=5)  
LVEDVi 78.01 (51.65-104.40) 71.99 (54.30-89.68) 0.58 
LVESVi 39.90 (18.85-60.94) 37.37 (12.14-62.80) 0.84 
LVMi 74.11 (58.19-90.03) 59.12 (40.75-77.49) 0.13 
LVEF 49.55 (40.32-58.78) 50.50 (29.96-71.04) 0.92 
Infarct size (%) 21.43 (9.62-33.23) 15.86 (0.42-31.30) 0.40 
AAR 35.71 (21.15-50.28) 31.74 (21.62-41.87) 0.51 
MSI 0.41 (0.31-0.51) 0.54 (0.30-0.78) 0.17 
MVO    
  No. (%)) 3 (75.0%) 1 (25.0%) 0.14 
  Amount (median (IQR)  1 (0-8.25) 1 (0-1) 0.09 
    
6 month CMR (n=2) (n=4)  
LVEDVi 109.94 (-184.6-404.5) 80.57 (60.05-101.1) 0.16 
LVESVi 64.97 (-216.3-346.2) 37.42 (25.62-49.21) 0.13 
LVMi 73.36 (-80.60-227.3) 52.14 (46.98-57.30) 0.05 
LVEF 42.43 (-61.45-146.30) 53.51 (43.38-63.65) 0.18 
Infarct size (%) 16.33 (-9.40-42.06) 10.59 (0.24-20.93) 0.32 
    
Table 3.7. CMR data for study population with TIMI ≤1 flow at presentation.  
Values shown as mean (95% CI) unless otherwise stated. Abbreviations: LVEDVi, Indexed 
left ventricle end-diastolic volume; LVESVi, Indexed left ventricle end-systolic volume; 
LVMi, Indexed left ventricle mass; LVEF, left ventricle ejection fraction; AAR, area at risk; 
MSI, myocardial salvage index; MVO, microvascular obstruction. 
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3.3.6 Acute safety and tolerability of nitrite across the whole cohort 
 
Following the administration of intra-coronary nitrite, 18 (45%) patients 
developed a >10% decrease in systolic blood pressure (within ten minutes) with 
a median decrease of 8.8mmHg (IQR: 0.5-30.1) however the magnitude and 
incidence was similar to the control group (23 patients, 57.5%, median drop 11.0 
IQR: 2.1-21.4mmHg) (Figure 3.11). The drop in blood pressure did not alter 
clinical management. Whilst there was a small (but clinically insignificant) rise in 
met-Hb in the patients receiving nitrite (median 0.1% IQR: 0.0-0.13) this was not 
different to the control (median 0.0 IQR: 0-0.2%). No patients in the nitrite group 
developed sustained ventricular arrhythmias (either ventricular tachycardia or 
ventricular fibrillation) during the infusion of the drug, nor in the 10 minutes 
following the infusion.  
 
3.3.7 Adverse events across the whole cohort 
 
During the first 48 hours after reperfusion, 7 adverse clinical events (17.5%) 
were recorded in the control group: 3 patients developed a >25% increase in 
creatine (CIN), 3 had episodes of heart failure and one had an episode of 
recurrent ischaemia which required further angiographic assessment. This 
compared to three adverse clinical events (7.5%) in the nitrite group: 1 episode 
of > 25% increase in creatine and 2 episodes of heart failure (p=0.311).  
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Figure 3.11 Assessment of the effect of study drug on systolic blood pressure.  
The size of the effect on blood pressure by the study drug for the study patients split by treatment 
group is shown. The median percentage drop in systolic blood pressure was larger in the placebo 
group than in the nitrite group but is not statistically significant. Significance evaluated using 
Unpaired t test and lines represent median effect for each treatment. 
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3.3.8 N-terminal pro-brain natriuretic peptide  
 
Blood analysis for N-terminal pro-brain natriuretic peptide (NT-proBNP) was 
performed on samples at baseline, 48 hours and 6 months for each patient.  In 
both the nitrite and placebo groups, NT-pro BNP levels increased from baseline 
to 48 hours and then returned to normal levels at 6 months. There was no 
difference in the levels of NT-proBNP in the nitrite group versus the placebo 
group over the time period (p=0.12, Figure 3.11A). However there was a 
significant decrease in NT-proBNP levels in the TIMI ≤1 group with the biggest 
difference seen at 48 hours (p=0.01, Figure 3.11B). Levels of NT-proBNP were 
shown to correlate with both LVEF (p=0.001, r=-0.401, Figure 3.12) and infarct 
size (CMR assessed Infarct size, p= 0.0001, r= 0.464, cardiac enzyme assessed 
infarct size, p=0.0001, r= 0.404 Figure 3.13)   
 
3.3.9 Medication 
 
Data was available on prescribed medication for 100% of patients at discharge, 
97.5% at 6 months and 90% at 1 year. Overall the majority of both patient groups 
were optimised on medical therapy at discharge, 6 months and 1 year (dual anti-
platelet agents, statin, beta-blocker and angiotensin-receptor blocking drugs). 
There were no differences in the prescription of medication between the 
treatment groups at discharge, 6 months or 1 year of follow-up (Table 3.8). No 
patient in either group underwent the insertion of cardiac devices (implantable 
cardiac defibrillator or cardiac resynchronization therapy) during the 1st year of 
follow-up.  
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Figure 3.11 NT-proBNP and treatment group.  
NT-proBNP levels were measured at baseline, 48 hours, and 6 months after coronary reperfusion. 
NT-proBNP levels over time for nitrite versus placebo for all patients are shown in panel A.  Panel 
B shows NT-proBNP levels in patients with TIMI flow <1. Data expressed as mean ± SEM.  
♯=P<0.05, for two-way repeated measures ANOVA, * for p<0.05 using two-way repeated 
measures ANOVA with Bonferroni’s multiple comparison test. 
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Figure 3.12 Associations between NT-proBNP and left-ventricular ejection fraction (LVEF).  
There was a significant negative correlation between NT-proBNP levels at 48 hours and LVEF 
assessed by CMR at 48 hours (r=-0.464), as shown in panel A. Panel B depicts a similar negative 
association between the NT-proBNP levels at 6 months and LVEF assessed by CMR (r=-0.401) at 
the same time-point. Associations determined using Spearmans correlation coefficient 
assessment.
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Figure 3.13 Associations between NT-proBNP and infarct size.  
There was a significant positive correlation between NT-proBNP levels at 48 hours and infarct 
size as assessed by Troponin T AUC (r=0.404), as shown in panel A. Panel B depicts a similar 
positive association between the NT-proBNP levels at 48 hours and infarct size assessed by late-
gadolinium enhancement on CMR (r=0.464). Associations determined using Spearmans 
correlation coefficient assessment. 
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 Nitrite  Placebo P value 
Medication at discharge (n=40)  (n=40)  
ACE inhibitor 39 (97.5%)  36 (90.0%) 0.359 
ARB 1 (2.5%)  2 (5.0%) 0.556 
Diuretic 2 (5.0%)  4 (10.0%) 0.396 
Ivabradine 1 (2.5%)  0 (0%) 0.314 
   β Blocker 37 (92.5%)  36 (90.0% 0.692 
   Statin 40 (100%)  40 (100%) 1.000 
   Aspirin 40 (100%)  40 (100%) 1.000 
   Clopidogrel 37(92.5%)  37 (92.5%) 1.000 
   Prasugrel 3 (7.5%)  2 (5.0%) 0.644 
   Organic Nitrate 0 (0%)  1 (2.5%) 0.314 
Medication at 6 months n=39  n=39  
ACE inhibitor 36 (92.3%)  34 (87.2%) 0.455 
ARB 3 (7.7%)  4 (10.3%) 0.692 
Diuretic 2 (5.1%)  2 (5.1%) 1.000 
   Spironolactone 0 (0.0%)  1 (100) 0.314 
   Ivabradine 2 (5.1%)  0 (0.0%) 0.147 
   β Blocker 36 (92.3%)  34 (87.2%) 0.455 
   Statin 39 (100%)  39 (100%) 1.000 
   Aspirin 39 (100%)  39 (100%) 1.000 
   Clopidogrel 35 (89.7%)  35 (89.7%) 1.000 
   Prasugrel 3 (7.7%)  2 (5.1%) 0.644 
   Organic Nitrate 0 (0.0%)  1 (2.6%) 0.314 
Medication at 1 year n=36             n=36  
ACE inhibitor 33 (91.7%)  31 (86.1%) 0.453 
ARB 3 (8.3%)  5 (13.9%) 0.453 
Diuretic 1 (2.8%)  1 (2.8%) 1.000 
Spironolactone 0 (0.0%)  1 (2.8%) 0.314 
   Ivabradine 2 (5.6%)  0 (0.0%) 0.152 
   β Blocker 33 (91.7%)  32 (88.9%) 0.691 
   Statin 36 (100.0%)  36 (100.0%) 1.000 
   Aspirin 36 (100.0%)  35 (97.2%) 0.314 
   Clopidogrel 27 (75.0%)  27 (75.0%) 1.000 
   Prasugrel 3 (8.3%)  2 (5.6%) 0.643 
   Nitrate 0 (0.0%)  1 (2.8%) 0.314 
Table 3.8 Prescribed drugs by study treatment.  
Values shown as number (%) unless otherwise stated. Abbreviations: ACEi: Angiotension-
converting enzyme; ARB: Angiotensin receptor blocker. 
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 3.3.10 Major adverse cardiac events 
 
1 year after infarction, six patients (15.8%) in the control group suffered MACE (2 
hospitalisations for heart failure, 1 recurrent myocardial infarction and 3 
unscheduled revascularizations) compared to 1 patient (2.6%) (1 unscheduled 
revascularization) in the nitrite group (p=0.04) (Figure 3.14).  
Figure 3.14. Kaplan Meier curves showing cumulative probability of major adverse cardiac 
events (MACE) after primary PCI according to treatment group.  
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3.4 Summary 
 
1. Intra-coronary nitrite infusion appears safe in patients undergoing primary 
PCI for AMI.  
2. In the whole trial population, nitrite infusion was not associated with a 
reduction in infarct size as assessed by cardiac enzymes (CK or Troponin T) 
or CMR imaging.  
3. Despite the negative primary endpoint there was a suggestion of benefit 
associated with nitrite in the whole trial population with a trend to 
improvement in the myocardial salvage index on CMR and a significant 
reduction in 1 year MACE in the nitrite treated group 
4. In a single sub-group analysis splitting the trial population by TIMI flow 
count, nitrite was associated with a significant reduction in infarct size 
assessed by CK in patients with TIMI flow ≤ 1. In this sub-group, nitrite was 
also associated with a significant reduction in CMR assessed infarct size and 
microvascular obstruction and a significant increase in the myocardial 
salvage index. 
5. No difference in infarct size was seen with nitrite treatment in patients with 
TIMI flow>1 
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Chapter 4.0 
 
 
Investigation of the 
potential mechanisms by 
which nitrite reduces  
I/R injury 
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4.1 Introduction 
 
Nitrite has been shown in pre-clinical studies to be cardioprotective and reduce 
myocardial infarct size, however the exact mechanisms by which this benefit is 
conferred are not clear.  It is clear however that the beneficial effects of nitrite are 
due to its conversion to NO, as evidenced by the complete block of nitrite-induced 
protection by the NO scavenger carboxy-PTIO, (Webb et al., 2004; Duranski MR et 
al., 2005). NO itself exerts a number of actions (Moncada, Higgs 1993) that are 
thought to be cardioprotective (Johnson 1991). In particular, NO plays an 
important role in modulating many aspects of the inflammatory response. Indeed 
evidence demonstrates that NO inhibits leukocyte recruitment (Kubes et al., 
1991) via a cGMP dependent manner (Ahluwalia et al., 2004), a component of the 
damage caused in I/R injury. Evidence has suggested that reducing the 
inflammatory cell-driven injury to the endothelium and perivascular myocardium 
(dPalazzo AJ et al., 1998) results in a positive outcome in I/R injury. Platelet 
adhesion and aggregation are also important and are well recognized as terminal 
events in the formation of thromboses leading to MI (Davi G, Patrono,C 2007). It 
is widely accepted that NO suppresses the adhesion of platelets to intact vascular 
endothelium (Radomski et al, 1987) and also platelet aggregation itself 
(Radomski et al, 1990).  These effects as with inflammatory cell recruitment are 
also mediated by cGMP. Interestingly a further common pathway of both NO-
mediated suppression of cell recruitment and platelet reactivity is a cGMP-
dependent suppression of P-selectin expression. It is therefore important to 
establish whether nitrite has effects on both platelet reactivity and inflammation 
when given intra-coronary during primary PCI.  
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Thus the aim of the study described in this chapter is to assess the mechanisms 
by which intra-coronary nitrite reduces reperfusion injury following primary PCI 
in patients with STEMI, specifically focusing on platelet activity and inflammation 
as per the study design described in section 2.1 and chapter 3.    
 
4.2 Studies for platelet reactivity and inflammatory markers 
 
The study was powered for infarct size however whether there was sufficient 
power for the assessment of platelet reactivity and inflammatory markers is 
unknown. However the aim of this part of the thesis was primarily for hypothesis 
generation. As per figure 4.1 and described in chapter 2, a number of assessments 
based upon platelet function and inflammatory cell recruitment and circulating 
mediators were conducted (Figure 4.1).  
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Figure 4.1 Flow diagram of Study design and mechanistic measurement points   
AMI: acute myocardial infarction, OTW: Over the wire balloon, PPCI: primary percutaneous 
coronary intervention, CMR: cardiac magnetic resonance imaging, MVO: microvascular 
obstruction, LVEF: Left ventricular ejection fraction 
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4.3 Results  
 
4.3.1 Effect of intra-coronary nitrite on platelet reactivity post-primary PCI 
 
4.3.1.1 Baseline Platelet measures  
 
The nitrite and placebo groups were similar with respect to all measures of 
platelet function and reactivity at baseline (Table 4.1).  
 
 Nitrite Placebo P value 
    
Platelet Count (x109/L) 245.6±8.8 262±11.7 0.264 
Platelet Volume (fL) 10.8±0.2 11.1±0.2 0.256 
P-selectin expression (%) 8.05±0.77 9.8±0.93 0.153 
WBA (AUC) 8.93±0.95 9.88±1.41 0.577 
    
 
Table 4.1 Baseline platelet characteristics of the study population 
All measures were performed in 40 nitrite and 40 placebo patients aside from mean platelet 
volume, which was measured in 30 nitrite and 30 placebo patients. P-Selectin expression and 
Whole Blood Aggrerometry (WBA) measured in response to control (PBS). Values expressed as 
mean ± SEM. Statistical comparisons performed using unpaired T test.  
 
 
 
Following reperfusion both P-selectin expression and spontaneous aggregation 
(PBS control) changed over time in both the whole cohort (Figure 4.2A and B) 
and the TIMI <1 cohort (Figure 4.2C and D). 
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Figure 4.2. P-selectin expression and spontaneous aggregation over time (Control) 
Platelet reactivity measured at baseline, 30 minutes, 4 hours, 24 hours and 6 months after 
coronary reperfusion. Platelet P-Selectin expression assessed in whole blood following incubation 
with phosphate buffered saline control (PBS) is shown for nitrite versus placebo for all patients in 
panel A.  Panel B show whole, blood impedance aggregometry in response to the same PBS 
stimulus in all patients. Panel C shows P-selectin expression in response to PBS in patients with 
TIMI flow <1. Panel D shows aggregation in response to PBS in the TIMI <1 subgroup. All panels 
show nitrite treated versus placebo. Data expressed as mean ± SEM. ♯ =P<0.05, ♯♯=P<0.01, for 
two-way repeated measures ANOVA. * p<0.05 using two-way repeated measures ANOVA with 
Bonferroni’s multiple comparison test.  PBS=Phosphate buffered saline.  
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4.3.1.2 Platelet count over time post-primary PCI 
 
Total platelet counts were measured at baseline, 4 hours, 24 hours and 6 months 
after coronary reperfusion.  In all patients platelet levels were at their highest at 
baseline (253.8±7.3x109) with a significant change over time with levels 
decreasing at 4 hours and the lowest levels seen at 24 hours compared to 
baseline (223.7±6.2x109 versus 253.8±7.3x109, P=0.002). Levels at 6 months 
were similar to but not back to baseline levels (237.2±7.2x109 versus 
253.8±7.3x109) (Figure 4.3).  
 
Figure 4.3 Platelet count over time post primary PCI 
Total platelet count measured at baseline, 4 hours, 24 hours and 6 months after coronary 
reperfusion. Platelet count assessed over time in all patients is shown. Data expressed as mean ± 
SEM.  **P<0.01 using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
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No difference was seen in total platelet counts when splitting patients into nitrite 
and control groups after coronary reperfusion (p=0.360) (Figure 4.4).   
 
Figure 4.4 Platelet count over time by treatment group after primary PCI. 
Total platelet count measured at baseline, 4 hours, 24 hours and 6 months after coronary 
reperfusion. Figure displays platelet count over time showing nitrite treated versus placebo. Data 
expressed as mean ± SEM. Statistical comparison performed using two-way repeated measures 
ANOVA. 
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4.3.1.3 Platelet reactivity in response to collagen pre and post primary PCI 
 
Platelet reactivity was assessed by whole blood aggreometry (WBA) and platelet 
P-selectin expression at baseline, 30 minutes, 4 hours, 24 hours and 6 months 
post reperfusion. Platelet aggregation and platelet P-selectin expression changed 
substantially over time in response to collagen (Figure 4.5) in both placebo and 
nitrite treated groups. The greatest response occurred at baseline with a 
decrease at 4 hours, followed by a slight elevation at 24 hours and a further 
decrease by 6 months. The response to collagen was similar at baseline between 
the two treatment groups, however, there was evidence of a decrease in 
aggregatory response in the nitrite group versus placebo as assessed by both P-
selectin expression (Figure 4.5A) and platelet aggregation (Figure 4.5B) in 
response to collagen over time after PCI.  
 
When looking at platelet reactivity in the TIMI <1 subgroup where a significant 
reduction in infarct size with nitrite was seen, these differences were still evident 
and statistically increased between the groups (Figure 4.5C and D).  
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Figure 4.5 Platelet reactivity (Collagen). 
Platelet reactivity measured at baseline, 30 minutes, 4 hours, 24 hours and 6 months after 
coronary reperfusion. Platelet P-Selectin expression assessed in whole blood in response to 
collagen (3 μmol/L) is shown for nitrite versus placebo for all patients in panel A.  Panel B show 
using whole blood impedance aggregometry in response to the same collagen stimulus in all 
patients. Panel C shows P-selectin expression in response to collagen in patients with TIMI flow 
<1. Panel D shows aggregation in response to collagen in the TIMI <1 subgroup. All panels show 
nitrite treated versus placebo. Data expressed as mean ± SEM. ♯ =P<0.05, ♯♯=P<0.01, for two-way 
repeated measures ANOVA, *=p<0.05 using two-way repeated measures ANOVA with 
Bonferroni’s multiple comparison test. 
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4.3.1.3 Platelet reactivity in response to ADP pre and post primary PCI 
 
Platelet aggregation and platelet P-selectin expression changed substantially over 
time in response to ADP (Figure 4.6) in both placebo and nitrite treated groups. 
Similar to the response to collagen the greatest response occurred at baseline 
with a decrease at 4 hours, followed by a slight elevation at 24 hours and a 
further decrease by 6 months. Responses to ADP were similar at baseline 
between the two treatment groups, however, there was evidence of a decrease in 
aggregatory response in the nitrite group versus placebo as assessed by both P-
selectin expression (Figure 4.6A) and platelet aggregation (Figure 4.6B) in 
response to ADP over time after primary PCI.  
 
When looking at platelet reactivity in the TIMI <1 subgroup, these differences 
were still evident and statistically increased between the groups (Figure 4.6C and 
D).  
 
Post-hoc analyses demonstrated that the reactivity of platelets was directly 
associated to CMR-determined infarct size (Figure 4.7). 6 month CMR infarct size 
was positively correlated with both P-selectin expression (r=0.401, p=0.002) and 
platelet aggregation (r=0.344, p=0.007) at 6 months in response to ADP.   
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Figure 4.6 Platelet reactivity (ADP). 
Platelet reactivity measured at baseline, 30 minutes, 4 hours, 24 hours and 6 months after 
coronary reperfusion. Platelet P-Selectin expression assessed in whole blood in response to ADP 
(10 μmol/L) is shown for nitrite versus placebo for all patients in panel A.  Panel B shows whole 
blood impedance aggregometry in response to the same ADP stimulus in all patients. Panel C 
shows P-selectin expression in response to ADP in patients with TIMI flow <1. Panel D shows 
aggregation in response to ADP in the TIMI <1 subgroup. All panels show nitrite treated versus 
placebo. Data expressed as mean ± SEM. ♯ =P<0.05, ♯♯=P<0.01, for two-way repeated measures 
ANOVA, *=p<0.05 using two-way repeated measures ANOVA with Bonferroni’s multiple 
comparison test.  (ADP: adenosine diphosphate). 
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Figure 4.7 Associations between platelet reactivity and infarct size on cardiac magnetic 
resonance imaging (CMR) at 6 months. 
There was a significant positive association between platelet P-selectin expression in response to 
ADP and LGE (late gadolinium enhancement) assessed infarct size on CMR (late gadolinium 
enhancement) at six months, as shown in panel A. Panel B depicts a similar positive association 
between platelet aggregation in response to ADP and LGE CMR infarct size at six months. 
Correlations determined using Pearson’s correlation coefficient. 
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4.3.2 Effect of nitrite on the systemic inflammatory response post primary 
PCI 
 
4.3.2.1 Total leukocyte cell count 
 
Total leukocyte cell counts were measured at baseline, 4 hours, 24 hours and 6 
months after coronary reperfusion in all patients. Total leukocyte count changed 
significantly over time with highest levels seen at baseline, declining slightly at 4 
hours with a further drop at 24 hours with the lowest levels seen at 6 months 
(P<0.0001) (Figure 4.8A).  Leukocyte cell counts were similar at baseline 
between the nitrite and placebo groups. However there was evidence of a 
decreased leukocyte count in the nitrite group compared to placebo group over 
time (P=0.0079) (Figure 4.8B) with the largest difference seen at 4 hours.     
 
4.3.2.2 Differential leukocyte cell count 
 
Differential leukocyte counts (neutrophils, lymphocytes and monocytes) were 
measured at the same time-points as the total leukocyte cell count (baseline, 4 
hours, 24 hours and 6 months). Neutrophil counts were high at baseline, 
increased slightly at 4 hours before declining significantly by 24 hours with the 
lowest levels seen at 6 months (p<0.0001) (Figure 4.9A).  Lymphocyte numbers 
were similar at baseline, 24 hours and 6 months, however significantly lower 
levels were seen at 4 hours (P<0.0001) (Figure 4.9C).  
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Figure 4.8 Total leukocyte count pre and post primary PCI. 
Total leukocyte count was measured at baseline, 4 hours, 24 hours and 6 months after coronary 
reperfusion. Leukocyte count assessed over time in all patients is shown in panel A.  Panel B 
shows leukocyte cell count over time showing nitrite (n=40) treated versus placebo (n=40). Data 
expressed as mean ± SEM.  ***P<0.0001, **P<0.01 using one-way ANOVA, with Bonferroni’s 
multiple comparison test. ♯♯=P<0.01, for two-way repeated measures ANOVA, * for p<0.05 using 
two-way repeated measures ANOVA with Bonferroni’s multiple comparison test.  
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Monocyte numbers were similar from baseline to 4 hours but increased 
significantly at 24 hours with a decline by 6 months (p<0.0001) (Figure 4.9E).   
 
All differential leukocyte cell counts were similar at baseline between the nitrite 
and placebo treatment groups. However, there was evidence of a decrease in the 
neutrophil cell count over time in the nitrite group versus placebo (p=0.0062, 
Figure 4.9B), with the largest difference seen at 4 hours. No difference was seen 
between either monocyte or total lymphocyte numbers between the 2 treatment 
groups over time (monocytes p=0.425, lymphocytes p=0.365) (Figures 4.9D/F)  
 
4.3.2.3 Leukocyte inflammatory marker expression  
 
Inflammatory marker expression (CD11b, CD62L and CD162) on each leukocyte 
population: neutrophils, monocytes (inflammatory, intermediate and resident), 
and T lymphocytes (CD4+ and CD8+) were measured. Measurements were made 
at 30 minutes, 24 hours and 6 months post reperfusion in 23 patients in the 
placebo group and 21 patients in the nitrite group.  
 
4.3.2.4 Neutrophil activation marker expression  
 
Neutrophil CD11b relative fluorescence intensity (RFI) was similar at 30 minutes 
and 24 hours post reperfusion with significantly lower levels seen at 6 months 
after reperfusion (p<0.0001) (Figure 4.10A). CD11b RFI was significantly lower 
in the nitrite treated patients compared to placebo over the time-points with the 
greatest difference evident at 24 hours (p=0.0034) (Figure 4.10B).  
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Figure 4.9 Differential Leukocyte count. 
Differential leukocyte count was measured at baseline, 4 hours, 24 hours and 6 months after 
coronary reperfusion. Neutrophil cell count over time in all patients is shown in panel A.  Panel B 
shows neutrophil cell count over time comparing nitrite (n=40) treated versus placebo (n=40). 
Panel C shows lymphocyte cell count assessed over time in all patients. Panel D shows 
lymphocyte count over time comparing nitrite treated versus placebo. Panel E shows monocyte 
cell count assessed over time in all patients with Panel F showing monocyte cell count over time 
comparing nitrite treated versus placebo. Data expressed as mean ± SEM.  ***P<0.0001 using one-
way ANOVA, with Bonferroni’s multiple comparison test. ♯♯ =P<0.01, for two-way repeated 
measures ANOVA, *P<0.05 fortwo-way repeated measures ANOVA with Bonferroni’s multiple 
comparison test.  
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Figure 4.10 Neutrophil Cd11b Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b was measured at 30 minutes, 24 hours and 6 
months after coronary reperfusion. RFI assessed over time in 44 patients (23 placebo patients 
and 21 nitrite patients) is shown in panel A.  Panel B shows RFI over time of nitrite (21 patients) 
treated versus placebo (23 patients). Data expressed as mean ± SEM.  ***P<0.0001 using 1-way 
ANOVA, with Bonferroni’s multiple comparison test. ♯♯=P<0.01, for two-way repeated measures 
ANOVA. ** for p<0.001 using  two-repeated measures ANOVA with Bonferroni’s multiple 
comparison test. 
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Neutrophil CD62L RFI changed substantially over time, with levels increasing 
from 30 minutes to 24 hours post reperfusion before declining significantly to 
lowest levels at 6 months (Figure 4.11A). This pattern was duplicated in CD162 
RFI with increased expression at 24 hours and lowest levels at 6 months (Figure 
4.11C). No difference was seen in either neutrophil CD162 or CD62L RFI between 
the nitrite or placebo groups over the time-points (Figure 4.11B and D).  
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Figure 4.11 Neutrophil CD62L/162 Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD62L/CD162 was measured at 30 minutes, 24 hours 
and 6 months after coronary reperfusion. CD62L RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD62L RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD162 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data expressed as 
mean ± SEM. ***P<0.0001 using 1-way ANOVA, with Bonferroni’s multiple comparison test.  Panel 
B and D comparisons performed using two-way repeated measures ANOVA. 
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4.3.2.5 T Lymphocytes 
 
4.3.2.5.1 CD4+ T lymphocytes 
 
CD4+ T lymphocyte CD11b, CD62L and CD162 expression all increased from 30 
minutes to 24 hours post reperfusion with significantly lower levels seen at 6 
months after reperfusion (Figure 4.12A,C and E). There were comparable levels 
of CD11b expression in the nitrite treated patients compared to placebo over the 
time-points (p=0.745, figure 4.12B). This pattern was duplicated in the relative 
expression of CD62L and CD162 with no difference seen in the expression of 
either CD162 (p=0.487) or CD62L (p=0.864) between the nitrite or placebo 
groups over the time-points (Figure 4.12D, F).  
 
4.3.2.5.2 CD8+ T lymphocytes 
 
CD8+ T lymphocyte CD11b and CD162 expression all increased from 30 minutes 
to 24 hours post reperfusion with significantly lower levels seen at 6 months 
after reperfusion (Figure 4.13A and E). CD62L levels increased marginally from 
30 minute to 24 hours with a significant decrease by 6 months (Figure 4.13C). 
There was slightly lower levels of CD11b expression in the nitrite treated patients 
compared to placebo over the time-points but this was not significant (P=0.435, 
figure 4.13B). There was no difference seen in the relative expression of either 
CD162 (p=0.717) or CD62L (p=0.889) between the nitrite and placebo groups 
over the time-points (Figure 4.13D, F).  
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Figure 4.12 CD4+ T Lymphocyte CD11b/CD62L/162 Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b/CD62L/CD162 was measured at 30 minutes, 24 
hours and 6 months after coronary reperfusion. CD11b RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD11b RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD62L RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD62L 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed 
over time in 44 patients (23 placebo patients and 21 nitrite patients) is shown in panel E.  Panel F 
shows CD162 RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data 
expressed as mean ± SEM. **P<0.01, *P<0.05 using 1-way ANOVA, with Bonferroni’s multiple 
comparison test.  Panel B, D, F comparisons performed using two-way repeated measures ANOVA. 
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Figure 4.13 CD8+ T lymphocyte Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b/CD62L/CD162 was measured at 30 minutes, 24 
hours and 6 months after coronary reperfusion. CD11b RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD11b RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD62L RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD62L 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed 
over time in 44 patients (23 placebo patients and 21 nitrite patients) is shown in panel E.  Panel F 
shows CD162 RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data 
expressed as mean ± SEM.  ***P<0.0001, *P<0.05 using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. Panel B, D, F comparisons performed using two-way repeated measures ANOVA. 
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4.3.2.6 Monocytes 
 
Monocytes were split into inflammatory (classical) monocytes (CD14+/CD16-), 
intermediate monocytes (CD14+/CD16+) and non-classical/resident monocytes 
(CD14+/CD16++) (Passlick et al., 1989; Ziegler-Heitbrock et al., 2010; Rogacev et 
al., 2012) 
 
4.3.2.6.1 Inflammatory monocytes (CD14+/CD16-) 
 
Inflammatory monocyte relative CD11b, CD62l and CD162 expression all 
increased from 30 minutes to 24 hours post reperfusion however only CD162 
increased significantly. There were significantly lower levels of each activation 
marker seen at 6 months after reperfusion (Figure 4.14 A, C and E). There was a 
trend to lower levels of CD11b expression in the nitrite treated patients 
compared to placebo over the time-points with the largest difference at 24 hours 
however this did not reach statistical significance (p=0.120, figure 4.14B). There 
was no difference in the relative expression of either CD162 (p=0.274) or CD62L 
(p=0.981) between the nitrite or placebo groups over the time-points (Figure 
4.14D, F).  
 
4.3.2.6.2 Intermediate monocytes (CD14+/CD16+) 
 
Intermediate monocyte relative CD11b, CD62l and CD162 expression all 
increased from 30 minutes to 24 hours post reperfusion, however similar to the 
inflammatory monocytes only CD162 increased significantly. There were 
significantly lower levels of each activation marker seen at 6 months after  
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Figure 4.14 Inflammatory monocyte Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b/CD62L/CD162 was measured at 30 minutes, 24 
hours and 6 months after coronary reperfusion. CD11b RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD11b RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD62L RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD62L 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed 
over time in 44 patients (23 placebo patients and 21 nitrite patients) is shown in panel E.  Panel F 
shows CD162 RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data 
expressed as mean ± SEM.  ***P<0.0001, **P<0.01,  *P<0.05 using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. Panel B, D, F comparisons performed using two-way 
repeated measures ANOVA 
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reperfusion (Figure 4.15 A, C and E). There was a trend to lower levels of CD11b 
expression in the nitrite treated patients compared to placebo over the time-
points with the greatest difference between the two groups occurring at 24 hours 
however this did not reach statistical significance (p=0.190, figure 4.15B). There 
was no difference in the relative expression of either CD162 (p=0.920) or CD62L 
(p=0.320) between the nitrite or placebo groups over the time-points (Figure 
4.15D, F).  
 
4.3.2.6.3 Resident monocytes (CD14+/CD16++)  
 
Resident monocyte relative CD11b, CD62l and CD162 expression all increased 
from 30 minutes to 24 hours post reperfusion, however similar to both 
inflammatory and intermediary monocytes only CD162 increased significantly. 
There were significantly lower levels of each activation marker seen at 6 months 
after reperfusion (Figure 4.16 A, C and E). There was a trend to lower levels of 
CD11b expression in the nitrite treated patients compared to placebo over the 
time-points with the largest difference at 24 hours however this did not reach 
statistical significance (p=0.180, figure 4.16B). A similar pattern was seen in the 
relative expression of CD62L (p=0.144) over time between the nitrite and 
placebo treated patients, with no difference in the relative expression of CD162L 
(p=0.320) between the nitrite or placebo groups over the time-points (Figure 
4.16D, F).  
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Figure 4.15 Intermediate monocyte Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b/CD62L/CD162 was measured at 30 minutes, 24 
hours and 6 months after coronary reperfusion. CD11b RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD11b RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD62L RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD62L 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed 
over time in 44 patients (23 placebo patients and 21 nitrite patients) is shown in panel E.  Panel F 
shows CD162 RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data 
expressed as mean ± SEM.  ***P<0.0001, **P<0.01,  *P<0.05 using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. Panel B, D, F comparisons performed using two-way 
repeated measures ANOVA.  
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Figure 4.16 Resident monocyte Relative Fluorescence Intensity. 
Relative Fluorescence Intensity (RFI) for CD11b/CD62L/CD162 was measured at 30 minutes, 24 
hours and 6 months after coronary reperfusion. CD11b RFI assessed over time in 44 patients (23 
placebo patients and 21 nitrite patients) is shown in panel A.  Panel B shows CD11b RFI over time 
of nitrite (21 patients) treated versus placebo (23 patients). CD62L RFI assessed over time in 44 
patients (23 placebo patients and 21 nitrite patients) is shown in panel C.  Panel D shows CD62L 
RFI over time of nitrite (21 patients) treated versus placebo (23 patients). CD162 RFI assessed 
over time in 44 patients (23 placebo patients and 21 nitrite patients) is shown in panel E.  Panel F 
shows CD162 RFI over time of nitrite (21 patients) treated versus placebo (23 patients). Data 
expressed as mean ± SEM.  ***P<0.0001, **P<0.01,  *P<0.05 using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. Panel B, D, F comparisons performed using two-way 
repeated measures ANOVA.  
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4.3.3 Inflammatory mediators 
 
Plasma levels of high-sensitivity C-reactive protein and monocyte-
chemoattractant protein-1 were measured at baseline, 4 hours, 24 hours and 6 
months post reperfusion.  
 
4.3.3.1 High-sensitivity C-reactive protein 
 
Plasma hs-CRP increased from baseline at 4 hours, and then to its highest level by 
24 hours. However, at 6 months levels had returned to below baseline levels 
(Figure 4.17A, p<0.0001). Between the treatment cohorts, plasma hs-CRP levels 
were comparable at baseline however in the nitrite treated patients the levels of 
hs-CRP over each of the remaining time-points were substantially reduced 
compared to placebo (p=0.003) with the greatest difference evident at 24 hours  
(Figure 4.17B). To determine whether the rise in hs-CRP was related to the size of 
the infarct post-hoc analyses were conducted using the levels of hs-CRP at their 
peak i.e 24 hours. These analyses demonstrated that plasma levels of hs-CRP are 
positively associated with infarct size (r=0.337, p=0.005) (Figure 4.19A) as 
assessed by cardiac enzymes.  
 
4.3.3.2 Monocyte-chemoattractant proten-1 (MCP-1) 
 
Plasma MCP-1 levels of the combined cohort increased from baseline at 4 hours 
and then to its highest level measured at 24 hours. However at 6 months levels 
had returned to below baseline values (Figure 4.18A, p<0.0001). Between the 
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two treatment cohorts plasma MCP-1 levels were comparable at baseline 
however in the nitrite treated patients the plasma levels of MCP-1 over the 
remaining time-points were substantially reduced compared to placebo 
(p=0.0058) with the greatest difference evident at 24 hours (Figure 4.18B).  
Further post-hoc analyses demonstrated that levels of plasma MCP-1 are 
positively associated with infarct size (r=0.309, p=0.020) (Figure 4.19B) and 
levels of plasma hs-CRP (r=0.341, p=0.005) (Figure 4.19C).  
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Figure 4.17 Effect of time and treatment on plasma hs-CRP.  
High-sensitivity C-reactive protein (hs-CRP) was measured at baseline, 4 hours, 24 hours and 6 
months after coronary reperfusion. hs-CRP assessed over time in 79 patients shown in panel A.  
Panel B shows hs-CRP over time showing nitrite (39 patients) treated versus placebo (40 
patients). Data expressed as mean ± SEM.  ***P<0.0001 using 1-way ANOVA, with Bonferroni’s 
multiple comparison test. ♯♯=P<0.01 using two-way repeated measures ANOVA, **= P<0.01, 
*=P<0.05 using two-way repeated measures ANOVA with Bonferronis multiple comparison test 
(Hs-CRP= High-sensitivity C-reactive protein). 
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Figure 4.18 Effect of time and treatment on plasma MCP-1.  
Monocyte chemoattractant Protein-1 (MCP-1) measured at baseline, 4 hours, 24 hours and 6 
months after coronary reperfusion. MCP-1 assessed over time in 74 patients (37 nitrite and 37 
placebo) is shown in panel A.  Panel B shows MCP-1 over time showing nitrite treated versus 
placebo. Data expressed as meanSEM.  ***P<0.0001, **P<0.01,  *P<0.05 using 1-way ANOVA, with 
Bonferroni’s multiple comparison test.. ♯♯=P<0.01 using two-way repeated measures ANOVA, *= 
P<0.05 using two-way repeated measures ANOVA with Bonferronis multiple comparison test (Hs-
CRP= High-sensitivity C-reactive protein). (MCP-1=monocyte chemoattractant protein 1) 
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Figure 4.19 Associations between Hs-CRP, MCP-1 and infarct size.  
There was a significant positive association between levels of Hs-CRP measured at 24 hours and 
infarct size assessed by troponin T AUC as shown in panel A. Panel B depicts a similar positive 
association between MCP-1 levels at 24 hours and CK AUC. Panel C shows a positive correlation 
between MCP-1 and Hs-CRP levels measured at 24 hours. Correlations determined using 
Pearson’s correlation coefficient. (MCP-1=monocyte chemoattractant protein 1, hs-CRP= High-
sensitivity C-reactive protein, CK= Creatine Kinase, AUC=Area under the curve). 
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4.3.3.3 Neutrophil chemokines 
 
Since the greatest changes were found in neutrophil numbers and activation 
states between treatment arms, the possibility that this might be related to 
differences in neutrophil chemokine levels was also investigated. Levels of CXCL-
1 and CXCL-5 were measured in all patients (40 nitrite and 40 placebo) at 
baseline, 4 hours, 24 hours and 6 months post reperfusion.  
 
4.3.3.3.1 CXCL-1 
 
Plasma CXCL-1 levels increased from baseline (907.27±208.83pg/ml) to the 
highest levels seen at 4 hours (1584.37±424.99pg/ml), with a slight decrease by 
24 hours (1360.39±347.62pg/ml). However at 6 months levels had returned to 
below baseline values (Figure 4.20A). Between the two treatment cohorts plasma 
CXCL-1 levels were comparable at baseline however in the nitrite treated 
patients the plasma levels of CXCL-1 over the remaining time-points were 
substantially reduced compared to placebo (p=0.04) with the greatest difference 
evident at 24 hours (p=0.043) (Figure 4.20B). Further post-hoc analyses 
demonstrated that levels of plasma CXCL-1 are positively associated with infarct 
size (r=0.369, p=0.001) (Figure 4.21A).  
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Figure 4.20 Effect of time and treatment on plasma CXCL-1.  
CXCL-1 levels were measured at baseline, 4 hours, 24 hours and 6 months after coronary 
reperfusion. CCL-1 assessed over time in all patients is shown in panel A.  Panel B shows CXCL-1 
over time showing nitrite treated versus placebo groups. Data expressed as mean ± SEM, **P<0.01 
using 1-way ANOVA, with Bonferroni’s multiple comparison test. ♯=P<0.05 using two-way 
repeated measures ANOVA, *= P<0.05 using two-way repeated measures ANOVA with 
Bonferronis multiple comparison test.  
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Figure 4.21 Associations between CXCL-1, CXCL-5 and infarct size.  
There was a significant positive association between levels of CXCL-1 measured at 24 hours and 
infarct size assessed by troponin T AUC as shown in panel A. Panel B depicts a similar positive 
association between CXCL-5 levels at 24 hours and Troponin T AUC. Panel C shows a positive 
correlation between CXCL-1 and CXCL-5 levels measured at 24 hours. Correlations determined 
using Pearson’s correlation coefficient. 
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4.3.3.3.2 CXCL-5 
 
Plasma CXCL-5 levels increased from baseline (1670.85±261.10pg/ml) to the 
highest levels seen at 4 hours (3018.14±277.76pg/ml), with a slight decrease by 
24 hours (2831.83±272.17pg/ml). However at 6 months levels had returned to 
below baseline values (Figure 4.22A, P<0.0001). Between the two treatment 
cohorts plasma CXCL-5 levels were comparable at baseline however in the nitrite 
treated patients the plasma levels of CXCL-1 over the remaining time-points were 
substantially reduced compared to placebo (p=0.04) with the greatest difference 
evident at 24 hours (p=0.044) (Figure 4.22B). Further post-hoc analyses 
demonstrated that levels of plasma CXCL-5 are positively associated with infarct 
size (r=0.314, p=0.004) (Figure 4.21B) and levels of plasma CXCL-1 (r=0.346, 
p=0.003) (Figure 4.21C). 
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Figure 4.22 Effect of time and treatment on plasma CXCL-5.  
CXCL-5 levels were measured at baseline, 4 hours, 24 hours and 6 months after coronary 
reperfusion. CXCL-5 assessed over time in all patients is shown in panel A.  Panel B shows CXCL-5 
over time showing nitrite treated versus placebo groups. Data expressed as mean ± SEM.  
***P<0.0001, **P<0.01 using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
♯=P<0.05 using two-way repeated measures ANOVA, *= P<0.05 using two-way repeated 
measures ANOVA with Bonferronis multiple comparison test.   
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4.3.4 Plasma NOx  
 
4.3.4.1 Acute measurement 
 
In chapter 3 plasma [NO2-] measurements at 30 minutes demonstrated effective 
administration of the IMP. However plasma NOx levels are also a reflection of 
systemic inflammation as a consequence of iNOS expression and activity. In light 
of this levels of both nitrite and nitrate were increased in the whole cohort at 
each time-point measured. Plasma NOx levels were measured at baseline, 30 
minutes, 4 hours, and 24 hours post reperfusion in all patients (40 patients in the 
placebo group and 40 patients in the nitrite group). Plasma levels of nitrite in the 
whole cohort significantly increased from baseline to 30 minutes post 
reperfusion with lower levels evident at both 4 hours and 24 hours (Figure 4.23A, 
P<0.0001).   
 
As indicated previously the rise in nitrite levels at 30 minutes post reperfusion is 
predominantly occurring within the nitrite treated patients (P<0.0001, figure 
3.3A, table 4.1) however a rise was also evident in the placebo group although 
this did not reach statistical significance (P=0.22, Figure 3.3C, table 4.1). At 4 and 
24 hours after reperfusion plasma nitrite levels were significantly lower in the 
nitrite treated patients compared to placebo (p=0.423, table 4.1) 
 
Plasma levels of nitrate in the whole cohort decreased steadily over the time-
period measurements with significantly lower levels evident at 24 hours 
compared to baseline (Figure 4.23B, P<0.05).  Baseline levels of nitrate were 
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similar between the nitrite and placebo treated patients with neither treatment 
group having an elevation in nitrate levels at 30 minutes post reperfusion (Nitrite 
group p=0.788, placebo p=0.868, Figure 3.3B and D, Table 4.1). Levels of nitrate 
at 4 and 24 hours after reperfusion were higher in the nitrite treated patients 
compared to placebo, however this however this difference was not significant 
(p=0.10, Table 4.1) 
 
 Baseline 30 minutes 4 hours 24 hours 
NO2- (μM)      
Nitrite 0.34 (0.30-0.38) 0.47 (0.41-0.53) 0.26 (0.24-0.29)* 0.27 (0.23-0.29)* 
Placebo 0.37 (0.32-0.42) 0.40 (0.35-0.45) 0.30 (0.25-0.34) 0.32 (0.26-0.38) 
NO3- (μM)     
Nitrite 37.91 (33.45-42.38) 38.88 (33.88-43.88) 36.26 (31.67-40.86) 36.08 (32.45-39.72) 
Placebo 40.44 (33.71-47.17) 40.62 (32.87-48.38) 32.88 (28.74-37.01) 32.14 (27.94-36.34) 
 
Table 4.2 Acute NOx measurements over time by treatment group  
Plasma NOx levels measured at baseline, 30 minutes, 4 hours, and 24 hours after coronary 
reperfusion in all patients (40 nitrite, 40 placebo). Data expressed as mean (95% CI). *P<0.05 
using two-way repeated measures ANOVA comparing nitrite versus placebo at 4 and 24 hours. 
(NO2-=Nitrite, NO3-=Nitrate)  
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Figure 4.23 Effect of time and treatment on plasma NOx levels. 
Plasma NOx levels were measured at baseline, 30 minutes, 4 hours, and 24 hours after coronary 
reperfusion.  Plasma NO2- assessed over time in all patients is shown in panel A.  Panel B shows 
plasma NO3- assessed over time in all patients. Data expressed as mean ± SEM. ***P<0.0001, 
**P<0.01, *P<0.05 using 1-way ANOVA, with Bonferroni’s multiple comparison test. (NO2- = 
Nitrite, NO3- = Nitrate) 
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4.3.4.2 6 month NOx levels 
 
There was a trend to higher levels of plasma nitrite and nitrate at 6 months in the 
nitrite treated patients compared to placebo however these differences were not 
significant (Figure 4.24).  
 
Figure 4.24 Six month plasma NOx.  
Plasma NOx levels measured at 6 months after coronary reperfusion in all patients. Panel A shows 
plasma NO2- levels, and panel B shows NO3- levels. Data expressed as mean ± SEM. Statistical 
comparisons between groups performed using unpaired T test. (NO2- = Nitrite, NO3- = Nitrite). 
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4.3.5 Plasma cGMP 
 
4.3.5.1 Acute measurement  
 
Levels of plasma cGMP were measured at baseline, 4 hours, and 24 hours post 
reperfusion. Levels of cGMP were highest at baseline and were significantly 
decreased at both 4 and 24 hours (Figure 4.25, P<0.0001).  
 
Levels of cGMP were comparable at baseline between the nitrite and placebo 
treated patients but were significantly lower in the nitrite treated patients over 
the time-period (p=0.0002) with the greatest difference evident at 24 hours 
(20.45±2.60 vs 26.99±2.91nM) (Figure 4.24). Post-hoc analyses demonstrated 
that levels of cGMP at 24 hours are positively associated with both infarct size 
(r=0.591, p<0.001) and hs-CRP (r=0.373, p=0.002) (Figure 4.26).   
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Figure 4.25 Effect of time and treatment on plasma cGMP levels.  
Levels of cGMP measured at baseline, 4 hours, and 24 hours after coronary reperfusion. C-GMP 
assessed over time in 76 patients shown in panel A.  Panel B shows c-GMP over time showing 
nitrite (38 patients) treated versus placebo (38 patients). Data expressed as mean ± SEM.  
***P<0.0001 using 1-way ANOVA, with Bonferroni’s multiple comparison test, ♯♯=P<0.001 using 
two-way repeated measures ANOVA, *= P<0.05, **=P<0.01 using two-way repeated measures 
ANOVA with Bonferronis multiple comparison test.  
 241 
 
Figure 4.26 Associations between cGMP levels, inflammation and infarct size.  
There was a significant positive association between levels of cGMP measured at 24 hours and 
infarct size assessed by Creatine Kinase AUC in the TIMI ≤1 subgroup shown in panel A. Panel B 
shows a significant positive association between levels of cGMP measured at 24 hours and plasma 
hs-CRP measured at 24 hours in the TIMI ≤1 subgroup. Correlations were determined using 
Pearson’s correlation coefficient. 
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4.3.5.2 6 month cGMP levels 
 
At 6 months there was a trend to higher plasma levels of cGMP in the nitrite 
group compared to placebo but this did not reach statistical significance 
(p=0.052, Figure 4.27) 
 
 
 
Figure 4.27 Six-month plasma cGMP. 
Plasma cGMP levels measured at 6 months after coronary reperfusion in 75 patients (37 nitrite 
and 38 placebo). Data expressed as mean ± SEM. Statistical comparisons between groups 
performed using unpaired T test. (cGMP = cyclic guanosine monophosphate). 
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4.4 Summary 
 
1. In patients following primary PCI for STEMI platelet reactivity was 
increased with elevated P-selectin expression that then decreased over 
time. The level of activation was significantly decreased in the nitrite 
compared to the placebo group.  
2. Despite anti-thrombotic therapy (anti-platelets, heparin and GPIIb/IIIa 
inhibition) ex-vivo exposure of platelets to activating stimuli, ADP and 
collagen resulted in increased P-selectin expression and platelet 
aggregation. These responses decreased over time in the whole cohort but 
the decreases were substantially greater in the nitrite treated patients.  
3. The decrease in platelet reactivity following nitrite was maintained out to 
6 months after reperfusion and both P-selectin expression and the platelet 
aggregatory response were positively associated with myocardial infarct 
size. 
4. In the whole cohort total circulating leukocytes were raised post 
reperfusion and then decreased over time. This rise was driven by 
increases in neutrophil numbers.  
5. In nitrite treated patients the levels of neutrophils were suppressed 
compared to placebo and this was specifically associated with a decrease 
in the level of activation markers involved in adhesion namely CD11b.  
6. There were no significant differences in the number of other leukocyte 
populations (monocytes and lymphocytes) or activation markers 
expressed by these cells between the treatment groups.   
7. In the whole cohort the levels of inflammatory mediators were increased 
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post-reperfusion, this included hs-CRP and both neutrophil and monocyte 
chemokines.  
8. The plasma levels of hs-CRP, neutrophil chemokines (CXCL-1 and CXCL-5) 
and MCP-1 were significantly lower in the nitrite group compared to 
placebo with the greatest difference evident at 24 hours. 
9. Levels of MCP-1, Hs-CRP and the neutrophil chemokines (CXCL-1 and 
CXCL-5) were positively associated with infarct size 
10. Whilst acutely nitrite levels were elevated at 30 minutes post-reperfusion 
this effect was largely due to the intervention in the nitrite arm. 
11. In general over time both nitrite and nitrate levels decreased post 
reperfusion. This effect was greater in the nitrite treated patients. 
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Chapter 5.0 
 
 
The investigation of the effect of 
nitrite on endothelial and smooth 
muscle cell growth  
and viability 
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5.1 Introduction  
 
In all patients undergoing PCI for the treatment of AMI endovascular stents are 
placed following the angioplasty procedure to prevent the vessel from collapsing 
or re-occluding again. A major limitation of this technique is re-growth of the 
tissue within the stented part of the artery, known as in-stent restenosis (ISR). 
The introduction of drug-eluting stents (DESs) was seen as a solution to this 
problem and have reduced the incidence of ISR considerably (Regar et al., 2002), 
however attention has shifted to the safety of these devices because of evidence 
suggesting an association with late-stent thrombosis (Stolker et al., 2010) (a 
process associated with inhibition of/delayed re-endothelialisation). Therefore 
there have been calls for therapies that prevent restenosis and thrombosis, to 
improve the safety and efficacy of coronary stenting (Jukema et al., 2012).   
 
Evidence exists supporting the concept that NO supplementation may be a viable 
solution to the above phenomena. As mentioned in chapter 1, section 13, NO 
plays a pivotal role as a multi-functional anti-platelet, anti-proliferative and 
vasorelaxant mediator of homeostasis that counteracts the restenotic process. 
Deficiencies in NO bioavailability have been shown to contribute to occlusive 
vascular diseases (Boger et al., 1996; Boger et al., 1997) and indeed genetic eNOS 
variants are also associated with clinical outcomes following PCI (Gorchakova et 
al., 2003). Additionally extensive pre-clinical studies across several species have 
demonstrated that NO supplementation in the form of NO donors inhibit smooth 
muscle cell proliferation (mediated via elevations of the cell cycling inhibitor 
p21waf1/cip1) in vitro (Ishida et al., 1997; Bauer et al., 2001; Alef et al., 2011) and 
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subsequent balloon induced experimental stenosis of coronary arteries (Janero 
and Ewing, 2000). Trials of NO donors in man have not been a success and have 
been limited by systemic side effects, complicated delivery, safety concerns, and 
failure to show efficacy in human trials (Lablanche et al., 1997; Suzuki et al., 
2002; Wohrle et al., 2003; Suzuki et al., 2002; Heiko and Chew, 2006). Recently it 
has been suggested that nitrite, via its conversion to NO, decreases the 
development of intimal hyperplasia following vascular injury, an effect also 
linked with changes in p21waf1/cip1 expression (Alef et al., 2011).  However, 
whether nitrite might alter cell survival acutely during an ischaemic stimulus, 
such as primary PCI for AMI or whether nitrite might exert similar repressive 
effects on endothelial cells during ischaemia, in addition to vascular smooth 
muscle cells, is uncertain.  
 
The purpose of this study was to investigate the effect of nitrite on the 
proliferation and viability of endothelial cells (EC) and vascular smooth muscle 
cells (VSMC) in normoxia, hypoxia and I/R. 
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5.2 Results 
 
5.2.1 Normoxia 
 
Under normoxic conditions, nitrite treatment for 24h had no significant effect on 
HCAEC, HUVEC or HmCASMC cell numbers or viability (Figure 5.1). 
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Figure 5.1 Nitrite and HCAEC, HUVEC and HmCASMC growth under normoxia.  
Bar charts showing the effect of nitrite (0.1 -10 µM) on A) Human coronary artery endothelial cell, 
B) human umbilical vein cell and C) human coronary artery smooth muscle cell growth under 
normoxic conditions (21% O2, 5% CO2 and 37oC). Data represent means ±SEM of (HCAEC n=7, 
HUVEC, n=13 and HmCASMC n=6 independent experiments). P > 0.05 comparing normoxia with 
0.1-10µM of nitrite using one-way ANOVA.  
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5.2.2 Effect of nitrite on cell growth under hypoxic conditions 
 
5.2.2.1 HUVECs  
 
5.2.2.1.1 Cell number 
 
In comparison to normoxia, hypoxia of either 5% or 1% attenuated proliferation 
of HUVECs, with 5% O2 causing a 21.2±2.8% and 1% O2 a 24.1±3.1% reduction 
compared to normoxia (P<0.001, n=10) (Figure 5.2).  
 
Figure 5.2 Effect of nitrite on HUVEC growth in hypoxic conditions. 
Effect of nitrite (0.1-10 µM) on human umbilical vein endothelial cell (HUVEC) growth under 5% 
hypoxia (5% O2, 5% CO2 and 37oC) and 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent 
means ±SEM of n=10 independent experiments. N = Normoxia, H = Hypoxia. Significance shown 
as **P<0.001 comparing Normoxia with hypoxia, ♯P<0.05, ♯♯P<0.01 comparing the relevant 
control with nitrite, using 1-way ANOVA, with Bonferroni’s multiple comparison test. 
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5.2.2.1.2 Cell Viability  
 
Hypoxia increased the numbers of apoptotic cells, decreasing viability of HUVECs 
by 7.4±1.4% in 5% O2 and 9.0±1.8% at 1% O2. (P<0.001, n=10) (Figure 5.3). 
Nitrite resulted in a concentration-dependent increase in endothelial cell number 
and viability with a peak effect (near complete reversal) occurring at 3µM in 
HUVECs (P<0.001, n=10) (Figure 5.2, Table 5.1 and 5.2). This is manifested by a 
decrease in the % of apoptotic cells with no difference seen in percentage cellular 
necrosis (Table 5.1/5.2).  
 
Figure 5.3 HUVEC Viability (5% hypoxia) in the presence of nitrite.  
Representative flow cytometry dot plots of HUVECs in normoxia, or treated with nitrite and 
exposed to 24 hours 5% hypoxia.  Representative FSC versus SSC and the annexin V-FITC versus 
PI plots are shown. Values in Q1 are positive for PI and negative for annexin and are necrotic cells. 
Q2 are cells positive for annexin V and PI and are apoptotic. Q3 are negative for both PI and 
annexin V (Viable), Q4 are early apoptotic (annexin positive and PI negative).  Figure A shows 
plots for cells treated in normoxia for 24 hours.  Figure B shows plots for cells treated in 5% 
hypoxia alone for 24 hours. Figure C shows plots for cells treated with 3µM nitrite in the presence 
of 5% hypoxia. 
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Table 5.1 HUVEC Viability under 5% hypoxia.  
Effect of nitrite (0.1-10 µM) on HUVEC viability under 5% hypoxia (5% O2, 5% CO2 and 37oC). 
Data expressed as mean±SEM of n=10. Statistical significance shown as * P<0.05 vs normoxia, ♯ 
P<0.05 vs 5% hypoxia alone using 1-way ANOVA, with Bonferroni’s multiple comparison test. 
 
 
 
Table 5.2 HUVEC Viability under 1% hypoxia.  
Effect of nitrite (0.1-10 µM) on HUVEC viability under 1% hypoxia (1% O2, 5% CO2 and 37oC). 
Data expressed as mean±SEM of n=10. Statistical significance shown as * P<0.05 vs normoxia, ♯ 
P<0.05 vs 5% hypoxia alone using 1-way ANOVA, with Bonferroni’s multiple comparison test. 
 
 
Quadrant (%) 
 
Normoxia 
 
Hypoxia 
(5%) 
 
0.1µM 
 
0.3µM 
+ Nitrite 
1µM 
 
3µM 
 
10µM 
1. Necrotic 3.05±1.09 3.27±1.30 3.41±1.19 2.94±1.12 2.52±0.76 1.14±0.20 3.20±1.33 
2. Apoptotic 11.54±1.86 17.16±2.78* 16.33±2.32 16.06±2.11 13.72±1.75 13.28±1.77
♯ 15.00±2.01 
3. Viable 80.84±1.38 73.41±1.97* 76.50±2.31 76.89±1.84 79.21±1.79 79.25±1.52
♯ 77.19±1.73 
4. Early Apoptotic 3.91±0.71 5.09±0.99 3.78±0.95 4.16±0.89 4.53±0.84 4.04±0.94 4.92±1.03 
 
Quadrant (%) 
 
Normoxia 
 
Hypoxia 
(1%) 
 
0.1µM 
 
0.3µM 
+ Nitrite 
1µM 
 
3µM 
 
10µM 
1. Necrotic  2.74±0.49 2.81±0.66 2.09±0.74 1.64±0.47 2.20±0.46  2.49±0.79  2.55±0.84  
2. Apoptotic 8.66±1.03 16.38±2.74* 8.51±1.40 8.39±1.24
♯ 8.91±0.95♯ 7.70±1.14♯ 9.73±1.11 
3. Viable 85.53±0.98 76.76±2.54* 85.23±1.08 85.76±1.1
♯ 86.19±1.20♯ 86.78±1.12 ♯ 84.19±0.82 
4. Early Apop 3.10±0.37 4.06±1.00 4.21±0.73 3.75±0.71 3.15±0.48 3.05±0.53 3.51±0.64 
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5.2.2.1.3 Nitrite reductase inhibitors 
 
To assess the nitrite reductase that might be involved in this effect experiments 
were conducted using a maximally effective concentration of nitrite under 1% 
hypoxic conditions. This effect of nitrite (3µM) on cell growth (figure 5.4) and 
viability (Figure 5.5) was partially attenuated by L-NMMA by ~85% (P<0.001, 
n=10) or by treatment with allopurinol (~80.0%, P<0.001, n=10) (Figure 5.4 and 
5.5).  
 
Figure 5.4 Nitrite and effect of inhibitors (L-NMMA and Allopurinol) on HUVEC growth.  
Nitrite and effect of inhibitors (L-NMMA (300 µM) and Allopurinol (100 µM)) on human umbilical 
vein endothelial cell (HUVEC) growth under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data 
represent means ±SEM of n=9 independent experiments. Statistical significance shown as  
**P<0.001 comparing hypoxia with hypoxia + 3µM nitrite, ♯ P<0.05 comparing Hypoxia + 3µM 
nitrite with hypoxia +3µM nitrite + L-NMMA and allopurinol, using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. 
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Figure 5.5 Nitrite and effect of inhibitors (L-NMMA and Allopurinol) on HUVEC viability.  
Nitrite and effect of inhibitors (L-NMMA (300 µM) and Allopurinol (100 µM)) on human umbilical 
vein endothelial cell (HUVEC) viability under 1% hypoxia (1% O2, 5% CO2 and 37oC). Figure A 
shows the percentage (%) viability of HUVEC, B shows the percentage of apoptotic cells and C 
shows the percentage necrotic cells. Data represent means ±SEM of n=9 independent 
experiments. Statistical significance shown as  **P<0.01 comparing hypoxia with hypoxia + 3µM 
nitrite, ♯ P<0.05 comparing Hypoxia + 3µM nitrite with hypoxia +3µM nitrite + L-NMMA and 
allopurinol, using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
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5.2.2.2 HCAECs 
 
5.2.2.2.1 Cell number 
 
In comparison to normoxia, hypoxia of either 5% or 1% attenuated proliferation 
of HCAECs, with 5% O2 causing a 30.1±4.1% and 1% a 31.4±3.6% reduction 
(P<0.001, n=10) (Figure 5.6).  
 
 
Figure 5.6 Effect of nitrite on HCAEC growth in hypoxic conditions.  
Effect of nitrite (0.1-10 µM) on human coronary artery endothelial cell (HCAEC) growth under 5% 
hypoxia (5% O2, 5% CO2 and 37oC) and 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent 
means ± SEM of n=10 independent experiments. Statistical significance shown as **P<0.001 
comparing normoxia with hypoxia, ♯P<0.001 comparing the relevant control with nitrite, using 1-
way ANOVA, with Bonferroni’s multiple comparison test.  
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5.2.2.2.2 Cell Viability  
 
Hypoxia increased the numbers of apoptotic cells, decreasing viability of HCAECs 
by 9.5±1.9% at 5% and 9.6±1.3% at 1% in HCAECs (P<0.001, n=10) (Figure 5.7). 
Nitrite resulted in a concentration-dependent increase in endothelial cell number 
and viability with a peak effect (near complete reversal) occurring at 3µM 
(P<0.001, n=10) (Table 5.3 and Table 5.4). 
 
 
Figure 5.7 HCAEC Viability (1% hypoxia) in the presence of nitrite (3µM).  
Representative flow cytometry dot plots of HCAECs in normoxia and treated with nitrite and 
exposed to 24 hours 1% hypoxia.  Representative FSC versus SSC and the annexin V-FITC versus 
PI plots are shown. Values in Q1 are positive for PI and negative for annexin and are necrotic cells. 
Q2 are cells positive for annexin V and PI and are apoptotic. Q3 are negative for both PI and 
annexin V (Viable), Q4 are early apoptotic (annexin positive and PI negative).  Figure A shows 
plots for cells treated in normoxia for 24 hours.  Figure B shows plots for cells treated in 1% 
hypoxia alone for 24 hours. Figure C shows plots for cells treated with 3µM nitrite in the presence 
of 1% hypoxia. 
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Table 5.3 Effect of nitrite on HCAEC viability in 1% hypoxia.  
Effect of nitrite (0.1-10 µM) on HCAEC viability under 1% hypoxia (1% O2, 5% CO2 and 37oC) 
Data expressed as mean±SEM of n=10 independent experiments. Statistical significance shown as 
* P<0.05 vs normoxia, ♯ P<0.05 vs hypoxia using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. 
 
 
Table 5.4 Effect of nitrite on HCAEC viability in 5% hypoxia.  
Effect of nitrite (0.1-10 µM) on HCAEC viability under 5% hypoxia (5% O2, 5% CO2 and 37oC). 
Data expressed as mean±SEM of n=10 independent experiments. Statistical significance shown as 
* P<0.05 vs normoxia, ♯ P<0.05 vs hypoxia using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. 
 
 
 
 
 
 
 
 
 
Quadrant (%) 
 
Normoxia 
 
Hypoxia       
(1%) 
 
0.1µM 
 
0.3µM 
+ Nitrite 
1µM 
 
3µM 
 
10µM 
1. Necrotic  2.41±0.57 3.41±1.22 3.93±1.37 2.29 ± 0.42 2.44±0.55  2.66±0.71  2.66±0.56  
2. Apoptotic 16.86±1.67 22.03±1.91* 19.23±2.62 19.33±2.44 17.18±2.20
♯ 16.54±1.26♯ 18.13±2.38 
3. Viable 78.04±1.80 68.49±3.00* 73.24±3.55 75.15±2.77
♯ 77.10±2.55♯ 77.69±2.53♯ 74.90±3.07 
4. Early Apoptotic 2.81±0.38 5.93±2.13 3.51±1.25 3.28±0.99 3.26±0.88 3.09±0.84 4.33±1.26 
 
Quadrant (%) 
 
Normoxia 
 
Hypoxia 
(5%) 
 
0.1µM 
 
0.3µM 
+ Nitrite 
1µM 
 
3µM 
 
10µM 
1. Necrotic  1.29±0.17 1.67±0.40 1.62±0.29 1.28 ± 0.24 1.30 ± 0.39  1.14 ± 0.20  2.64 ± 0.92  
2. Apoptotic 10.43±1.10 14.66±0.89* 12.58±1.01 10.51±1.16 9.52 ± 1.09
♯ 9.88± 1.26♯ 11.66±0.90 
3. Viable 85.20±1.09 76.90±0.94* 80.74±1.02 83.37±1.41 84.47 ± 1.20
♯ 84.67±1.60♯ 81.08±1.35 
4. Early Apoptotic 3.70±0.68 6.74±0.88 5.03±0.82 4.86±0.62 4.70 ± 0.32 4.28 ± 0.73 5.49 ± 0.93 
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5.2.2.2.3 Nitrite reductase inhibitors 
 
The effect of nitrite (3µM) on HCAEC growth (figure 5.8) and viability (Figure 5.9) 
was partially attenuated by L-NMMA by ~75% (P<0.001, n=10) or by treatment 
with allopurinol (~70.0%, P<0.001, n=10) (Figure 5.8). The decrease in apoptosis 
seen with nitrite (3µM) was reversed by the addition of either inhibitor (Figure 
5.9B). 
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Figure 5.8.Nitrite and the effect of inhibitors (L-NMMA and Allopurinol) on HCAEC growth.  
Nitrite and the effect of inhibitors (L-NMMA (300µM) and Allopurinol (100µM) on human 
coronary artery endothelial cell (HCAEC) growth under 1% hypoxia (1% O2, 5% CO2 and 37oC). 
Data represent means ±SEM of n=9. Statistical significance shown as  **P<0.001 comparing 
hypoxia with hypoxia + nitrite (3µM), ♯P<0.05 comparing Hypoxia + nitrite (3µM) with hypoxia + 
nitrite (3µM) + L-NMMA and allopurinol, using 1-way ANOVA, with Bonferroni’s multiple 
comparison test.  
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Figure 5.9 Nitrite and effect of inhibitors (L-NMMA and Allopurinol) on HCAEC viability. 
Nitrite and effect of inhibitors (L-NMMA (300µM) and Allopurinol (100µM) on human coronary 
artery endothelial cell (HCAEC) viability under 1% hypoxia (1% O2, 5% CO2 and 37oC). Figure A 
shows the percentage viability, B shows the percentage of apoptotic cells and C shows the 
percentage necrotic HCAECs. Data represent means±SEM of n=9 independent experiments. 
Statistical significance shown as  **P<0.01 comparing hypoxia with hypoxia + 3µM nitrite, ♯ 
P<0.05 comparing Hypoxia + 3µM nitrite with hypoxia +3µM nitrite + L-NMMA and allopurinol, 
using 1-way ANOVA, with Bonferroni’s multiple comparison test. 
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5.2.2.2.4 Effects of sGC inhibition on nitrite-induced effects on endothelial cells  
 
Treatment of cells with the sGC inhibitor ODQ almost abolished the effect of 
nitrite (3µM) on HCAEC growth (figure 5.10) and viability (Figure 5.11) (P<0.05, 
n=6). The decrease in apoptosis seen with nitrite (3µM) was reversed by the 
addition of ODQ (Figure 5.11B). 
 
Figure 5.10 Nitrite and the effect of sGC inhibitor ODQ.  
Nitrite and the effect of ODQ (3µM) on human coronary artery endothelial cell (HCAEC) growth 
under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=6 independent 
experiments. Statistical significance shown as  **P<0.001 comparing hypoxia with hypoxia + 
nitrite (3µM), ♯P<0.05 comparing Hypoxia + nitrite (3µM) with hypoxia + nitrite (3µM) + L-
NMMA and allopurinol, using 1-way ANOVA, with Bonferroni’s multiple comparison test. 
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Figure 5.11. The effect of the sGC inhibitor ODQ on nitrite induced changes in viability of 
HCAEC  
The effect of the sGC inhibitor ODQ (3µM) on nitrite-induced changes in viability of human 
coronary artery endothelial cells (HCAEC) under 1% hypoxia (1% O2, 5% CO2 and 37oC). Figure A 
shows the percentage viability, B shows the percentage of apoptotic cells and C shows the 
percentage necrotic HCAECs. Data represent mean±SEM of n=6 independent experiments. 
Statistical significance shown as  **P<0.01 comparing hypoxia with hypoxia + 3µM nitrite, ♯ 
P<0.05 comparing Hypoxia + 3µM nitrite with hypoxia +3µM nitrite + L-NMMA and allopurinol, 
using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
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5.2.2.2.5 Cyclic GMP measurement  
 
Levels of cGMP were significantly elevated in HCAECs treated with 3µM nitrite 
compared to 1% hypoxia control samples (P<0.001). This increase in cGMP was 
reversed by the addition of ODQ (Figure 5.12). 
 
 
Figure 5.12 Level of cGMP in HCAECs.  
Effect of 3µM nitrite and ODQ on cGMP levels under 1% hypoxia (1% O2, 5% CO2 and 37oC) Data 
represent means ± SEM of n=4 independent experiments. Statistical significance shown as 
**P<0.001 comparing Normoxia with hypoxia, *P<0.05 comparing the relevant control with 
nitrite, using 1-way ANOVA, with Bonferroni’s multiple comparison test 
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5.2.2.2.6 Nitrite promotes endothelial cell wound closure 
 
To further assess the effects of nitrite on endothelial cell growth scratch wounds 
were inflicted on cells cultured in 6 well plates with or without nitrite (1 or 3μm) 
treatment in 1% hypoxia for 24 hours (Figure 5.13). The addition of nitrite 
resulted in enhanced endothelial cell proliferation and migration compared to 
control. The wound surface area at 24 hours after treatment was significantly 
reduced in the nitrite (3μM and 1μM treated) cells in a concentration dependent 
fashion compared to control (Figure 5.14).  
 
Figure 5.13 Effect of nitrite on endothelial cell wound healing.  
Example microphotographs of wound closure in control and 3μM nitrite (NO2-) treated cells.  
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Figure 5.14 The effect of nitrite on endothelial cell (HCAEC) wound closure. 
Panel A shows the wound size at baseline and 24 hours of treatment (1% hypoxia in presence or 
absence of nitrite (1 or 3µM). Panel B shows the percentage wound closure at 24 hours compared 
to baseline cells. Data represent mean±SEM of n=5 independent experiments. Statistical 
significance shown as  * P<0.05, **P<0.01, ***P<0.001 comparing hypoxia with hypoxia + nitrite, 
using 1-way ANOVA, with Bonferroni’s multiple comparison test. H=Hypoxia.  
 266 
5.2.2.3 HmCASMCs 
 
5.2.2.3.1 Cell number 
 
Since we saw similar effects of both 1% and 5% O2 in ECs cell experiments with 
SMC were conducted in 1% O2 conditions only. 1% Hypoxia resulted in a 
significant (p<0.05) decrease in HmCASMC growth compared to normoxia. The 
addition of nitrite resulted in a concentration-dependent decrease in cell growth 
compared to control under hypoxic conditions with the greatest effect occurring 
at 3µM nitrite (Fig 5.15). 
 
Figure 5.15 Nitrite and HmCASMC growth (1% hypoxia).  
Effect of nitrite (0.1-10 µM) on human coronary artery smooth muscle cell (HmCASMC) growth 
under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=7 independent 
experiments. Statistical significance shown as ** p<0.05 comparing Normoxia with 1% hypoxia, 
♯P<0.05 comparing 1% hypoxia with 3µM nitrite, using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. H=Hypoxia 
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5.2.2.3.2 Cell Viability 
 
1% hypoxia had no effect on HCASMC viability or the apoptotic cell number 
(Table 5.5) and nitrite treatment did not alter this.   
 
 
Table 5.5 Cell viability of HmCASmCs under 1% hypoxia.  
Data expressed as mean±SEM of n=7 independent experiments. Statistical significance shown as  * 
P<0.05 vs normoxia, ♯ P<0.05 vs hypoxia using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. 
 
5.2.2.3.3 Nitrite reductase inhibitors  
 
The effect of nitrite (3µM) on HmCASMC growth (Figure 5.16) was significantly 
attenuated by treatment with allopurinol (~70.0%, P<0.001, n=10). No difference 
was seen in cell viability (Figure 5.17). The effects of L-NMMA were not assessed 
since eNOS is not expressed in these cells.  
 
Mechanism  
(Quadrant) 
 
Normox
ia  
 
Hypoxia  
 
0.1µM 
 
0.3µM 
+Nitrite 
1µM 
 
 
3µM 
 
10µM 
Necrosis  0.74 ± 1.03 1.58 ± 0.30 1.24 ± 0.39 1.36 ± 0.49 1.29±0.25  1.74±0.53  1.36±0.49 
Apoptosis 1.20 ±0.97 1.40 ± 0.18 1.53 ± 0.38 1.70±0.46 1.61±0.32 2.04±0.42 2.10±0.46 
Viable 97.61 ±1.98 95.61 ± 1.98 96.69 ± 0.89 96.46±1.06 96.41±0.81 95.61±1.06 95.16±1.06 
Early apoptosis  0.65 ±0.13 0.54 ± 0.16 0.48 ± 0.16 0.48 ± 0.16 0.73±0.16 0.61±0.17 1.38±1.25 
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Figure 5.16 Nitrite and the effect of Allopurinol on HmCASMC growth.  
Nitrite and the effect of allopurinol on human coronary artery smooth muscle cell (HmCASMC) 
growth under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=6 
independent experiments. Statistical significance shown as  **P<0.05 comparing hypoxia with 
hypoxia + nitrite (3µM), ♯P<0.05 comparing Hypoxia + nitrite (3µM) with hypoxia + nitrite (3µM) 
+ allopurinol, using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
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Figure 5.17 Nitrite and the effect of Allopurinol on HmCASMC viability.  
Nitrite and the effect of Allopurinol on human coronary artery smooth muscle cell (HmCASMC) 
growth under 1% hypoxia (1% O2, 5% CO2 and 37oC). Figure A shows the percentage cell viability, 
B shows the percentage of apoptotic cells and C shows the percentage necrotic HmCASMCs. Data 
represent mean±SEM of n=6 independent experiments. No differences were seen between 
treatment groups. Statistical comparison made using 1-way ANOVA, with Bonferroni’s multiple 
comparison test.  
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5.2.2.3.3 Effects of sGC inhibition on nitrite-induced effects on smooth muscle cells  
 
The effect of nitrite (3µM) on HmCASMC growth (Figure 5.18) was partially 
attenuated by the sGC inhibitor ODQ by ~58% (P<0.05, n=6). No difference in the 
viability of HmCASC was seen with the addition of ODQ (Figure 5.19). 
 
 
 
Figure 5.18 Nitrite and the effect of sGC inhibitor ODQ on HmCASMC growth. 
Nitrite and the effect of ODQ (3µM) on human coronary smooth muscle cell (HmCASMC) growth 
under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=6 independent 
experiments. Statistical significance shown as  *P<0.05 comparing hypoxia with hypoxia + nitrite 
(3µM), using 1-way ANOVA, with Bonferroni’s multiple comparison test.  
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Figure 5.19 The effect of the sGC inhibitor ODQ on nitrite induced changes in viability of 
HmCASMC.  
The effect of the sGC inhibitor ODQ (3µM) on nitrite induced changes in viability of human 
coronary artery smooth muscle cells (HmCASMC) under 1% hypoxia (1% O2, 5% CO2 and 37oC). 
Figure A shows the percentage viability, B shows the percentage of apoptotic cells and C shows 
the percentage necrotic HmCASMCs. Data represent mean±SEM of n=6 independent experiments. 
No differences seen between treatment groups. Statistical comparison made using 1-way ANOVA, 
with Bonferroni’s multiple comparison test.  
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5.2.2.3.4 Cyclic GMP measurement  
 
Levels of cGMP were significantly elevated in HmCASMCs treated with 3µM 
nitrite compared to 1% hypoxia control samples (P<0.001). This increase in 
cGMP was reversed by the addition of ODQ (Figure 5.20). 
 
 
 
Figure 5.20 Cyclic GMP levels in HmCASMCs.  
Effect of 3µM nitrite and ODQ (3µM) on cGMP levels under 1% hypoxia (1% O2, 5% CO2 and 37oC) 
Data represent means ± SEM of n=5 independent experiments. Statistical significance shown as 
**P<0.001 comparing Normoxia with hypoxia, *P<0.05 comparing the relevant control with 
nitrite, using 1-way ANOVA, with Bonferroni’s multiple comparison test 
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5.2.2.3.5 Nitrite inhibits smooth muscle cell proliferation 
 
Scratch wounds were inflicted on HmCASMCs treated with or without nitrite (1 
or 3μm) in 1% hypoxia for 24 hours (Figure 5.21). The addition of nitrite resulted 
in decreased smooth muscle cell proliferation and migration compared to control. 
The number of cells migrated into the wound area at 24 hours after treatment 
was significantly reduced in the nitrite treated cells in a concentration dependent 
fashion compared to control  (p=0.0003) (Figure 5.22).  
 
 
Figure 5.21 Effect of nitrite on smooth muscle cell wound healing.  
Example microphotographs of wound closure in control and 3μm nitrite treated cells.  
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Figure 5.22 Nitrite and the effect on smooth muscle cell (HmCASMC) wound healing.  
The effect of nitrite (1 or 3μm) on HmCASMC migration and proliferation tested with scratch 
assay.  Data represent mean±SEM of n=5 independent experiments. Statistical significance shown 
as  * P<0.05, **P<0.01 comparing hypoxia with hypoxia + nitrite, using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. H=Hypoxia.  
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5.3 I/R Injury 
 
5.3.1 HCAEC 
 
Compared to normoxia, EC growth following I/R was significantly attenuated. 
Restoration of O2 did not recover cell numbers to normoxia levels at any time 
point. The addition of nitrite (1 or 3 µM) resulted in a significant concentration 
dependent improvement in cell growth compared to hypoxia alone (Figure 5.23). 
 
Figure 5.23 Effect of nitrite on HCAEC cell growth following I/R injury. 
Effect of nitrite on HCAEC cell growth following I/R injury (24h 0.1% hypoxia and the presence or 
absence of nitrite (1 or 3 µM) during re-oxygenation  (21% O2, 5% CO2 and 37oC) at 8,24 and 48 
hours. Data represent means ±SEM of n=7 independent experiments. Statistical significance 
shown as **P<0.001 comparing normoxia with I/R, and ♯ for p<0.001 and comparing I/R with I/R 
+ nitrite using 2-way ANOVA. 
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5.3.1.1 Cell Viability 
 
Following ischaemia, cell viability was significantly attenuated in comparison to 
normoxia caused by an increase in apoptotic cell number (Figure 5.24) as shown 
previously. Restoration of O2 did not recover cell viability to normoxic levels at 
any time point up to 48-hours post reperfusion. The addition of nitrite (1 or 3 
µM) resulted in a significant concentration-dependent improvement in cell 
viability as a result of decreased apoptosis compared to hypoxia alone (Figure 
5.24). No differences were seen between necrotic cell percentages between 
nitrite treated and hypoxia alone, although necrotic cell numbers were higher in 
hypoxia compared to normoxia (Figure 5.24).  
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Figure 5.24 Effect of nitrite on HCAEC viability following I/R injury. 
Effect of nitrite on HCAEC cell viability following I/R injury (24h 0.1% hypoxia) and the presence 
or absence of nitrite (1 or 3 µM) during re-oxygenation  (21% O2, 5% CO2 and 37oC) at 8, 24 and 
48 hours. Figure A shows the percentage cell viability, B shows the percentage of apoptotic cells 
and C shows the percentage necrotic HCAECs. Data represent mean±SEM of n=7 independent 
experiments. Statistical significance shown as *P<0.05, **P<0.001 comparing normoxia with I/R, 
and ♯ for p<0.001 and comparing I/R with I/R + nitrite using 2-way ANOVA. 
I/R=Ischaemia/Reperfusion.  
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5.3.2 HmCASMC 
 
Compared to normoxia, HmCASMC growth following I/R was significantly 
(P<0.001) inhibited. The addition of 1µM and 3µM nitrite significantly decreased 
cell numbers compared to I/R alone following reperfusion (Figure 5.25). 
 
 
Figure 5.25 Effect of nitrite on HmCASMC growth following I/R injury.  
Effect of nitrite on HmCASMC growth following I/R injury (24h 0.1% hypoxia) and the presence 
or absence of nitrite (1 or 3 µM) during re-oxygenation  (21% O2, 5% CO2 and 37oC) at 8, 24 and 
48 hours. Data represent means ± SEM of n=5 independent experiments. Statistical significance 
shown as ***P<0.001 comparing normoxia with I/R, and ♯ for p<0.001 and comparing I/R with 
I/R + nitrite using 2-way ANOVA. 
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5.3.2.1 Cell Viability 
 
Following ischaemia, cell viability was significantly attenuated in comparison to 
normoxia caused by an increase in apoptotic cell number (Figure 5.26). 
Restoration of O2 did not recover cell viability to normoxia levels at any time 
point. Despite the addition of nitrite (1 or 3 µM) being associated with a 
significant decrease in cell number, there was no significant effect on cell viability 
with no difference in rates of apoptosis or necrosis between nitrite treated and 
I/R control (Figure 5.26).  
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Figure 5.26 Effect of nitrite on HmCASMC viability following I/R injury. 
Effect of nitrite on HmCASMC viability following I/R injury (24h 0.1% hypoxia) and the presence 
or absence of nitrite (1 or 3 µM) during re-oxygenation  (21% O2, 5% CO2 and 37oC) at 8, 24 and 
48 hours. Figure A shows the percentage cell viability, B shows the percentage of apoptotic cells 
and C shows the percentage necrotic HmCASMCs. Data represent mean±SEM of n=5 independent 
experiments. Statistical significance shown as *P<0.05, **P<0.001 comparing normoxia with I/R, 
using 2-way ANOVA. I/R=Ischaemia/Reperfusion.  
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5.4 Cell cycle markers 
 
5.4.1 HCAEC 
 
Nitrite decreased p21 protein levels in a concentration-dependent fashion under 
1% hypoxia with a significant decrease in p21 levels with 3µM and 1µM nitrite 
treatment compared to control conditions (P<0.05) (Figure 5.27)   
 
Figure 5.27  Effect of nitrite (1 and 3 µM) on p21 expression in HCAECs. 
Nitrite and the effect on p21 expression in human coronary artery endothelial cells (HCAEC) 
under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=5 independent 
experiments. Statistical significance shown as *P<0.05 comparing hypoxia with hypoxia + nitrite 
(3µM or 1µM), using 1-way ANOVA, with Bonferroni’s multiple comparison test. H=Hypoxia. 
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5.4.2 HmCASMC 
 
Nitrite increased p21 protein levels in a concentration-dependent fashion under 
1% hypoxia with a significant increase in p21 levels shown with 3µM and 1µM 
nitrite treatment compared to control conditions (Figure 5.28). This increase in 
p21 was associated with a decrease in cyclin D1 levels (figure 5.29).  
 
Figure 5.28  Effect of nitrite (1 and 3 µM) on p21 expression in HmCASMCs. 
Nitrite and the effect on p21 expression in human coronary artery smooth muscle cells 
(HmCASMC) under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=5 
independent experiments. Statistical significance shown as  ** P<0.01 and *P<0.05 comparing 
hypoxia with hypoxia + nitrite (3µM or 1µM), using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. H=Hypoxia. 
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Figure 5.29  Effect of nitrite (1 and 3 µM) on Cyclin D1 expression in HmCASMCs. 
Nitrite and the effect on Cyclin D1 expression in human coronary artery smooth muscle cells 
(HmCASMC) under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=5 
independent experiments. Statistical significance shown as  ** P<0.01 and *P<0.05 comparing 
hypoxia with hypoxia + nitrite (3µM or 1µM), using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. H=Hypoxia. 
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5.5 Expression of nitrite reductases 
 
5.5.1 E-NOS/P-eNOS/XOR expression in HCAECs 
 
The expression of eNOS appeared to be decreased under hypoxic conditions 
however did not reach statistical significance. The addition of nitrite (0.3µM-
10µM) did not alter eNOS expression (Figure 5.30A). Similar trends were seen 
with P-eNOS levels although again no statistically significant differences were 
seen (Figure 5.30B). The expression of XOR was greatest under normoxic 
conditions and lowest under hypoxic conditions, again nitrite increased XOR 
expression in comparison to hypoxia, although this trend was not significant 
(Figure 5.31) 
 
5.5.2 XOR expression in HmCASMC 
 
XO expression was the lowest under hypoxic conditions and highest with 
normoxia. The addition of nitrite increased the expression of XO compared to 
hypoxia alone, however, this trend was not significant (Figure 5.32). 
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Figure 5.30  Effect of nitrite (0.3-10 µM) on nitrite reductases in HCAECs. 
Nitrite and the effect on nitrite reductase (e-NOS and phospho-ENOS) expression in human 
coronary artery endothelial cells (HCAEC) treated under 1% hypoxia (1% O2, 5% CO2 and 37oC). 
Panel A shows e-NOS expression with panel B showing phospho-ENOS. Data represent means 
±SEM of n=9 independent experiments for eNOS and n=6 independent experiments for phospho-
ENOS. Statistical significance performed using 1-way ANOVA, with Bonferroni’s multiple 
comparison test. H=Hypoxia. 
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Figure 5.31  Effect of nitrite (0.3-10 µM) on XOR expression in HCAECs. 
Nitrite and the effect on XOR expression in human coronary artery endothelial cells (HCAEC) 
treated under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of n=5 
independent experiments. Statistical significance performed using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. H=Hypoxia, XOR=Xanthine oxidoreductase.   
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Figure 5.32  Effect of nitrite (0.3-10 µM) on XOR expression in HmCASMC. 
Nitrite and the effect on XOR expression in human coronary artery smooth muscle cells 
(HmCASMC) treated under 1% hypoxia (1% O2, 5% CO2 and 37oC). Data represent means ±SEM of 
n=5 independent experiments. Statistical significance performed using 1-way ANOVA, with 
Bonferroni’s multiple comparison test. H=Hypoxia. XOR=Xanthine oxidoreductase, 
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5.6 Summary 
 
1. Nitrite had no effect on the proliferation or viability of HCAEC/HUVEC or 
HmCASMC under normoxic conditions. 
2. Hypoxia (5 and 1%) attenuated the proliferation and viability of both 
HUVECs and HCAECs compared to normoxia, associated with an increase 
in apoptosis.  
3. Treatment of HUVECS and HCAECs with nitrite caused a concentration-
dependent increase in endothelial cell number and viability in hypoxia 
with a peak effect occurring at 3µM in both cell types. The improvement in 
viability was associated with a reduction in apoptosis.  
4. In contrast, whilst hypoxia also caused a decrease in HmCASMC numbers 
this effect was not associated with an increase in apoptosis. Moreover, the 
addition of nitrite caused a concentration-dependent decrease in cell 
growth with a peak effect occurring at 1µM vs normoxia. This decrease in 
cell number was not associated with a decrease in cell viability.  
5. The effects of nitrite upon cell number and viability were attenuated by L-
NMMA and allopurinol in endothelial cells and by allopurinol in 
HmCASMCs. 
6. The sGC inhibitor ODQ attenuated the effects of nitrite on both HCAEC and 
HCASMC number and viability and these effects were associated with 
changes in cGMP. 
7. Levels of cellular cGMP were significantly elevated in HCAECs and 
HmCASMCs treated by nitrite under 1% hypoxia compared to hypoxia 
alone, with levels of cGMP reduced by the addition of ODQ. 
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8. Nitrite (3μM and 1μM) resulted in enhanced endothelial cell proliferation 
and migration with reduced wound surface area compared to control 
using the scratch assay.  This contrasted to HmCASMCs where decreased 
cell migration and proliferation was seen with nitrite treatment (3μM and 
1μM).  
9. Levels of p21 protein expression were increased in nitrite (3μM and 1μM) 
treated HmCASMC with a contrasting decrease in levels seen in HCAECs. In 
HmCASMCs an associated decease in cyclin D1 protein expression was 
seen with the elevation in p21 expression.  
10. No difference in the expression of nitrite reductases (e-NOS, p-ENOS or 
XOR in endothelial cells or XOR in smooth muscle cells) were seen with 
nitrite treatment in cells treated under hypoxia.  
11. I/R experiments demonstrated that reperfusion with nitrite (3μM and 
1μM) following 0.1% O2 (24h) resulted in a concentration dependent 
improvement in HCAEC growth and viability compared to reperfusion at 
all time points (P<0.01).  
12. In HmCASMCs reperfusion with nitrite (3μM and 1μM) resulted in a 
concentration dependent decrease in HmCASMC growth with no 
detrimental effect on cell viability. 
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Chapter 6.0  
 
Discussion 
 
 291 
6.1 Introduction 
 
This thesis has examined the use of intra-coronary nitrite as a strategy to reduce 
myocardial I/R injury in patients undergoing primary PCI for AMI.  Since 
myocardial I/R injury was first described, there is yet to be a successfully 
translated technique adopted to routine clinical practice for its treatment. Few 
therapies have replicated the protection shown in the animal setting. Coronary 
heart disease still represents a huge burden of morbidity and mortality (see 
Chapter 1) and there is no doubt that further improvement in treatment is 
needed. Novel strategies are required and ‘cardioprotection’ has long been 
regarded as one method, which may be successful in accomplishing this.  
 
This thesis suggests that intra-coronary nitrite infusion appears to be safe and 
tolerable in patients undergoing primary PCI for AMI. Furthermore in patients 
with TIMI flow ≤1 at time of drug delivery it may reduce reperfusion injury, and 
subsequent infarct size.  This thesis proposes that this effect is achieved through 
several mechanisms with effects demonstrated on both platelet reactivity, and 
inflammation. It appears that nitrite has selective effects on the production of 
neutrophil specific cytokines, and subsequent neutrophil activation, reducing the 
inflammatory component of I/R injury. The data presented also proposes that 
nitrite may have potential beneficial effects on outcomes following stent 
implantation, both inhibiting smooth muscle proliferation and therefore 
preventing in-stent restenosis and also promoting re-endotheliasation of drug-
eluting stents minimising the potential for stent thrombosis. 
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Three key aims were set out by this thesis, which will be discussed in detail 
during this discussion.  
 
6.2 Intra-coronary nitrite is safe, tolerable and may reduce infarct size 
during primary PCI in patients with AMI. 
 
In chapter 3, it was demonstrated in a proof-of-concept study that the intra-
coronary administration of nitrite at the time of reperfusion in patients with AMI 
is safe but was not associated with a reduction in infarct size assessed by cardiac 
enzymes, compared to that seen with placebo. However, there was a trend to a 
greater myocardial salvage index with an 18% increase in the nitrite group 
compared to placebo (this was on the boundaries of conventional statistical 
significance (p=0.051)), and significant reductions in MACE at both 6 months and 
1 year. This weight of evidence could suggest an effect associated with nitrite 
treatment despite no reduction in cardiac enzyme assessed infarct size.   
 
 In a single sub-group analysis of patients with TIMI flow ≤1, at the time of 
primary PCI, treatment with nitrite was associated with a 20% reduction in 
infarct size compared to placebo as assessed by cardiac biomarkers (AUC for CK). 
This observation was supported by the CMR analyses in this sub-group 
demonstrating a reduction of infarct size in the region of 25%, a reduction in 
microvascular obstruction by 48% and an association with a significantly greater 
myocardial salvage index. This data is therefore suggestive of an effect with 
multiple supporting modalities however it is important to note that although this 
was a single subgroup anlaysis it was not pre-specified. No evidence of a 
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difference in infarct size was seen between nitrite and placebo in patients with 
TIMI flow >1.  
 
6.2.1 Ischaemia time and AAR are important confounding variables 
 
Important determinants of infarct size after primary PCI include the duration of 
ischaemia (Christian et al., 1992) and the AAR (Reimer et al., 1977), both of which 
were confounding variables in this study. Despite the use of best practice through 
randomization and double-blinding nitrite-treated patients had a longer mean 
ischaemia time compared to the placebo treated group, which is known to 
adversely effect potential myocardial salvage and infarct size (Keeley and Hillis, 
2007; Armstrong et al., 2009). In this study ischaemia time was directly 
correlated to infarct size measured by either CK or troponin T confirming the 
relationship in this cohort. It is therefore possible that the absence of a significant 
effect of nitrite in all-comers has been influenced by this variation. Importantly, 
in the single sub-group analysis based on TIMI flow, where a beneficial effect of 
nitrite was seen there were no differences in ischaemia time. The mean ischaemia 
time in the whole cohort (~189 minutes) reflects well when compared to other 
studies assessing potential adjunctive cardioprotective strategies e.g. 
cyclosporine (Piot et al., 2008) and postconditioning (Staat et al., 2005) (Thuny et 
al., 2012) with values ranging from an average of 331-252 mins. It is known that 
myocardial reperfusion accrues the most benefit in terms of myocardial salvage 
in patients presenting within 3 hours of chest pain onset (Gersh et al., 2005). 
Whether infarct size reduction with a study intervention is greater in patients 
presenting early (within 3 h) or later (3 h and beyond) is not clear however two 
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clinical studies have reported greater benefit (myocardial salvage) with potential 
cardioprotective agents adenosine (Kloner et al., 2006) or exenatide (Lonborg et 
al., 2012a) in patients presenting within 2–3 h of chest pain onset, suggesting that 
the former may be true. However laboratory studies suggest the relative 
importance of different mechanisms of I/R injury may depend on the duration of 
ischaemia, with mitochondrial permeability transition playing a more prominent 
role after prolonged ischaemia (60 minutes) (Ruiz-Meana et al., 2011). The 
median ischaemia time of 189 minutes in our cohort or 181 minutes in the TIMI 
<1 subgroup reflects well compared to this 3-hour mark. Importantly, the 
ischaemia time in this study likely underlies the smaller infarct sizes seen when 
compared to other myocardial injury studies (Piot et al., 2008) (Staat et al., 2005).  
 
The size of the AAR is a major determinant of the final infarct size (Reimer et al., 
1977). Previous clinical cardioprotection studies in STEMI patients suggest that 
the patients most likely to benefit from a study intervention administered as an 
adjunct to myocardial reperfusion are those presenting with a large AAR (>30% 
of the LV) (Staat et al., 2005; Piot et al., 2008; Botker et al., 2010). Indeed recently 
recommendations suggest that potential cardioprotective agents are tested in 
patients with AAR >30% (Hausenloy et al., 2013). The mean AAR in the whole of 
the study cohort was 33% assessed by CMR and just under 30% by either 
angiographic score which compares well to these recommendations.  
 
Assessing the AAR is particularly important as the size of the AAR can vary 
greatly from patient to patient (from 10 to 50% of the LV) depending on which 
coronary artery is involved (LAD, RCA, or Cx) and where along the vessel the 
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occlusion has occurred (proximal, mid-vessel, or distal) (Ortiz-Perez et al., 2007). 
In this study the mean AAR assessed by either CMR or angiographic scores whilst 
not statistically different displayed a trend to be larger in the nitrite-treated 
relative to the placebo group, in the whole cohort with increases ranging from 
5% to 14% depending on the method of assessment. There are recognised 
limitations to each of the methods that were used to assess AAR (Botker et al., 
2012), however, the data showed significant positive correlations between them 
with consistently larger scores in the nitrite group. This could confound the 
results with theoretically larger infarcts in the nitrite group in view of the larger 
AARs. The myocardial salvage index, which corrects for the AAR was greater in 
the whole cohort (although not significantly so) in the nitrite group, which 
further suggests that the larger AARs and longer ischaemia times are likely to be 
significant confounding factors.   
 
6.2.2 Lack of benefit in patients with TIMI flow >1 is not unexpected 
 
Despite the important confounders of AAR and ischaemia time, in patients with 
significant coronary flow (TIMI flow >1) prior to nitrite infusion a lack of benefit 
of nitrite is not entirely unexpected. Pre-clinical models have shown beneficial 
effects of nitrite on I/R injury that occur with nitrite administrated prior to 
reperfusion (TIMI flow ≤1). The rationale for evaluating the ability of nitrite to 
reduce infarct size in patients with ongoing AMI was based on extensive pre-
clinical evidence demonstrating the cytoprotective properties of nitrite in models 
of AMI (Webb et al., 2004; Duranski MR et al., 2005; Shiva et al., 2007b; Baker JE 
et al., 2007) and in other organs including the liver (Duranski MR et al., 2005), 
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kidney (Tripatara et al., 2007) and brain (Pluta et al., 2005). In all of these studies 
the beneficial effects were evident with application of nitrite into or on the 
ischaemic organ with the culprit vessel occluded at time of drug delivery i.e. zero 
flow. Whilst nitrite bioactivation to NO within the circulation does occur under 
physiological conditions in humans (Cosby et al., 2003) (Maher et al., 2008), this 
phenomenon is enhanced with decreasing oxygen tension and this enhancement 
underlies its improved bioactivity under hypoxic/ischaemic conditions (Gladwin 
et al., 2005).  
 
If a cardioprotective strategy needs to be administered prior to or at the 
immediate onset of myocardial reperfusion, it could be argued that there is little 
rationale for recruiting patients who do not have a fully occluded coronary artery 
(TIMI >1) at presentation. However standard care pathways for STEMI patients 
presenting to hospitals for primary PCI include early and efficient administration 
of therapies especially anti-platelet and anti-thrombotic drugs, as in the present 
study. As a consequence it has been suggested that >40% of patients will have 
spontaneously reperfused in the infarct related territory resulting in significant 
coronary flow (TIMI flow >1) within the culprit coronary artery prior to the 
procedure (Botker et al., 2010; Lonborg et al., 2010). Assessing whether nitrite 
would benefit or indeed cause no harm to a representative group of patients 
including those with TIMI flow >1 is important, particularly when one considers 
that translation of cardioprotective interventions can only legitimately occur if 
there is no delay to revascularization. Thus, a strategy that might be standardly 
administered to all patients with no need for time spent on assessing suitability 
or not is the ideal scenario and underlies the rationale for the design of the trial. 
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However, the low numbers of patients with TIMI flow >1 (10%), in our cohort 
prevent drawing any reliable conclusions with respect to the effects of nitrite in 
these circumstances. In contrast the findings do suggest that, as expected, for 
nitrite to be most effective against myocardial I/R injury administration should 
occur while the culprit artery is occluded and prior to myocardial reperfusion, as 
in the TIMI flow ≤1. This is similar to other cardioprotective agents such as 
remote ischaemic conditioning where patients presenting with an occluded 
culprit artery accrued the most benefit in terms of infarct size reduction (Botker 
et al., 2010), although occasional studies have shown an overall benefit in all 
comers irrespective of TIMI flow (Botker et al 2010). In view of the numbers of 
patients with TIMI flow >1 being low i.e. nine in total with only four in the nitrite 
group, further appropriately powered studies assessing safety in patients with 
TIMI flow >1 are essential to determine the generalised safety of intra-coronary 
nitrite administration in patients presenting with AMI.  
 
6.2.3 Intracoronary nitrite appears safe with no demonstrated acute 
adverse effects  
 
The intra-coronary administration of nitrite exerted no adverse effects in the 
cohort as a whole or in either of the TIMI flow ≤1 or >1 subgroups. Specifically, 
blood pressure was assessed due to the known vasodilator (Cosby et al., 2003; 
Frenneauz et al 2007) and blood pressure lowering effects (Dejam et al., 2007; 
Pluta et al., 2011) of raised circulating nitrite levels. In this study circulating 
nitrite levels were significantly elevated in the patients who received intra-
coronary nitrite but not in the patients who received placebo. The data 
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demonstrate that whilst blood pressure did drop in some patients this was 
equally evident in both arms. Bradycardia and hypotension are a common feature 
of reperfusing occluded coronary arteries (Bezold-Jarisch reflex) particularly the 
right coronary artery. Studies have shown that 65% of reperfusing right coronary 
artery occlusions (Esente et al., 1983) can result in this phenomenon and it is a 
well-established feature (Mark, 1983). A large proportion of the effect occurred 
in patients with occluded right coronary artery with accompanying bradycardia 
(70%). Similarly levels of methaemoglobin were monitored due to the known 
interaction of nitrite with oxyhaemoglobin to generate methaemoglobin and, in 
particular, the elevated levels of this measure with systemic nitrite infusions 
(Pluta et al., 2011). Levels of methaemoglobin were comparable between the two 
treatment arms and at levels that are not symptomatic. In this study, nitrite 
administration was not associated with either lowering of blood pressure or 
methaemoglobinaemia, the two main potential concerns with this form of 
treatment.  
 
6.2.4 Comparison with other studies assessing nitrite in AMI  
 
The results of this study demonstrating no evidence of a benefit of intra-coronary 
nitrite in the whole cohort is consistent with recent emerging data from an 
intravenous nitrite in AMI study which also showed no reduction in infarct size 
(Siddiqi et al., 2014). An important difference with this study is Siddiqi and 
colleagues only recruited patients with TIMI ≤ 1 flow and not all-comers. They 
recruited a total of 229 patients presenting with AMI who were randomized to 
receive either an intravenous infusion of 70μmol sodium nitrite (n = 118) or 
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matching placebo (n = 111) over 5 min immediately before primary PCI. This 
dose was chosen assuming a mean body weight of 70 kg, corresponding to 1 
µmol/kg. The primary endpoint of myocardial infarct size (assessed at 6–8 days 
by CMR) did not differ between nitrite and placebo groups with a median infarct 
size of 22% in the nitrite and 20% in the placebo groups [difference −0.7% (95% 
CI: −2.2, +0.7; P = 0.30)]. After adjustment for AAR, diabetes, or each recruitment 
centre (patients were recruited at 4 different centres) there was still no 
difference between the groups (effect size −0.7% 95% CI: −2.2%, +0.7%; P = 
0.34). There were also no significant differences in any of the secondary 
endpoints, including plasma troponin I or CK AUC (72-hour), LV volumes or LVEF 
measured at 6–8 days and infarct size at 6 months. This study would suggest that 
the intravenous route of nitrite administration does not result in decreased 
infarct size or improve outcomes after primary PCI with the secondary endpoints 
and subgroup analyses all consistent with their negative primary endpoint.  
 
The study by Siddiqi and colleagues was based on a protocol employed in dogs 
(Gonzalez et al., 2008) in which a 5 min infusion of sodium nitrite administered 
immediately prior to opening of the infarct-related artery was shown to 
substantially reduce infarct size. The study by Gonzalez and colleagues showed 
similar reductions in infarct sizes with either a 5 or 60 min infusion prior to 
reperfusion suggesting that increasing the duration of the infusion is unlikely to 
be of benefit. With respect to dose, pre-clinical evidence indicates that nitrite is 
cytoprotective against I/R injury only when given at concentrations (2.5-10 
μmol) that far exceed physiological (0.1-0.4 μmol/L) levels of circulating nitrite 
levels. In the study by Siddiqi and colleagues circulating nitrite levels achieved 
 300 
with a 5 minute infusion were elevated to 1.4μmol/L, which is lower than that 
seen in dogs where the same dosing regime led to circulating levels of 5 μmol/ 
(Gonzalez et al 2008). However the levels achieved were 7.8-fold higher than in 
the placebo group and consistent with levels achieved in a previous murine 
periconditioning study that demonstrated at least some molecular effect of nitrite 
in mice at such concentrations (Duranski MR et al., 2005).  
 
It is possible that the lack of benefit in the Siddiqi study simply reflects the 
complexities of translation of animal studies into the clinical setting.  However 
the lack of benefit seen could be due to an insufficient elevation of nitrite levels 
achieved in the target myocardium to induce cardioprotection, and that achieving 
this is not possible via the intravenous route. Indeed raising circulating levels of 
nitrite to those shown effective in most pre-clinical studies is likely to be 
associated with adverse effects such as hypotension and methaemoglobinaemia 
as demonstrated in healthy volunteers (Pluta et al 2011).  We speculate that the 
lack of adverse effect seen in our study despite the use of high (supra-
physiological) levels of nitrite given intra-coronary likely reflects the advantage 
of intra-coronary nitrite administration. This route achieves high local 
concentrations (2.5-10μM) within the myocardium only, minimising the potential 
systemic side-effects which may occur with systemic nitrite administration. 
Indeed although levels of systemic nitrite were elevated in the study patients who 
received intra-coronary nitrite indicating a degree of systemic absorption, levels 
achieved were approximately 0.5μM/L, only marginally elevated compared to 
physiological levels, which would be in keeping with the low rates of side-effects 
seen in the study.  
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The intra-coronary route has other potential advantages. If agents are to be 
delivered at reperfusion i.e. following angiography to ensure TIMI flow ≤1 the 
intra-coronary route will not delay reperfusion. This is compared to other 
therapies such as cyclosporine and exenatide where intra-venous administration 
may result in both greater side-effects and a delay in reperfusion whilst 
administered. Mechanical therapies associated with re-intervention such as 
ischaemic postconditioning, where repeat balloon inflation is conducted after the 
opening of the culprit vessel, carry a potential risk of damaging the vessel or 
inducing peripheral embolization.  
 
6.2.5 Improvement in clinical outcomes after intracoronary nitrite 
 
This thesis demonstrated a reduction of infarct size of ~19-24% evident in 
response to nitrite treatment in those patients with TIMI flow ≤1. This value is 
comparable to the reductions of infarct size estimated to occur with other 
cardioprotective agents (Piot et al., 2008; Mewton et al., 2010; Thibault et al., 
2008) tested in similar patient populations (TIMI ≤1 flow). Whether such a 
difference might result in an improvement of outcome long-term is uncertain, 
with none of the studies mentioned above having clinical endpoints such as 
MACE.  Infarct size has been shown to be associated with a reduction in mortality 
but the majority of studies testing cardioprotecive agents have either not shown 
or not tested for this effect. However in the study described in this thesis, nitrite 
treatment in the whole cohort was associated with a reduction in MACE at both 6 
months and 1 year, which would correspond to the decreased myocardial infarct 
size. It is important to recognise the low number of total events reported and 
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acknowledge that larger studies with MACE as primary outcome are needed to 
verify this. However, in support of this data is very recent evidence 
demonstrating that cardioprotective strategies such as post-conditioning post-
PCI do positively impact on long term outcome measures (Sloth et al., 2014) and 
it should be noted that at least in one study exploring the value of post-
conditioning strategies, reductions in cardiac biomarkers release was associated 
with significant improvements in cardiac function (left ventricular ejection 
fraction) at 1 year (Thibault et al., 2008). To date few studies have been 
sufficiently powered to determine whether cardioprotective strategies might 
improve outcome and although in this present study a reduction in MACE was 
evident in patient’s 1-year post-nitrite treatment, the study was not powered for 
MACE events. This data warrants further investigation in larger phase III clinical 
trials powered by reduction in MACE. 
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6.3 Mechanisms by which nitrite reduces reperfusion injury, focusing 
specifically on inflammation and platelet activity 
 
The second key aim of this thesis was to investigate the potential mechanisms by 
which intra-coronary nitrite reduces I/R injury and subsequent infarct size. It 
was clear from pre-clinical models that the beneficial effects of nitrite are due to 
its conversion to NO, as evidenced by the complete block of nitrite-induced 
protection by NO scavengers (Webb et al., 2004; Duranski MR et al., 2005). NO 
itself exerts a number of actions (Moncada, Higgs 1993) that are thought to be 
cardioprotective (Johnson 1991). In particular NO plays an important role in 
modulating many aspects of the inflammatory response. (Kubes et al., 1991; 
Ahluwalia et al., 2004; dPalazzo et al., 1998) and in reducing platelet aggregation 
and reactivity (Davi, Patrono, 2007; Radomski et al, 1987; Radomski et al, 1990). 
Potential anti-platelet and anti-inflammatory effects of nitrite when given intra-
coronary during primary PCI were therefore assessed. 
 
6.3.1 Inflammatory response following primary PCI for AMI 
 
AMI evokes an intense inflammatory response both systemically and within the 
infarcted myocardium with a release of pro-inflammatory cytokines as discussed 
in detail in chapter 1, but including TNF-α, CXCL-1 and CXCL-5. Patients with 
large infarcts often have elevation of body temperature, WBC count, complement, 
CRP, and other inflammatory markers compatible with a systemic inflammatory 
response syndrome reaction (Balbay et al., 2001; Modica et al., 2009). This 
release of inflammatory cytokines has been shown in patients after primary PCI 
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for AMI but not in control patients (Neumann et al., 1995). The scale of this 
response reflects the size of the infarction (Van Diepen et al., 2013) with 
excessive early inflammation after AMI associated with adverse left ventricular 
remodeling and poor outcomes (Anzai et al., 1997; Suleiman et al., 2006) with the 
inflammatory response known to be a key component of reperfusion injury 
(Yellon and Hausenloy, 2007). Modulating and reducing this inflammatory 
response is therefore likely key to improving outcomes after primary PCI for AMI.  
 
A marker of this early inflammation is enhanced synthesis of CRP (Frangogiannis 
et al., 2002). We showed that hs-CRP increased in the first few hours after 
reperfusion, peaking at 24 hours, which is consistent with the current literature 
(Uehara et al., 2003). CRP release is stimulated by upstream cytokines (such as 
IL-6, with which CRP keeps a high correlation in the release pattern after AMI 
(Gabriel et al., 2004)), and reflects the degree of the inflammatory response (Nian 
et al., 2004; Orn et al., 2009; Suleiman et al., 2006).  Indeed, the extensive 
presence in the context of AMI, and its known participation in complement 
activation mean that CRP has been postulated as an actual mediator of intense 
myocardial damage (Nian et al., 2004; Orn et al., 2009). However, irrespective of 
whether CRP is a marker of the post AMI inflammatory response or a 
contributory component, levels of hs-CRP were significantly reduced after 
reperfusion in the nitrite treated group compared to placebo suggesting a 
reduced inflammatory response in this group. Hs-CRP levels were shown to 
correlate with infarct size and therefore rather than this reduction being due to a 
direct effect of nitrite it is likely to simply reflect the smaller infarcts seen in the 
nitrite group.  Indeed, such a view is substantiated by associated reductions in 
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other markers of inflammation such as WBC and MCP-1. Importantly CRP 
determination in the first 2 days after primary PCI has been found to show 
significant predictive value for clinical outcomes, (Ohlmann et al., 2006) therefore 
irrespective of aetiology, lower levels of hs-CRP in the nitrite treated group would 
suggest a benefit.  
 
6.3.2 Reduction in general markers of inflammation with nitrite treatment 
 
Aside from CRP, another general marker of inflammation linked with damage 
after AMI is an increase in the peripheral white blood cell (WBC) count, which 
correlates with outcomes after AMI (Furman et al., 1996). A large-scale study 
with 153,213 patients aged 65 years or older with AMI demonstrated that a 
higher WBC count within 24 h of admission was associated with higher mortality 
within 30 days (Barron et al., 2001). Studies have also demonstrated that 
elevated WBC, specifically neutrophils, either pre or post primary PCI is 
associated with increased infarct size and impaired LV function (Sabatine et al., 
2002; Shinozaki et al., 2005; Chia et al., 2009). In fact data exists to suggest that 
WBC count post procedure is a better predictor of outcome than at baseline 
(Shinozaki et al., 2005) and that WBC count after AMI not only decreases within 
hours but is also related to the success of reperfusion therapy as reflected by 
TIMI flow and MBG (Smit et al., 2006; Mariani et al., 2006). This would indicate 
that the rise in neutrophils after AMI is dependent on microvascular function and 
may be used as a non-invasive marker of failed or incomplete myocardial 
reperfusion or degree of I/R injury. Our data is consistent with this, 
demonstrating a decline in WBC count early (4 hours) after reperfusion and that 
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lower levels of WBC found in the nitrite patients post procedure appear to be 
associated with both improved ST segment resolution (a similar measure to 
MBG), smaller infarct size and improved outcomes. This adds further indirect 
evidence of reduced injury in the nitrite group but also suggests that a reduction 
of the systemic and perhaps local inflammatory response in the nitrite group 
could be responsible for this benefit.  
 
6.3.3 Nitrite treatment was associated with decreased neutrophil specific 
chemokine expression  
 
In myocardial I/R injury, inflammatory cell recruitment in the myocardium is 
dominated by early neutrophil recruitment, which induces tissue damage 
through a variety of mechanisms as discussed in chapter 1 (for review see 
Vinten-Johansen, 2004). Thus, the selective inhibition of neutrophil 
chemoattractant bioactivity might prevent myocardial injury during the early 
phases of reperfusion. Key to this recruitment are neutrophil specific chemokines 
(such as CXCL-5 and CXCL-1) that have been shown to be up-regulated in models 
of experimental AMI and promote activation of neutrophils and chemotaxis to the 
site of tissue injury (Frangogiannis and Entman, 2005; Frangogiannis, 2004; 
Kobayashi, 2008). CXCL-1 (also known as human growth-related oncogene- α and 
KC) was first described as a growth factor for human melanoma cell lines, binds 
to CXCR2, and belongs to the IL-8 family (Frevert et al., 1995; Bozic et al., 1995). 
The release of CXCL-1 and CXCL-5 are regulated by pro-inflammatory cytokines 
(TNF-α) and transcription factors such as NF-κB (Chandrasekar et al., 2001). 
Increased plasma CXCL-1 levels and induction of CXCL-1 expression has been 
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detected in both rat (Chandrasekar et al., 2001; Getting et al., 2004), and mouse 
(Mersmann et al., 2010) models of myocardial I/R injury and has also been 
observed after I/R in murine kidneys and skeletal muscle (Molls et al., 2006). 
Plamsa CXCL-5 levels have also been shown to be elevated in rat models of 
myocardial I/R I injury (Chandrasekar et al 2001). In a model of renal I/R, 
neutralizing CXCL-1 antibodies decreased mortality and improved renal function 
(Miura et al., 2001). This is in accordance with smaller infarcts seen after 
myocardial I/R in mice lacking CXCR2 (Tarzami et al., 2003) and importantly a 
reduction in reperfuson injury seen in a mouse model of AMI following a single 
administration of the CXC Chemokine-Binding Protein, Evasin-3 which prevented 
CXCL1 induced neutrophil recruitment and reactive oxygen species production in 
the myocardium (Montecucco et al., 2010). Therefore, the reduced levels of CXCL-
1 seen in the nitrite treated patients may result in reduced neutrophil activation, 
which is likely to be key to any reduction in infarct size seen in this group 
Importantly this reduction in neutrophil activation was demonstrated by the 
lower levels of CD11b expression seen in the nitrite treated patients. The levels of 
CXCL-1 and CXCL-5 were both shown to be related to infarct size and be reduced 
in the nitrite treated patients, implying that by preventing cell death and 
reducing infarct size the subsequent inflammatory response is less.  
 
It is also possible that nitrite-derived NO is directly affecting CXCL-1 generation. 
Release of CXCL-1 from human endothelial cells (HUVECs) in response to TNF-α 
has been shown to be dependent upon p38 MAPK and PI-3kinase-mediated 
secretory processes (Lo et al., 2014). Since NO is known to effect various 
intracellular signaling molecules including MAPK and JAK (Stamler et al., 2001) it 
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is possible that nitrite-derived NO effects cytokine release during I/R injury. 
Additionally cytokine generation in the myocardium is regulated at the 
transcriptional level by NF-κB (activated by cytokines themselves or by ROS) 
(Chandrasekar and Freeman, 1997; Fan et al., 2002) and at high concentrations 
NO inhibits NF-κB activation (Cooke and Losordo, 2002). 
 
MCP-1 expression has been shown to be markedly but transiently induced in 
infarcted hearts (Dewald et al 2004, Frangogiannis 2007) with it appearing to 
critically regulate the healing response (Gonzalez-Quesada, Frangiogiannis 2009) 
Studies using post ischaemic cardiac lymph collected during canine reperfused 
infarction suggest that MCP-1 may be a major factor responsible for mononuclear 
cell recruitment into the ischaemic myocardium during the first five hours of 
reperfusion (Birdsall et al 1997). In addition, in a rat model of experimental 
myocardial infarction, administration of a neutralizing antibody to MCP-1 
significantly reduced infarct size decreasing adhesion molecule expression and 
macrophage infiltration (Ono et al 1999). Beyond these actions, MCP-1 has 
important effects on infarct healing mediated through its direct angiogenic effects 
on the vascular endothelium, or by modulation of fibroblast phenotype and 
activity (Gharaee-Kermani M et al 1996). Prolonged elevation of plasma MCP-1 
therefore may identify patients who mount a more intense cardiac inflammatory 
reaction following a coronary event, or show impaired resolution and defective 
containment of the post-infarction inflammatory response (Gonzalez-Quesada, 
Frangiogiannis 2009). Therefore the higher levels of MCP-1 seen in the placebo 
group are consistent with the overall increased inflammatory response compared 
to nitrite treated patinets. Additionally MCP-1 levels have been demonstrated to 
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be independently associated with the development of no-reflow and 3-year 
mortality in patients with ST-segment elevation myocardial infarction 
undergoing primary PCI (Buyukkaya et al 2103), a finding consistent with the 
lower MACE rates and accompanying the lower peak MCP-1 levels seen in the 
nitrite group.  
 
6.3.4 NOx levels after primary PCI are a reflection of iNOS activity  
 
Intuitively it may have been expected that plasma nitrite levels were higher in 
those patients who received intra-coronary nitrite, however whilst acutely nitrite 
levels were elevated at 30 minutes post-reperfusion by the intervention, over 
time both nitrite and nitrate levels decreased with a greater reduction in the 
nitrite treated patients.  This elevation in NOx levels in the placebo group is likely 
to reflect the greater systemic inflammatory response seen in these patients as a 
consequence of the greater infarct size. This would result in a greater degree of 
iNOS expression and subsequent elevated levels of NOx. This data is supported by 
the higher levels of inflammatory mediators (hs-CRP and MCP-1) seen in the 
placebo group and significant correlations between infarct size, levels of 
inflammatory mediators and cGMP levels.  
 
Evidence of iNOS induction in the heart following AMI comes mainly from pre-
clinical studies, however levels have also been shown to be elevated in human 
myocardium (Wildhirt et al., 1995a). Wildhirt and colleagues identified the 
presence of iNOS in hearts subjected to MI in a rabbit coronary ligation model, 
demonstrating at least a two-fold increase in iNOS expression in the infarcted 
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region, mainly localized to the infiltrating macrophages (Wildhirt et al., 1995b). 
However, whether iNOS is harmful or protective during I/R injury after AMI has 
been much debated with apparent discrepancy among previous studies, some of 
which have concluded that iNOS is beneficial (Bolli et al., 1997; Das et al., 2005; Li 
et al., 2006; Heger et al., 2002), and crucial to the effects of pre-conditioning, 
whereas others have found it to be detrimental (Feng et al., 2001; Gealekman et 
al., 2002; Sam et al., 2001; Liu et al., 2005). Reasons for these discrepancies are 
unclear however they may relate to the source of iNOS and levels of NO. A recent 
study using mouse models of myocardial infarction, demonstrated that selective 
deletion of iNOS from peripheral blood cells (with no change in myocardial iNOS 
content) reduces infarct size, suggesting that iNOS derived from peripheral blood 
cells is detrimental during myocardial I/R injury whereas myocardial iNOS is 
protective (Guo et al., 2012). If iNOS can be beneficial or detrimental depending 
on the cell type in which it is expressed this would explain the differences in the 
studies performed to date with results depending on the level of inflammatory 
cell activation and infiltration into the infarct, which may be related to model 
specific factors. This would fit with the data shown in this thesis, with high local 
(myocardial) NO levels beneficial during I/R injury associated with a reduction in 
infarct size whereas those patients with larger infarcts, greater cytokine release 
and greater inflammatory responses will have greater systemic iNOS activation, 
which is both detrimental and also might explain the higher NOx levels seen.  
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6.3.5 Reduced reperfusion injury demonstrated in nitrite treated patients 
 
A direct measurement of reperfusion injury in the study was provided by the 
CMR assessed microvascular obstruction (MVO) and the degree of ST-segment 
resolution on the ECG, both of which were found to be reduced in the nitrite 
treated TIMI <1 patients compared to placebo. MVO, a type of irreversible 
reperfusion injury is believed to be a consequence of factors such as distal 
embolisation, leucocyte migration and plugging and platelet aggregation (Lee and 
Tse, 2010). Importantly, MVO has been implicated in worse clinical outcomes due 
to poor myocardial perfusion despite epicardial coronary artery 
revascularization (Hombach et al., 2005). In this study, the incidence of MVO 
detected by the initial CMR scan in the whole CMR population decreased from 
69.7% in placebo to 48.5%, in the nitrite treated group, whilst in the TIMI flow <1 
subgroup it decreased from 72.4% to 37.0% respectively. It is worth noting that 
factors known to impact on MVO, such as the presence of comorbid conditions 
and the use of antiplatelet and anticoagulant therapy, were similar between the 
two treatment groups. It is known that infarct size is related to the degree of MVO 
(Iwakura et al., 2001) and this association may simply underlie the apparent 
decrease. However, whilst CMR-determined infarct size was reduced by 24%, 
MVO was reduced by 48% suggesting that factors other than the size of infarct 
are involved. These factors could include the reduced platelet reactivity that has 
been demonstrated in the nitrite treated patients or reduced leucocyte 
migration/plugging as a consequence of reduced neutrophil activation 
(decreased levels of neutrophil chemokines/activation markers).   
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Persistent ST elevation on the ECG despite normal epicardial blood flow is 
indicative of impaired tissue and microvascular perfusion and hallmarks of I/R 
injury (van't Hof et al., 1998; Santoro et al., 1998). It is associated with poor 
recovery of left ventricular function and increased mortality after primary PCI 
even with successful restoration of TIMI grade 3 flow in the infarct artery 
(Somitsu et al., 1997; Claeys et al., 1999). In the study cohort ST segment 
resolution of >70% was evident in 88.5% of both treatment groups. However 
when looking at TIMI ≤ 1 subgroup, 100% of the nitrite group and 84.8% of the 
placebo groups had ST segment resolution (p=0.02). This observation provides 
further support for the view that nitrite treatment appeared to result in a 
decreased I/R injury in the nitrite-treated patients.  
 
6.3.6 Reduced platelet reactivity is a consequence of reduced inflammation 
 
In patients following primary PCI for STEMI, platelet reactivity was enhanced 
with elevated P-selectin expression that decreased over time, and with the 
decrease significantly enhanced in the nitrite compared to the placebo group. The 
response of platelets to activating stimuli (ADP and collagen) also decreased over 
time in the whole cohort but the decreases were substantially greater in the 
nitrite-treated patients. Although NO has well documented direct anti-platelet 
effects this reduction in platelet reactivity probably reflects the reduced infarct 
size and systemic inflammation that exist in the nitrite group, rather than a direct 
effect.  Indeed post-hoc analyses show a direct correlation between platelet 
reactivity and infarct size supporting this hypothesis. However, irrespective of 
aetiology, lower platelet reactivity is likely to contribute to the reduced 
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complications evident at 6 months and 1 year after STEMI in the nitrite patients, 
with platelet reactivity at 6 months after STEMI linked to the recurrence of 
coronary events during this time period, even in the modern era of multiple 
antithrombotic therapy (Scalone et al., 2011).  
 
Interestingly platelet reactivity was not the only measure shown to be reduced in 
the nitrite group at 6 months, there was also a reduction in the levels of 
circulating WCC, systemic hs-CRP/MCP-1 levels and reduced NT-pro-BNP all 
which may be all related to reduced levels of inflammation however 6 months 
after reperfusion and infarction there may be other explanations and a potential 
link with vascular function. 
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6.3.7 Improved vascular health at 6 months in nitrite treated patients 
 
Prospective epidemiological studies have shown that serum hs-CRP levels are a 
simple tool for detecting low-level systemic inflammation and are a strong 
predictor of the occurrence of cardiovascular events such as MI in apparently 
healthy subjects (Ridker et al., 1997; Ridker et al., 2000) and in patients with a 
recent coronary event (Ridker et al., 2005). This elevation in hs-CRP is believed to 
reflect inflammation in the vascular bed or an intensification of focal 
inflammatory processes that destabilize vulnerable plaques (Morrow and 
Braunwald, 2003). As discussed previously the acute inflammatory response 
associated with myocardial necrosis is associated with a significant elevation in 
hs-CRP levels but this elevation has been shown to subside within 4 to 6 weeks, 
with hs-CRP levels returning to baseline values (James et al., 2005; Argaud et al., 
2005). At this time, elevated hs-CRP levels again reflect the degree of vascular 
inflammation and are predictive of future coronary events (Ridker et al., 2005). 
Therefore, importantly hs-CRP levels measured in patients following AMI, after 
levels return to normal (after 30 days), are predictive of further cardiovascular 
events. This is of particular relevance to this thesis as higher levels of hs-CRP 
were demonstrated at 6 months in patients treated with placebo compared to 
those that received nitrite. This is likely to reflect a persistently elevated level of 
inflammation with impaired vascular health and endothelial dysfunction in these 
patients compared to those that received nitrite therapy. Whether this is related 
to the reduction in infarct size seen acutely or another mechanism is unclear. 
However levels of hs-CRP have been shown to be related to measures of vascular 
and endothelial function (Huang et al., 2007) such as pulse wave velocity (Nagano 
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et al., 2005; Kim et al., 2007) and therefore these higher levels would support this 
impaired function.   In our study we did not assess vascular function and these 
further studies measuring both endothelial function and vascular stiffness post 
PCI and nitrite treatment would be of value. 
 
The hypothesis of impaired endothelial dysfunction at 6 months is supported by 
the lower levels of cGMP, nitrite and nitrate in the placebo treated patients, 
supporting the concept of impaired vascular health and endothelial dysfunction 
in these patients. Higher levels of MCP-1 have also been shown to predict adverse 
events and reflect elevated levels of inflammation (Martinovic et al., 2005), which 
were again seen in the placebo group at 6 months, as were higher levels of NT-
proBNP. NT-proBNP, a circulating hormone released in response to increased 
cardiac wall stress, has been shown to be a strong predictor of cardiovascular 
events and congestive heart failure but has also been associated with endothelial 
dysfunction in patients with coronary artery disease (Huang et al., 2006).  A study 
by Huang and colleagues has shown that endothelial vasodilator dysfunction in 
patients with suspected coronary artery disease is associated with elevated hs-
CRP, MCP-1, and NT-pro-BNP compared to patients with a normal chronotropic 
response to exercise and no endothelial dysfunction. Therefore this combination 
of factors shown at 6 months in the nitrite group; reduced platelet reactivity, 
lower levels of NT-pro-BNP, hs-CRP and MCP-1 levels coupled with higher levels 
of nitrite/nitrate and cGMP are likely to reflect reduced inflammation, improved 
endothelial function and vascular health in these patients which is reflected by 
the reduced rate of major adverse cardiac events seen in the cohort at this time-
point.   
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6.4 Does prolonged nitrite treatment alter endothelial, or vascular smooth 
muscle cell growth under normoxia, hypoxia and I/R injury 
 
The 3rd main aim of this thesis was addressed in chapter 5 where it was 
demonstrated that sodium nitrite enhances EC proliferation, viability (HCAECs 
and HUVECS) and the wound healing of ECs (HCAECs) in hypoxic conditions at 
physiological concentrations. In comparison, similar physiological concentrations 
of nitrite resulted in a concentration-dependent inhibition of SMC (HmCASMC) 
proliferation under the same hypoxic conditions with no adverse effect on cell 
viability. Moreover the studies revealed that sodium nitrite appears to be 
metabolized to biologically active NO by XOR to limit SMC proliferation via a p21–
dependent mechanism and that both XOR/eNOS metabolise nitrite to active NO 
to promote endothelial ell growth/viability by inhibiting apoptosis and 
promoting proliferation by a p21 dependent mechanism.  These effects appear to 
be cGMP dependent with elevation of cGMP seen in the treated cells compared to 
control and with the addition of sGC inhibitors both blocking the effect of nitrite 
on cell proliferation but also inhibiting the rise seen in cGMP.   
 
Under hypoxic conditions there were distinct responses to nitrite by the different 
cell types. The distinct pattern of activity is likely due to the differing effects NO 
exerts on the cell types following its conversion from nitrite under the hypoxic 
conditions. This is supported by the elevation in cGMP seen with nitrite 
treatment in both cell (HCAECs and HmCASMCs) types. Evidence exists that NO 
stimulates EC proliferation and the regeneration of healthy endothelium (Metaxa 
et al., 2008; Ziche et al., 1997; Cooke and Losordo, 2002) whilst NO conversely 
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limits SMC proliferation and migration via both cGMP-dependent and 
independent mechanisms (Zuckerbraun et al., 2010; Zuckerbraun et al., 2007). 
These effects were seen with nitrite treatment in the respective cell types which 
coupled with the elevation of cGMP would support the notion that nitrite under 
hypoxia was converted to NO to elicit these cGMP dependent effects.  
 
6.4.1 Nitrite inhibits apoptosis in endothelial cells 
 
The treatment of ECs (both HCAECs and HUVECs) was associated with decreased 
hypoxia-induced apoptosis with this reduction in apoptosis appearing to drive 
the increased EC number.  As discussed in chapter 1 section 13, high levels of NO 
have been shown to induce apoptosis whereas lower levels of NO function as an 
important inhibitor of apoptosis by interfering with signal transduction pathways 
that control apoptotic cell death (Dimmeler and Zeiher, 1997; DeMeester et al., 
1998; Tzeng et al., 1997; Rossig et al., 1999). Despite this the effect of nitrite on 
endothelial cell apoptosis is less well established but the data that does exist is 
consistent with the inhibitory effect demonstrated in our studies.  Studies 
mimicking I/R injury in mouse lung vascular endothelial cells have demonstrated 
that nitrite (50μM) treatment significantly decreases I/R induced apoptosis 
(Sugimoto et al., 2012). Whilst other studies looking at the effect of UVA 
irradiation on rat aortic endothelial cells have demonstrated that nitrite (1-
10mM) reduced UVA induced apoptosis (Suschek et al., 2003).  
 
The down-stream targets of NO beyond cGMP that mediate these anti-apoptotic 
effects are still debated. For endothelial cells NO is thought to inhibit apoptosis by 
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targeting a number of distinct pathways. These anti-apoptotic effects include 
inhibition of caspases, increase of HSPs (heat shock proteins) and the anti-
apoptotic B-cell lymphoma-2 protein (Bcl-2), nitration of p53 and activation of 
Akt/PKB pathway, which induces cytoprotective gene expression through NF-κB 
activation (for review see (Leon et al., 2008)). Nitrite specifically has been shown 
to protect endothelial barrier function against hypoxic challenge by regulating 
caspase-3 activity (Lai et al., 2011). Studies in zebrafish and murine ECs showed 
that nitrite promotes S-nitrosation and consequent inactivation of caspase-3, 
leading to a sustained barrier function through better maintenance of cadherin 
junctions (Lai et al., 2011). Whether caspase 3 was likewise affected in tis study is 
uncertain and warrants investigating.  
 
In addition to the decrease in apoptosis of ECs following nitrite treatment in 
hypoxia there was also a decrease in expression of the cell cycle regulator p21. 
This is consistent with previous studies that have also demonstrated that p21 
levels are down-regulated with increased cell proliferation in nitrite treated 
neutrophilic cell line HL-60. In these cells its was shown that a similar dose of 
nitrite (3μM) administered for 24 hours resulted in a significant augmentation of 
the S phase of the cell cycle, an effect associated with reduction in p21 levels 
(Kumar et al., 2011). These effects were also shown to be NO mediated with 
effects blocked by NO scavengers. The results of chapter 5 are therefore 
consistent with the literature and do suggest that the enhanced EC proliferation 
seen with nitrite treatment in hypoxic conditions appears to be due to both 
reduced levels of apoptosis and enhancement of cellular proliferation through 
inhibition of p21 expression.   
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6.4.2 Nitrite inhibits VSMC growth under hypoxic conditions 
 
In chapter 5, it was demonstrated that nitrite inhibited VSMC growth under 
hypoxic conditions. This is consistent with other studies that have shown an 
inhibitory effect of NO on VSMC growth.  Early studies with NO donors 
demonstrated that NO donor agents inhibit the proliferation of isolated rat and 
rabbit VSMCs in tissue culture (Kariya et al., 1989; Garg and Hassid, 1989; 
Assender et al., 1992; Mooradian et al., 1995). Despite these documented 
inhibitory effects of NO on VSMC proliferation, not all studies have found an 
inhibitory effect of nitrite on VSMC growth. A study by Vavra and colleagues 
demonstrated that neither nitrite nor nitrate inhibited rat aortic VSMC 
proliferation in vitro (Vavra et al., 2011).  The reason for this lack of effect may 
relate to the fact that activity was assessed under normoxic conditions and 
perhaps some hypoxia is required to enhance nitrite reduction.  
 
The mechanism underlying the nitrite-associated reduction in proliferation in 
VSMC is different to those by which nitrite promoted EC growth. Whilst it was 
demonstrated that nitrite promoted EC proliferation during hypoxia by reducing 
cell apoptosis, an opposing increase in apoptosis did not appear to be the case in 
VSMC. In the VSMCs despite slightly increased numbers of apoptotic cells 
associated with nitrite treatment these levels were not significantly elevated. 
Apoptosis of VSMCs has an important role in the prevention of neointimal 
hyperplasia with studies showing that NO induces apoptosis. Pollman and 
colleagues (Pollman et al., 1996) showed that the administration of NO donors S-
nitroso-N-acetyl penicillamine or sodium nitroprusside to cultured rabbit VSMC 
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caused apoptosis in a concentration-dependent fashion as measured by PI 
staining. Also in 1996, Nishio and colleagues (Nisoli et al., 2005) exposed rabbit 
VSMC to S-nitroso-N-acetyl penicillamine and showed a concentration-dependent 
increase in apoptosis by NO as measured by terminal deoxynucleotide 
transferase-mediated dUTP biotin nick end-labeling (TUNEL). The data shown in 
chapter 5 is different with no increase in apoptosis seen, which may relate to 
differences in coronary artery VSMC compared to aortic VSMC or reflect that low 
levels of apoptosis were seen in each of the VSMC experiments/treatments and 
therefore a greater number of experiments may be required to see a difference.  
It therefore appears that the inhibition of VSMC proliferation was due to a 
different mechanism.    
 
6.4.3 Inhibition of VSMC proliferation is dependent on p21 expression 
 
We demonstrated that nitrite induced inhibition of VSMC proliferation was both 
mediated by cGMP and dependent on increased expression of the cyclin-
dependent kinase inhibitor p21. This is consistent with previous studies that 
demonstrate a central role for p21Waf1/Cip1 protein in NO-mediated inhibition of 
smooth muscle cell proliferation (Ishida et al., 1997; Kibbe et al., 2000; Tanner et 
al., 2000; Bauer et al., 2001). Recently data has emerged that the effects of nitrite 
on smooth muscle cell proliferation are also NO mediated, and induce p21 
expression. Studies in rat pulmonary artery smooth muscle cells (PASMC) 
demonstrated that sodium nitrite inhibited hypoxia-dependent PASMC 
proliferation in vitro, an effect associated with an increase in p21Waf1/Cip1 protein 
levels. Additionally, nitrite failed to inhibit proliferation in PASMCs that were 
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deficient in p21Waf1/Cip1 (Zuckerbraun et al., 2010). Further studies in rat thoracic 
SMCs also showed that sodium nitrite was metabolized to NO and limits VSMC 
proliferation via a p21Waf1/Cip1 dependent-mechanism (Alef et al., 2011).  
 
Both of these studies also provided direct evidence that XOR is critical for the 
reduction of nitrite to NO. Zuckerbraun and colleagues demonstrated that 
inhibition of XOR by allopurinol in PASMC proliferation studies diminished the 
antiproliferative effects of nitrite by 70%. Similarly, in their in vivo model of 
pulmonary arterial hypertension, supplementation with tungsten, which inhibits 
XOR activity by replacing molybdenum in the active site, reversed the protective 
effects of nebulized nitrite on the development of pulmonary arterial 
hypertension indicating a critical role for XOR. In similar experiments Alef and 
colleagues demonstrated that the use of either allopurinol or tungsten reversed 
the anti-proliferative effects of nitrite in rat models of Intimal hyperplasia (IH). 
Both of these studies demonstrate similar inhibitory effects on nitrite reduction 
with XOR inhibitors (70%) which are identical to the levels seen in our studies 
which together strongly suggest that in VSMCs and specifically intimal 
hyperplasia (where high levels of XOR have been demonstrated) XOR is the 
crucial nitrite reductase.  
 
6.4.4 Different nitrite reductases appear important in different cell types  
 
The effect of nitrite on HmCASMc’s is likely to be due to its conversion to NO by 
XOR as discussed above (with no eNOS present on HmCASMc) with existing data 
suggesting the importance of XOR from other studies. However as discussed in 
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chapter 1, the metabolism of nitrite to NO can occur by several mechanisms, 
including acidic disproportionation along oxygen and pH gradients, as well as by 
enzymatic reduction by other proteins in addition to XOR including eNOS 
deoxyhemoglobin and deoxymyoglobin (Cosby K, 2003; Shiva et al., 2007a; 
Huang et al., 2005; Lundberg JO and Weitzberg E, 2008). In our experiments the 
concentration-dependent increase in cell proliferation and viability caused by 
nitrite administration in both HUVEC and HCAECs was blocked by either L-
NMMA or allopurinol implying roles for both XOR and eNOS in the conversion of 
nitrite to NO. The loss of efficacy was similar with both L-NMMA and allopurinol 
intimating that both eNOS and XOR are central nitrite reductases in the hypoxic 
environment and perhaps work in a synergistic manner with near complete 
reversal of nitrite effect with either inhibitor. This is not the first time that it has 
been shown that both eNOS and XOR could be important nitrite reductases, 
recent studies looking at models of pulmonary hypertension have demonstrated 
similar outcomes (Baliga et al., 2012)   
 
6.4.5 Nitrite had no effect on cell proliferation or viability in normoxia 
 
We showed that under normoxic conditions nitrite (0.1-10µM) did not affect 
endothelial or smooth muscle cell proliferation or viability. Nitrite is accepted as 
an endocrine reservoir of NO that can be reduced to bioavailable NO as oxygen 
concentrations and pH decrease over a physiological gradient (Lundberg JO and 
Weitzberg E, 2008) Previous studies have shown that it takes high concentrations 
of nitrite (>1-200µM) to have physiological effects under normoxic conditions 
(Rassaf et al., 2002; Lauer et al., 2001). It is under conditions of low pH and 
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oxygen tensions that nitrite at physiological levels (low as 100nM) exerts 
biological effects following its conversion to bioactive NO (Modin et al., 2001), 
with the first set of studies from Zweier’s laboratory observing a 100-fold 
increase in the generation and accumulation of NO from nitrite under the acidic 
and highly reduced conditions of the ischaemic myocardium (Zweier et al., 1995). 
Virtually all studies to date showing authentic NO generation from nitrite are 
conducted under anaerobic conditions. However there is evidence that nitrite 
exerts changes in vascular tone under physiological conditions (Cosby et al 2003; 
Dejam et al 2007; Maher et al 2008) It is possible that in terms of vasodilation the 
downstream signaling pathways are more sensitive to the relatively small levels 
of conversion of nitrite under such conditions.  The lack of any effect of nitrite on 
cell viability and proliferation in the present study may simply be a reflection of 
the differences in sensitivity of the pathways involved in the distinct effects of 
nitrite on cell growth/proliferation and viability compared to vasodilation.  
 
6.4.6 NO, Nitrite, intimal hyperplasia and restenosis in man 
 
Whether the effects of nitrite on cell growth might be of use following I/R injury 
or stent implantation in humans is unknown. The proliferation of VSMC is 
accepted as a common event in the pathophysiology of intimal hyperplasia and 
restenosis (Ross, 1993; Vogt et al., 2008). Delivery of NO in the form of L-
arginine, pharmacological NO donors, inhaled NO, or overexpression of NOS 
proteins have been shown in pre-clinical models to inhibit proliferation of VSMCs 
and reduce the injury responses within the blood vessel wall (Napoli et al., 2001; 
Kibbe et al., 2000; Napoli et al., 2013). Consistent with these observations, VSMCs 
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transfected with eNOS showed inhibition of cell proliferation and of key cell cycle 
regulatory molecules (Sharma et al., 1999). Unfortunately, administration of 
systemic NO has not consistently demonstrated inhibition of neointimal 
hyperplasia in human studies. The Angioplastic Coronaire Corvasal Diltiazem 
(ACCORD) study showed that patients undergoing angioplasty who received NO 
from intravenous linsidomine while an inpatient, followed by oral molsidomine 
as an outpatient for a total of 6 months, had an improvement in angiographic 
results, with a 10% reduction in luminal diameter (Lablanche et al., 1997). 
However, in a separate study in patients receiving high-dose oral molsidomine 
for 6 months after coronary angioplasty; no effect on angiographic restenosis rate 
was found (Wohrle et al., 2003). In addition to the conflicting results in human 
clinical trials, NO administered systemically can have the undesirable effects of 
vasodilation, hypotension, headaches, and tolerance, ultimately limiting its 
clinical application. Therefore, alternative sources of NO are desirable and the 
delivery of NO in the form of a stable reservoir such as nitrite or nitrate is an 
attractive solution to this problem. It has been demonstrated that low dose 
sodium nitrite given prior to balloon injury in vivo prevents vascular intimal 
hyperplasia in both rat and mouse injury models (Alef et al., 2011). Moreover, it 
has been shown that nitrite delivered after the establishment of intimal 
hyperplasia could reverse the pathological process (Alef et al., 2011). In addition 
to these effects on cellular proliferation recent evidence also suggests that indices 
of restenosis (incl. late loss and target vessel revascularisation) can be further 
reduced by additional pharmacotherapy that is anti-inflammatory and anti-
platelet in activity (Lee et al., 2008). Data in this thesis suggests that nitrite 
displays all these properties with convincing in-vitro evidence of anti-platelet and 
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anti-inflammatory effects displayed in chapter 4 and important anti-proliferative 
effects on VSMCs and pro-angiogenic effects on endothelial cells shown in chapter 
5, in all an ideal combination to prevent restenosis and a strong rationale to 
translate this therapy into man. Thus evidence of the efficacy of sustained 
systemic nitrite levels post primary PCI would be of value and therefore a trial 
designed to test this would be important. Longer follow-up of the NITRITE-AMI 
patinets is ongoing with both 2 and 3-year MACE rates being collected with this 
data available in the future.   
 
6.5 Limitations 
 
NITRITE-AMI was powered based on the enrolment of all-comers to prevent any 
treatment delay and to test the therapy in as broad a group as possible. Therefore 
the assessment of infarct size by TIMI flow subgroups was not pre-defined. 
However despite this sufficient numbers of patients with TIMI flow≤1 were 
available to conduct powered statistical analyses.  For the secondary CMR 
endpoints, the study was powered for single statistical comparisons, we did not 
conduct multiple testing or correct for multiple comparisons. 
 
Infarct size is an intermediate outcome measure that is commonly used to assess 
cardioprotective strategies in STEMI patients. However, as an intermediate 
outcome measure this does not provide clear understanding on hard outcomes 
such as MACE. The study was not powered to detect changes in MACE and 
although evidence of benefit was seen the low number of events prevent drawing 
of any reliable conclusion.  This data suggests strong support for conducting a 
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phase 3 study in patients with TIMI≤1 flow at point of revascularisation assessing 
the therapeutic potential of intra-coronary nitrite administration with MACE as 
the primary outcome measure. 
 
The results regarding the potential mechanisms underlying the effect of nitrite on 
infarct size are interesting and raise important questions regarding these effects. 
However these studies were not powered to detect statistical significance and 
should be seen as hypothesis generating.  
 
6.6 Future work 
 
The data in the thesis suggests that intracoronary nitrite may have a therapeutic 
role in the treatment of AMI that warrants further investigation in larger phase III 
studies, which are powered by major clinical endpoints rather than surrogate 
endpoints (e.g. infarct size). There are important considerations that need to be 
addressed in the design of this study.  The first of which is to determine the 
primary endpoint. In terms of designing larger clinical outcome studies, it is 
crucial to choose clinical events e.g. major adverse cardiac events (MACEs), which 
are relevant to the infarct size limiting effects of the study intervention. In this 
regard, the combined rates of cardiac death and hospitalization for heart failure 
are most relevant to infarct size limitation in STEMI patients as a combined 
primary study endpoint, and would be the ideal outcome measure in the majority 
of cardioprotection trials. However as this thesis has demonstrated intracoronary 
nitrite has beneficial effects on the rates of coronary revascularization and non-
fatal MI and therefore these should also be included in the MACE endpoint of the 
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phase III study. This endpoint would therefore include cardiovascular death, 
hospitilisation for heart failure, target vessel revascularization and recurrent MI.  
 
As demonstrated in this thesis, for nitrite to be most effective against myocardial 
I/R injury administration should occur while the culprit artery is occluded and 
prior to myocardial reperfusion, as in the TIMI flow ≤1. This is similar to other 
cardioprotective agents such as remote ischaemic conditioning where patients 
presenting with an occluded culprit artery accrued the most benefit in terms of 
infarct size reduction (Botker et al., 2010), although occasional studies have 
shown an overall benefit in all comers irrespective of TIMI flow (Botker et al 
2010). On this basis, for clinical cardioprotection studies, it is advisable to only 
include those STEMI patients with an occluded culprit artery and therefore for 
the phase III trial, the inclusion criteria should specify that only patients with 
occluded vessels at the time of angiography  (TIMI≤1) should be included.   
 
Despite the primary endpoint being MACE, it would be important to assess 
cardiac function, myocardial area at risk and markers of both infarct size and 
reperfusion injury. Therefore patients should undergo CMR scanning in addition 
to the assessment of the clinical endpoints. The timing of this scan or scans is 
debated. For NITRITE-AMI delayed enhancement infarct size was assessed at 
both 2 days and 6 months after infarction. There are advantages and 
disadvantages of both these timepoints, with both shown to be associated with 
histopathological assessed infarct size and both associated with prognosis (Kim 
et al, 2009). However the early scan may overestimate infarct size due to the 
presence of odema whereas a late scan has been shown to potentially 
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underestimate infarct size due to shrinkage (Kim et al 2009). The other 
advantage of performing an early (2 day) scan is that it provides an assessment of 
the area at risk for calculation of myocardial salvage. For the phase III study we 
would therefore perform an early scan at 2-3 days to enable an assessment of 
myocardial salvage and infarct size which although may overestimate infarct size 
it would do so for both treatment groups and provides comparison to other 
studies (Piot et al 2008).  
 
Another major confounding factor for cardioprotective strategies is concomitant 
medication, which patients are on for their cardiovascular risk factor, co-morbid 
condition, or as part of the treatment of the ongoing acute MI. These 
pharmaceutical agents have been shown in pre-clinical and clinical studies to 
either block the cardioprotective effect (for example, certain oral anti-diabetic 
sulphonylureas, nitrates when nitrate tolerance develops, certain statins) or 
induce cardioprotection themselves. Specifically for nitrite it has been suggested 
that the prior use of organic nitrates (e.g. GTN) may induce a degree of 
cardioprotection limiting the potential for additonal cardioprotection by nitrite. 
This fact has been raised by 2 recent clinical studies, the first of which being the 
NIAMI study where 90% of patients had received organic nitrates acutely prior to 
reperfusion and it was suggested the lack of benefit of intravenous nitrite may be 
due to this prior cardioprotection (Siddiqi et al 2014). The 2nd recently presented 
study, NOMI (Nitric Oxide for inhalation to reduce reperfusion injury in acute ST-
elevation Myocardial Infarction) where although no difference in infarct size was 
seen between patients who received inhaled nitric oxide and those who did not 
(18% vs 19.4%, P=0.44) they found in a pre-specified sub-group analysis of 
 329 
patients who had received intracoronary or intravenous nitroglycerin (IC/IV 
NTG) a significant interaction  (P=0.014) with the use of inhaled nitric oxide. 
Among NTG-naïve patients (n=132), nitric oxide inhalation was associated with 
significantly smaller infarcts compared to patients who had previously received 
NTG (n=93) (Janssens 2014). Although it has been suggested that the use of 
organic nitrates could be an important reason for the discrepancy seen between 
the preclinical data and the clinical data in these 2 studies, new therapies need to 
be effective when given to patients receiving standard therapy and therefore 
patients should not be excluded from the study based on acute organic nitrate 
use. However pre-specified sub-group analysis of patients who had received 
intracoronary or intravenous nitroglycerin will be included.  
 
6.7 Conclusions 
 
In summary the infusion of intra-coronary nitrite appears safe when delivered 
during primary PCI for AMI with no documented adverse effects associated with 
the drug. However when delivered in all-comers, it had no significant effect on 
infarct size but did result in reduced MACE at 1 year. In patients with TIMI flow 
≤1 there was a significant reduction in cardiac enzyme release and infarct size, 
with reduced microvascular obstruction and an increased myocardial salvage 
index demonstrated on CMR, suggesting a potential beneficial effect when 
delivered in this group of patients.   
 
Mechanistically, levels of platelet reactivity were significantly reduced after 
primary PCI in the nitrite compared to the placebo group, as were levels of the 
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inflammatory mediators hs-CRP and MCP-1. These markers were associated with 
infarct size and therefore are likely to reflect reduced levels of systemic 
inflammation associated with this reduction in infarct size. Importantly these 
decreases in the nitrite group were maintained out to 6 months after reperfusion 
suggesting improved outcomes irrespective of aetiology. In nitrite treated 
patients the elevation of neutrophils associated with AMI was suppressed 
compared to placebo and this was specifically associated with a decrease in the 
level of activation markers involved in adhesion, CD11b and the neutrophil 
chemokines (CXCL-1 and CXCL-5).   
 
Nitrite appears to protect ECs from the damaging effects of ischaemia or I/R 
injury but exerts an opposing repressive influence over SMC growth, suggesting 
that in an environment where improved EC growth but repressed SMC growth is 
desired, such as in restenosis following stent implantation, raising circulating 
nitrite levels may be of some therapeutic utility.  
 
Together this data suggests that intracoronary nitrite may have a therapeutic role 
in AMI that warrants further investigation in larger phase III studies with 
separate phase II studies addressing the use of nitrite to prevent restenosis 
following PCI also justified. 
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8.0 Appendix 
8.1 Summary Patinet information sheet (PIS) 
 
NITRITE-AMI version 2.1 12.04.12 
 
 
NITRITE- AMI Trial 
 
A randomised, double-blind, placebo-controlled trial assessing the safety and 
efficacy of intracoronary nitrite infusion during acute myocardial  
Infarction 
 
Protocol number 2.1 
 
Summary Information Sheet 
 
This is a summary of the research study. Please read the attached information which 
explains the study in more detail before making the decision whether or not to take part.  
 
 
· You are invited to join a research study , recruiting patients having a heart attack and being 
admitted via the Heart Attack Centre. This study involves a new treatment, which we hope 
will limit damage to the heart muscle caused by a heart attack.  
 
· If you agree to take part in the study, the angioplasty procedure to treat your heart attack,  
will go ahead as usual however we will also inject a drug down the affected artery at the 
time of the procedure.   
 
· We will inject either a drug called sodium nitrite or saline (placebo) down the affected 
artery and into the damaged tissue. The drug is designed to prevent som e of the damage 
that will continue to occur despite the artery  being opened. This may or may not be 
effective 
 
· Sodium nitrite is a source of the chemical nitrite, which is found occurring naturally in your 
blood and tissues. During a heart attack it acts as a source of nitric oxide, which is 
essential for blood vessel function.  
 
· The trial is randomised, so you will be randomly allocated to receive either the sodium 
nitrite or placebo. There is a 50/50 chance of you being allocated to either group.  
 
· Following the treatment, you will return to the ward and receive standard care for all 
patients having had treatment for a heart attack, aiming for discharge as usual between 2 -
5 days. 
 
· There are no known major adverse effects from sodium nitrite being given in this situation 
however as this is a first of its kind study there may be potential risks that are unknown.  
 
· The study will involve:- 
 
o Extra blood tests and ECGs (electrical heart tracings) during your hospital stay  
o a clinic visit at 6 months  
o yearly telephone calls for the next 3 years.  
 
Thank you for taking the time to read this. Please ask if there are any questions 
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8.2  Detailed Patient information sheet (PIS)  
 
 
 
 
The London Chest Hospital, 
Barts Health NHS Trust, 
Bonner Road, 
London, 
E2 9JX  
 
Patient Information Sheet 
 
NITRITE-AMI:- A randomised, double-blind, placebo-
controlled trial assessing the safety and efficacy of 
intracoronary nitrite infusion during acute myocardial 
infarction 
 
When you arrived at the London Chest Hospital having your heart attack you kindly 
agreed to participate in a research study. This research study consists of 2 parts; the 1
st
 
of which you have already agreed too and has started. The purpose of this patient 
information sheet is to provide more information about this 1
st
 part of the study that 
you have already agreed to participate in and also to explain details about a 2
nd
 
optional part of the study.  
 
One of our research team will go through the information with you to make sure that 
you understand. Ask us if there is anything that is unclear or if you would like more 
information or time. 
 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. 
 
 Part 1 tells you about the 1st part of the study, explaining what has 
happened already and what will happen in the future 
 Part 2 explains about the 2
nd
 part of the study and what will happen to 
you if you agree to take part 
 
Why are we doing this research?  
Despite advances in the treatment of heart attacks such as balloon treatment to the 
blocked artery (primary angioplasty), the complications and death rates from failure of 
the heart to pump adequately and from heart rhythm problems remain high. The size of 
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the heart attack is the major reason for these adverse outcomes. Whilst re-opening the 
artery allows the blood to flow to the area of the heart starved of blood and oxygen, 
this process also causes considerable damage itself (called “reperfusion injury”) and 
increases the size of the heart attack. The aim of this study is to decrease the amount of 
this reperfusion injury and subsequently reduce the size of the heart attack. We aim to 
do this be giving a substance called sodium nitrite down the damaged artery and into 
the tissue. This has been shown in models of a heart attack to decrease reperfusion 
injury and the size of heart attacks.   
 
 
Why was I chosen? 
You were chosen because you were admitted as an emergency with a heart attack 
(‘myocardial infarction’), and underwent an emergency coronary balloon angioplasty 
and stent insertion 
 
This study aims to recruit 80 similar people who are having emergency coronary 
balloon angioplasty and coronary stents insertion within Barts and the London NHS 
trust within the next 2 years. 
 
Part 1  
 
What has happened to me so far? 
This research study involves the use of sodium nitrite to try and limit the damage to the 
heart muscle caused by a heart attack. To test whether this works this study is 
‘randomised’. This means that half of the patients will receive nitrite and the other half 
will receive a ‘placebo’ or ‘dummy’. The placebo used for this study will be saline 
(water). The decision is made in a way similar to ‘flipping a coin’ and neither you nor 
anyone involved in your care will know which treatment you have received. This 
enables us to compare both groups to assess the effectiveness of this new treatment.  
The trial process will be exactly the same for all patients enrolled in the study.  
 
Therefore during the PCI procedure either the sodium nitrite or placebo (saline) was 
injected down your damaged artery over a period of 30 seconds as the artery was being 
opened.  
 
Following this procedure we have so far taken regular blood tests, which will help 
monitor the condition of your heart (a total of 6 extra teaspoons of blood will be taken 
in addition to the routine blood samples taken before your treatment (already taken) 
and at discharge).  
 
What is Sodium Nitrite? 
Sodium nitrite is a source of nitrite, a substance that is found naturally in your blood 
and tissues.  It is an important store of nitric oxide (NO), which is essential for 
maintaining the blood vessel in a normal healthy state. It maintains the blood vessel 
diameter (by relaxing the muscle in the vessel) and prevents blockages by stopping 
white blood cells from crossing the endothelial wall and by stopping platelets from 
sticking to the blood vessel wall. During a heart attack, we know that levels of nitric 
oxide are reduced which removes these helpful effects. In situations like this, sodium 
nitrite can be used to replace these low levels of nitric oxide. It has been shown in 
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animals to help decrease the damage caused by a heart attack but up until now no 
study looking at whether it works in humans has been performed, that is the purpose 
of this study.  
 
What happens to me during the rest of the study? 
During the rest of your hospital stay and throughout the study, you will be followed up 
closely. This will include electrical tracings of your hearts activity – 
Electrocardiogram (ECG) and blood tests, which will help to assess the health of your 
heart and regular assessments by your doctor. The ECG will involve small metal 
electrodes stuck onto your arms, legs and chest. Wires from the electrodes are 
connected to the ECG machine. The machine detects and amplifies the electrical 
impulses that occur at each heartbeat and records them on to a paper or computer. A 
few heartbeats are recorded from different sets of electrodes. The test takes about five 
minutes to do.  
 
At 6 months you will need to attend the hospital to have a physical examination, a 
blood test (4 teaspoons of blood), and a further heart tracing (ECG) 
  
Following this, you will be contacted by telephone at 12 months and then at 2 years to 
ask about your health. 
 
Are there any long-term risks to my health of having the treatment? 
The sodium nitrite treatment itself is not associated with any major side effects or 
risks, however as this the first of this kind there may be potential risks that are 
unknown. The delivery of this drug during the procedure did not lead to any significant 
changes in the standard therapy being administered.  
 
What are the benefits from taking part? 
You have already kindly agreed to participate in the 1
st
 part of the research study 
where the treatment has been given. Studies performed in animals have shown that this 
treatment may lead to a decrease in the size of the heart attack that you suffered, 
however this is the first study to look at its use in people like yourself so we don't 
know if this effect will occur. There is also a 50/50 chance that you received 
placebo/saline and therefore there may or may not be any benefit to taking part in this 
study. You will however have received the standard optimal treatment for your 
condition.  
 
What will happen if I don’t want to carry on in the study? 
You are under no obligation to take part in this study and are free to withdraw at 
anytime with no reason, this will not affect the standard of care you receive.  If you do 
decide to withdraw from the study we will still need to use the data collected up to 
your withdrawal  
 
Will my taking part in this study be kept confidential? 
Data will be collected about your medical history, investigations, treatments and any 
complications. All information collected during the research will be kept strictly 
confidential.  
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Data will be stored in a locked room on a secure computer database. Identifiers such as 
name, address, hospital number will not be used.  
 
Your records may be reviewed by staff from Barts and the London NHS Trust to 
ensure that the data collected is accurate for the purposes of analysing the results. 
Your records may be reviewed by people from the regulatory authorities to check that 
the study is being carried out correctly. All will have a duty of confidentiality to you 
as a research participant and nothing that could reveal your identity will be disclosed 
outside the research site. 
 
What if something goes wrong? 
Barts and the London NHS Trust has agreed that if you are harmed as a result of your 
participation in the study, you will be compensated, provided that on balance of 
probabilities, an injury was caused as a direct result of the procedures you received 
during the course of the study. These special compensation arrangements apply where 
an injury is caused that would not have occurred if you were not in the trial. If you are 
harmed due to someone’s negligence, then you may have grounds for a legal action as 
with all NHS care.  
 
What happens to the results of the research study? 
When the research is completed and the results analysed, our findings will be 
presented at scientific conferences and published in scientific journals. Your identity 
will not be divulged in any publication, presentation or report. We are happy to 
provide you with a copy of any publication of the findings of the study at your request. 
 
Who is organising and funding the research? 
Barts and the London NHS Research and Development Department is the sponsor of 
this study and is responsible for ensuring all aspects of the study are carried out to the 
highest standard. The research is funded by a grant received from Barts and the 
London Charities. 
 
What if new information becomes available? 
Sometimes new information becomes available during the course of a research project 
that is directly relevant to participants within the research. If significant new 
information came to light that had a bearing on the study and your participation, then 
this information would be considered by a committee who oversee the conduct of the 
trial and you would be informed. 
 
What happens when the research study stops? 
When the study is completed you will not be required to continue with any of the 
study procedures and your care will continue as usual. 
 
This completes Part 1 of the information sheet. Please continue to read the additional 
information in Part 2 regarding the 2
nd
 part of the study to decide if you wish to also 
undertake it. 
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Part 2  
 
2
nd
 part of study 
 
Before deciding whether to also take part in the 2
nd
 part it is important for you to 
understand what it will involve. Please take time to read the following information 
carefully. Talk to others about the study if you wish. This will have no bearing on the 
1
st
 part of the study, this will proceed as discussed. 
 
Do I have to take part? 
NO. It is up to you to decide whether or not to take part. The purpose of this 
information sheet is to help you make a decision, a member of the research team will 
go though any details you wish explaining. If you decide to take part you will be asked 
to sign a second consent form. You are free to withdraw from this part or the 1
st
 part of 
the study at any time without giving a reason. A decision to participate, not participate 
or withdraw from the study will not affect your future medical treatment.   
 
What will happen to me if I take part? 
Before discharge from hospital (at least 2 days following your procedure), you will 
undergo a cardiac magnetic resonance scan (CMR) scan. This will further assess the 
pumping ability of your heart. At 6 months when you come back to the hospital for the 
clinic visit for part 1, you will have another CMR scan. This will be identical to the 1
st
 
scan. 
 
What does the CMR scan involve? 
Cardiac magnetic resonance scans (CMR) use a magnet, radio-waves and a computer 
to take detailed pictures of the inside of your body. It does not use x-rays, is painless 
and safe. It involves lying down on a bed and being taken into a scanner shaped like a 
tunnel. Inside the scanner you will be asked to lie still in order to get clear pictures. 
You will not feel anything. During the scan you hear a rhythmical banging noise. This 
is quite normal. The radiographer will be in contact with you throughout the 
examination, which typically takes 30-60 minutes and will require for you to have an 
injection of contrast through a cannula in your arm. 
 
What are the possible risks and side effects of any treatment received 
when taking part? 
As always, your health is our priority. If at any time you experience a recurrence of 
symptoms, or your condition requires a different treatment strategy, you will receive 
appropriate treatment regardless of the study. This research is at the forefront of our 
understanding and technology and as such, potential risks apart from those mentioned 
below, are unknown. However, given our current understanding of this technology we 
do not foresee any major problems. Potential risks mentioned below are minimised as 
procedures are performed by experienced staff. 
 
CMR scan − the CMR scan does not use radiation. There are no major known side 
effects or risks attached to CMR although some patients may find it a little 
claustraphobic. The main issues are related to possible allergy to contrast agent and 
the scanning process. Most CMR exams are painless, however, some patients find it 
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uncomfortable to remain still during the scan, whilst others may experience a sense of 
being closed in (claustrophobia). Therefore, sedation can be arranged for those 
patients who anticipate anxiety, but fewer than one in 20 require it. You will be alone 
in the exam room during the procedure, however, the technologist will be able to see, 
hear and speak with you at all times using a two-way intercom. If you wish the scan to 
be stopped at any point, it will be. There is a very slight risk of an allergic reaction if 
contrast material is injected. Such reactions usually are mild and easily controlled by 
medication. If you experience allergic symptoms, a radiologist or other physician will 
be available for immediate assistance. You will be assigned a study nurse or doctor 
whom you can contact in case you have any concerns or questions about the study.  
 
What are the benefits of taking part? 
You have already agreed to participate in the 1
st
 part of this research study where the 
treatment or placebo has been given.  There would be no symptomatic or health benefit 
from taking part in this 2
nd
 part. The only benefit be that we would be able to get a 
more detailed look at your heart and how it pumps which we would otherwise not 
perform.  
 
Expenses and Payments 
The costs of your transport to hospital for the 6 month clinic follow-up are already 
covered,  
There will be no additional payment in exchange for your participation in the 2
nd
 part 
of the study.  
 
What will happen if I don’t want to carry on in the study? 
The 2
nd
 part of this study primarily involves two CMR scans, if you dislike the 1
st
 scan 
you can withdraw prior to the 2
nd
, this will not affect your participation in the 1
st
 part 
of the study.  
 
What if there is a problem? 
If you have concerns about any aspects of this study, you should ask to speak with the 
research team who will do their best to answer your questions (Dr Dan Jones or Prof 
Anthony Mathur)  
 
If you remain unhappy and wish to complain formally you can do this by contacting: 
The Patient Advisory Liaison Service (PALS) if you have any concerns regarding the 
care you have received, or as an initial point of contact if you have a complaint. Please 
telephone 0207 377 6335 or email pals@bartshealth.nhs.uk. You can also contact 
PALS by asking at the hospital reception. 
 
 
 
 
 
 
 
 
 
 
Contact Details:  If you require any further information please contact 
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Dr Dan Jones,       Prof Anthony Mathur 
Clinical Research Fellow     Consultant Cardiologist 
Department of Cardiology,     Department of Cardiology, 
The London Chest Hospital,     The London Chest Hospital, 
Barts Health NHS Trust,     Barts Health NHS Trust, 
Bonner Road,  London, E2 9JX   Bonner Road, London,  E2 9JX 
  
Tel: 0208 983 2213      Tel: 0208 983 2448 
Fax: 0208 983 2381      Fax: 0208 983 2381 
Email:dan.jones@bartshealth.nhs.uk   Email:crissy.race@bartshealth.nhs.uk 
 
For Information out of hours call switchboard (020 7377 7000) and ask for the on call 
cardiology registrar at the London Chest Hospital.   
Thank you for taking the time to read this patient information sheet. If you decide to 
take part we will ask you to sign a consent form, of which you will be given a signed 
copy. 
 
Thank you for taking the time to read this. Please ask if there are any 
questions.  
 
 
 
 
 
 
